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ROLE OF p53 AND ITS ISOFORMS IN THE EXPRESSION OF FGF-2 
AND TUMORAL NEOVASCULARIZATION 
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 The tumour suppressor p53 actually exists as 9 protein isoforms. Among them, 
∆133p53 α, β and γ result from the use of an alternative promoter and lack the N-terminal 
transactivation domain. In addition to its multiple functions maintaining cell integrity, p53 is 
also able to block angiogenesis, a process strongly contributing in tumour development. Here I 
have examined the role of p5 isoforms in the regulation of angiogenesis and tumor progression. 
I also focused my work on FGF-2 regulation by p53. 
 In a first part, full length p53 (p53) and/or ∆133p53 isoforms were selectively 
knocked-down with siRNAs in human glioblastoma cells U87. Conditioned medium produced 
by tumour cells knocked- down for ∆133p53 inhibited endothelial cell - EC - migration and 
tubulogenesis. Furthermore, in the chicken chorioallantoïd membrane CAM, ∆133p53 
knockdown gave rise to smaller tumours devoid of vessels, whereas, in mice, it strongly 
inhibited tumour growth. Interestingly, the double knockdown of p53 and ∆133p53 also slowed 
town tumour growth in mice. Taqman Low Density Array revealed distinct gene expression 
profiles of pro and anti-angiogenic factors regulation following ∆133p53 and/or p53 
knockdown. In particular, ∆133p53 knockdown resulted in specific down-regulation of 
Angiogenin and hepatocyte growth factor, whereas the main angiogenic factors FGF-2 and 
VEGF-A were not significantly affected. 
 Secondly we investigated the regulation of FGF-2 by p53 and its isoforms 
∆133p53 in a human osteosarcoma cell line U2OS, at translational, transcriptional and secretion 
levels. It resulted in a sophisticated mode of regulation mediated by a transient IRES-dependent 
translation inhibition of FGF-2.  
 Our data reveal ∆133p53 isoforms as activators of angiogenesis and tumour 
progression, through a specific modulation of the angiogenic balance. These isoforms exhibit 
dominant-negative effect towards p53 but also intrinsic activities, while underlining the 
importance of considering ∆133p53 expression in cancers, as well as the potential antitumoural 
interest of drugs targeting this p53 isoform. 
ROLE DE p53 ET DE SES ISOFORMES DANS LA REGULATION DE 
L’EXPRESSION DU FGF-2 ET DANS LA NEOVASCULARISATION 
TUMORALE  
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 Le suppresseur de tumeur p53 est exprimé sous forme de neuf isoformes. Parmi 
celles-ci, ∆133p53 α, β et γ sont issues de l’utilisation d’un promoteur alternatif induisant la 
perte du domaine de transactivation N-terminal. En supplément de ses multiples fonctions 
comme le maintien de l’intégrité cellulaire, p53 est également capable de bloquer l’angiogenèse, 
un processus contribuant fortement au développement tumoral. Au cours de ma thèse, j’ai 
analysé le rôle des isoformes de p53 dans la régulation de l’angiogenèse et dans la progression 
tumorale. J’ai également porté mes recherches sur la régulation de l’expression du FGF-2 par 
p53. 
 Tout d’abord, p53 pleine taille (p53) et/ou les isoformes ∆133p53 ont été 
disruptés spécifiquement par une approche de SiARN dans des cellules humaines de 
glioblastome - U87. En particulier, le milieu conditionné produit par les cultures traitées au 
Si∆133p53 inhibe la migration des cellules endothéliales et leur tubulogenèse. De plus, dans un 
modèle de membrane chorioallantoïde de poulet, l’inhibition de l’expression de ∆133p53 
provoque l’apparition de tumeurs U87 plus petites et dépourvues de vaisseaux. En parallèle, les 
mêmes cellules traitées implantées en sous cutané chez la souris croient beaucoup moins 
rapidement. De manière intéressante, le traitement double SiARN p53/∆133p53 ralentit 
également le développement des tumeurs.  Des experiences de Taqman Low Density Array ont 
montré des profils d’expression pro et anti-angiogéniques tres différents après traitement 
SiARN p53 et/ou ∆133p53. Le knock down de ∆133p53 révèle en particulier une inhibition de 
l’expression de l’Angiogénine et du HGF (facteur de croissance hépatique) alors que 
l’expression du FGF-2 et du VEGF-A ne sont pas modifiés de manière significative.  
 Dans une seconde partie j’ai étudié le rôle de la régulation du FGF-2 par p53 
mais également par l’isoforme ∆133p53, dans un modèle de lignée cellulaire d’ostéosarcome 
humain U2OS, aux niveaux transcriptionnel, traductionnel et sécrétoire. J’ai mis en évidence 
un mode de régulation sophistiqué impliquant un inhibition transitoire de la traduction IRES-
dépendente du FGF-2 suiteà l’inhibition de l’expression de p53.  
 Mes travaux de recherche ont permis la découverte d’un nouvel acteur de 
l’angiogenèse et de la progression tumorale, à savoir les isoformes ∆133p53, par un 
méchanisme spécifique de régulation de la balance angiogénique. Celles-cis démontrent un effet 
de dominant négatif envers p53 mais également des activités intrinsèques permettant ainsi de 
dévoiler leur importance dans les cancers et le potentiel thérapeutique de stratégies ciblant ces 
isoformes. 
ABBREVIATIONS  
 
ARN interférence      ARNi   
Blood Vessels      Bvs 
Checkpoint kinase      ChK 
Chorio-Allantoic membrane     CAM 
Chromatin immunoprecipitation    ChIP    
Desoxyribonucleic acid     DNA    
DNA binding domain     DBD  
EncephaloMyocarditis virus     EMCV      
Endoplasmic reticulum     ER     
Endothelial Cells      ECs 
Eukaryotic Initiation Factors    eiFs     
Extra Cellular Matrix     ECM   
Fibroblast Growth Factor 2     FGF-2 
Glioblastoma Multiform     GBM   
Guanosine Triphosphate     GTP   
Heterogeneous Nuclear Ribonucleoprotein   hnRNP 
High Molecular Weight     HMW   
Hypoxia Inducible Factor-1α      HIF-1α 
Immunohistochemistry     IHC 
Internal Ribosome Entry Sites    IRES   
IRES Trans-Acting Factor     ITAF   
Low Molecular Weight     LMW   
Messenger Ribonucleic Acid    mRNA   
Mouse Double Minute 2     MDM2   
Nuclear Localisation Signal     NLS   
p53 core domain      p53C      
p53 Responsive Element     p53RE     
Polychain Reaction      PCR   
Reactive Oxygen Species     ROS   
Ribonucleic Acid      RNA   
Simian Virus 40      SV40  
 Single DNA Strand Breaks    SSB 
Smooth Muscle Cells     SMC 
Transactivation Domain    TAD 
Ultraviolet      UV 
Untranslated region     UTR 
Vascular Endothelial Growth Factor   VEGF 
 
1 
GLOSSARY 
INTRODUCTION 5
A. p53 6
Prelude – The history of p53 protein characterization.......................................................................6
A.I. The p53 gene 8
A.I.1 The p53 promoter and its regulation 8
A.I.2 p53 gene expression 9
A.I.2.a. p53 transcripts. 9 
A.I.2.b. p53 translation regulation. 11 
A.II p53 structure and post translational modifications. 11
A.II.1 The N-Terminal region. 11
A.II.2 The DNA Binding domain – DBD. 12
A.II.3. The C-terminal domain 13
A.III. p53 Modes of action 14
A.III.1 Input signals for p53 activation 14
A.III.2. Regulation of p53 protein 18
A.III.2.a. MDM2, the headman. 18 
A.III.1.b. Other p53 regulators 19 
A.IV. p53 pathways 20
A.IV.1. Survival pathways 21
A.IV.1.a.Cell cycle 22 
A.IV.1.b DNA repair 23 
A.IV.2. Cell death pathways 23
A.IV.2.a. Apoptosis 23 
A.V. p53 family 24
A.V.1. p63 and p73 family genes. 24
A.V.1.a. p63 gene. 24 
A.V.1.b. p73 gene. 25 
A.V.2. p53 isoforms 26
A.V.2.a. 40p53 isoforms 28 
A.V.2.b. Full length p53 spliced isoforms. 28 
A.V.2.c. 133p53 isoforms 29 
A.V.2.d. p53 isoforms in tumourigenesis 29 
B. Angiogenesis 32
B.I. Circulatory system 32
B.I.1. Structure and functions of the blood vessels. 32
B.I.1.a. Arteries and Veins 32 
B.I.1.a.. The tunica intima and endothelial cells. 33
B.I.1.a.. The tunica media and the smooth muscle cells. 34
B.I.1.a.. The tunica adventitia and the fibroblasts. 35
B.I.1.b. The capillary network 35 
B.I.2. The lymphatic system 36
B.I.2.a. Role of the lymphatic network 36 
B.I.2.b. Tumour Lymphangiogenesis 36 
B.II. Physiologic and pathologic angiogenesis. 37
B.II.1 The angiogenic switch 37
B.II.2. Steps of blood vessel formation. 38
B.II.2.a. Sprouting angiogenesis 38 
2 
B.II.2.b. Intussusception. 40 
B.II.2.c. Recruitment of endothelial progenitor cells – EPC. 40 
B.III. Tumour Angiogenesis. 41
B.III.1. Tumour-related angiogenesis 41
B.III.1.a. Vasculogenic mimicry – VM. 41 
B.III.1.b. Cooption. 42 
B.III.1.b. Mosaic vessels. 43 
B.IV. Molecular signaling in tumour angiogenesis 43
B.IV.1. VEGFs 43
B.IV.1.a. VEGF-A 44 
B.IV.1.a.. VEGF-A expression 44
B.IV.1.a.. VEGF-A pathways. 45
B.IV.1.a.. Biological Effects of VEGF-A. 45
B.IV.1.b. Other VEGF members 47 
B.IV.2. FGF-2 47
B.IV.2.a. FGF-2 Biosynthesis 48 
B.IV.a.. FGF-2 gene expression 48
B.IV.2.a.. FGF-2 translation regulation 48
B.IV.2.b. FGF-2 isoforms 49 
B.IV.2.c. FGF-2 Molecular interactions 50 
B.IV.2.c.. Interactions with ECM and Receptors 50
B.IV.2.c.. FGF-2 transduction pathways. 51
B.IV.2.c.. Intracellular protein partners. 53
B.IV.2.d. FGF-2 biological activities in tumour angiogenesis 54 
B.IV.2.d.. FGF-2 and angiogenesis 54
B.IV.2.d.. FGF-2 and transformation 54
B.IV.3. PDGF 54
B.IV.3.a. PDGF Ligands and receptors 55 
B.IV.4. TGF- 55
B.IV.4.a. TGF- pathways 56 
B.V. p53 and angiogenesis 56
B.V.1. Correlations between angiogenic behavior and p53 status. 57
B.V.2. p53 and hypoxia. 58
B.V.3. Regulation of proangiogenic targets. 59
B.V.4. Regulation of antiangiogenic targets. 59
B.V.5. Activation of collagen derived antiangiogenic factors. 61
B.VI. Models of angiogenesis. 62
B.VI.1. In vitro models 63
B.IV.2. Ex vivo models 64
B.VI.3. In vivo models 64
B.VI.4. The chick embryo chorio-allantoic membrane – CAM 65
B.VI.4.a. Function and structure in embryonic development. 65 
B.VI.4.b. The CAM as a tool. 65 
C.I. Introduction to glioblastomas 68
C.II. Angiogenesis in glioblastomas. 69
C.III. Treatment of glioblastomas. 70
C.III.1. Antiangiogenic therapy 71
C.III.2. Current limitations of antiangiogenic therapy in glioblastomas 73
C.IV. Glioblastomas and experimental models. 74
C.IV.1. Mouse models 74
3 
C.IV.2. CAM model of glioblastoma. 74
PROBLEM76
MATERIAL AND METHODS ..........................................................................................................78
A. 79
Cells and embryos. 79
B. Transfections, transductions, drugs treatment and western blotting. 79
B.I. SiRNA and plasmid transfections in cells 79
B.II. Transductions 79
B.III. Drugs treatment and Western Blot 79
C. Endothelial cell migration, tube formation and proliferation. 80
C.I. Wound Healing Assay 80
C.II. Boyden Chamber assay 80
C.III. Matrigel 80
C.IV. Cell proliferation assay 81
C.V. ELISA 81
C. Tumour in CAM and xenografts in mouse. 81
D. Histology and immunochemistry. 82
E. RNA extraction, nested RT PCR, real time qRT-PCR and TLDA. 83
F. Plasmid constructions 83
G. Luminoter assays 83
H. Statistical analysis 84
RESULTS 85
CHAPTER 1: 88
Involvement of the 133p53 isoforms in angiogenesis and tumour 
progression in a glioblastoma model 88
Α. ∆133P53 knockdown activates p53 expression. 93
C. 133P53 knockdown is anti-angiogenic and prevents tumour growth in 
CAM. 101
D. ∆133P53 knockdown prevents tumour angiogenesis and growth in mouse. 106
E. ∆133p53 modulates the angiogenic balance towards angiogenesis. 109
F. Further insights into 133p53 role in angiogenesis 117
F.I. Verification of Si133p53-2 efficiency 117
F.II. EC migration & proliferation assays with U87 conditioned media. 120
F.II.1. EC treatment with conditioned media of siRNA transfected U87. 120
F.II.2. Conditioned media from U87 cell line overexpressing p53 
isoforms. 124
F.III. Construction and verification of inducible 133p53 isoforms 
lentivectors 129
F.IV. Analysis of the secreted angiogenic factors from U87 cells. 133
F.V. Proliferation of SiRNA transfected U87 cell lines 134
F.VI. Angiogenesis & tumour proliferation assessment in mice xenografts 136
F.VII.1. Antiangiogenic factors – Fig 26B 138
F.VII.1.a. MMP-2 138 
F.VII.1.b. IL12A. 139 
F.VII.1.c. COL4A2. 139 
F.VII.2. Proangiogenic factors - Fig 26C 140
4 
F.VII.2.a. Angiogenin 140 
F.VII.2.b. Midkine 141 
F.VII.2.c. Hepatocyte growth factor 141 
F.VII.2.d. VEGF-C 141 
F.VII.2.e. Pleiotrophin 142 
F.VII.3. The angiogenic marker ANGPTL4 – Fig 26D 142
CHAPTER 2:                       Regulation of FGF-2 by p53 143
A. p53 and translation 144
A.I. Mechanisms of translation initiation. 144
A.I.1. Cap dependent translation initiation. 144
A.I.2. IRES dependent translation initiation. 145
A.II. p53 regulates translation 147
B. Regulation of FGF2 expression by p53 150
B.I. Translational control of p53 150
B.II.1. p53 knockdown 153
B.II.2.Response to p53 induction 155
B.II.2.Response to p53 induction 156
B.II.2.a. Actinomycin D 156 
B.II.2.b. Doxorubicin 158 
BII.2.c. Overexpression of p53 160 
B.II.3. FGF-2 secretion 162
CONCLUSION, DISCUSSION & PERSPECTIVES 164
A. Mechanistic considerations about the role of 133p53 166
A.1. Which step and what mechanism are blocked? 166
A.2. Intrinsic versus extrinsic activity of 133p53 167
A.3. p53 mRNA regulation by 133p53 167
B. Mechanism of translation regulation by p53. 168
ANNEX             159 
BIBLIOGRAPHY           160 
5 
INTRODUCTION 
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A. p53 
Prelude – The history of p53 protein characterization. 
The most investigated protein in cancer – more than fifty thousands Pubmed 
results up to now – has been jointly discovered thirty years ago by four laboratories, all 
working on DNA viruses (reviewed in Kress et al. 1979; Lane and Crawford 1979 ; 
Linzer and Levine 1979; Melero et al. 1979; Finlay et al. 1988). In fact, Lane and 
Crawford were the first to publish and characterize the ability of the simian virus Large-
T antigens to bind a host protein of a 53 kDa molecular weight, in hamster cells. These 
findings opened the widest field on oncology: the p53 world. But it all begun by a 
collegiate misunderstanding in the aspect that p53 was thought to be an oncogene.  
The first studies revealed that not only the simian virus 40 – SV40 – large T 
antigen binds to p53 but other viral proteins from different viruses target it to transform 
cells (Rotter et al. 1980; Levine 1988). Although there were no evidence of the 
molecular key steps leading to cell transformation, experimental proof showed a link 
between DNA tumour viruses and use of proto-oncogene to form carcinomas (Lane and 
Benchimol 1990).  Interestingly p53 was also found overexpressed in Non SV40 
infected embryonic carcinomas (Linzer and Levine 1979). Several studies confirmed the 
relation between transformed cell/tumour and immunogenicity against p53 (DeLeo et 
al. 1979; Melero et al. 1979; Rotter et al. 1980; Crawford et al. 1982). 
On another hand, two groups correlated p53 expression levels in lymphocytes 
and fibroblasts with DNA synthesis and overcome of G0/G1 and G1/S cell cycle 
transition stages (Milner and McCormick 1980; Mercer et al. 1984). p53 was 
upregulated by growth serum from a quiescent to a proliferate state, and particularly 
expressed in G1 and S phases (Reich and Levine 1984) Consistent with these results 
Shohat et al. in 1987 transfected p53 antisense plasmids in non-transformed NIH3T3 
cells which showed a slower rate of DNA synthesis, as assayed by incorporation of [3H] 
thymidine (Shohat et al. 1987). All these findings supported the notion that wild type 
p53 was important for continuous cell proliferation. On the contrary, gross deletions of 
p53 gene in both alleles or even the 17q chromosome in which p53 gene is located, 
leading to irrevocably loss of p53 functions, indicated that p53 was not essential for cell 
growth (Wolf et al. 1984; Mowat et al. 1985).  
7 
But the strongest evidence that really embedded this misbelief came from 
experiments using p53 plasmids transfection. Three different groups demonstrated that 
this p53 was one of the key steps leading to malignancy (Eliyahu et al. 1984; Jenkins et 
al. 1984; Parada et al. 1984; Jenkins et al. 1985). It could cooperate with an activated 
Ras to form foci from embryonic normal cells and tumours in vivo. Jenkins et al cloned 
the mouse p53 cDNA and immortalized finite lifespan cells. Importantly, Rotter’s group 
showed by three different publications that non expressing p53 Ab-MuLV-transformed 
L12 cell line would only end up to be lethal in mice when transfected with p53 (Parada 
et al. 1984). These results confirmed that restoration of p53 in an overexpressed fashion 
would allow tumour formation.  
As if research in virology was leading p53 field, the first discrepancies 
concerning oncogenicity of p53 rose from a study in Friend murine erythroleukemia. 
Theses cancers are induced by the integration of the spleen focus-forming virus – SFFV  
– provirus in few loci of the whole genome (Moreau-Gachelin et al. 1985). One of them 
frequently targeted the p53 gene, inactivating it (Mowat et al. 1985; Munroe et al.
1988). In all cases, the second allele was either lost through loss of the chromosome, or 
inactivated by deletion. In this tumour model, functional inactivation of the p53 gene 
seemed to confer a selective growth advantage to erythroid cells during the development 
of Friend leukemia in vivo. 
A second set of studies highlighted some matter about the genetics of p53 gene. 
Two different approaches permitted to access the conserved sequence between species 
and showed p53 mutations in tumour cells. In fact, Levine’s and Oren’s groups used a 
mutated p53 cDNA clone, the clone 11-4,  derived from F9 embryonic carcinoma cells 
to point out  the fact that overexpression brought by stronger promoters from the 
original SV40 did not induce foci formation in Ras oncogene activated cells (Finlay et 
al. 1988). However, when inserting an inactivating sequence into the N-terminal of p53 
protein, foci were formed. By recombination and analysis between the 11-4 clone and a 
mutant they found a single mutation – Cys to Phe – at position 132 essential for 
tumourogenicity. They also compared the 11-4 clone to the genomic sequence and 
found one mutation at position 135 – Val to Ala (Li et al. 2008). At this time they only 
considered it was a sequencing error or a polymorphism. The second team gathered 
multiple sequences from frog, mouse and human p53 gene (Soussi et al. 1987). They 
went to the conclusion that only five blocks in all three species had highly conserved 
amino-acid sequence. Moreover they showed that the frog p53 shared epitopes with 
8 
human p53. This mapping made up a useful tool in order to segregate point mutations 
activity. The same group published two years later a more complete mapping of these 
regions in several organisms – Figure 1 (Soussi et al. 1989). These findings permitted to 
settle wild type p53 core domains, succeeding to refund the p53 cDNA clone library. 
It was now revealed that most studies used mutant p53 cDNA with transforming 
activity, but very few were known about wild type p53. Very shortly after these 
findings, two groups cleared this out, and announced its tumour suppressor activity 
(Baker et al. 1989; Finlay et al. 1989). Finlay et al. co-transfected wild type p53 with 
mutant p53 and activated Ras gene and observed a strong decrease in cell foci 
transformation while Baker et al. sequenced the p53 gene in tumours and found 
mutations in highly conserved regions. These experiments were the first to suggest that 
wild type p53 can negatively regulate cell growth and stop tumour formation.  
A.I. The p53 gene
The p53 gene is a 19.1 Kb length gene localized on the small arm of the 
chromosome 17 at locus 17p13.1 – NCBI ref: NC_000017.10. It contains eleven exons 
varying from 22 to 1268 bp and ten introns varying from 81 to 10000 bp (Lamb and 
Crawford 1986). In this study, they compared the human and mouse p53 gene 
sequences. Strikingly, they found a very conservative homology in the length and the 
structure of the exons.  
 A.I.1 The p53 promoter and its regulation
Figure 1. Evolutionary conservation of p53 DNA-binding domain sequence.   
From (Soussi et al. 1989). Part of the Core domain is shown here. Black areas show sites where 
the SV40 larget Antigen binds to p53. Open boxes represent the 4 of 5 cores DNA binding 
domains. 
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Initially the murine p53 promoter was thought to be quite short – 700 bp – but 
recent results extend it to a bit more than 1 Kb – Figure 2 (Boggs and Reisman 2006; 
Boggs and Reisman 2007). 75 % sequence identity is shared between mouse and human 
promoters, suggesting evolutionary conserved binding elements. Two human promoters 
were first described: one upstream the first exon and the second in the intron 1 (Tuck 
and Crawford 1989). This latter encodes for transcript of 1125 bp and is considered only 
as a pseudogene whose expression varies during terminal differentiation of myeloid 
leukemia cells. Research in our lab showed another promoter located in the intron 4, 
giving birth to N-truncated forms of p53, and a second transcription initiation site 
located fifty four nucleotides downstream the 5’ exon site. 
A.I.2 p53 gene expression
A.I.2.a. p53 transcripts. 
If we summarize the results from different groups there are 30 different 
transcripts of p53 gene. In this part I will just summarize the findings upon the different 
p53 transcripts – Figure 3. A further analysis will be given later in this report. Two 
different groups identified in the 5’ untranslated region characterized by Tuck and 
Crawford two translational regulating elements: Internal Ribosome Entry Sites – IRES – 
upstream the start codon – -140 to -1 – and also in part in the ORF – -140 to +39 (Ray et 
al. 2006; Yang et al. 2006). Three groups found an alternative translation initiation site 
in exon 4 following either alternative splicing or alternative translation initiation 
mechanism. Our laboratory identified an internal promoter in intron 4 which is 
consistent with the dual gene structure of the other p53 family members, p63 and p73. 
Additionally, they found two alternative splicings –  and  – in intron 9 both 
containing stop codons. Finally Rohaly et al. detected an exon 8 truncated transcripts. 
Numerous factors bind p53 promoter and modulate its activity: PBF1 and 2: prolamin box-binding 
factor-1 and 2, PF1 and 1: PHD zinc fingers protein 1 and 2, USF: upstream stimulatory factor, NF-
1: neurofibromin 1, C/EBP-2: CCAAT/enhancer binding protein--2. From (Boggs and Reisman 
2006) 
Figure 2. Map of murine p53 promoter
C/EBP-2
-972/-953  
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Nevertheless our lab has never confirmed the existence of a splicing event between 
exon 7 to 9 despite the use of specific primers (Bourdon et al. 2005; Rohaly et al.
2005). 
Few investigations have been made on the 5’UTR of p53 gene but since the 
discovery of two IRESs it is believed that new effectors will soon be revealed. Human 
and murine p53 5’ untranslated regions – 5’UTR – are predicted to form stable stem-
loop secondary structures inhibiting translation. p53 has been shown to in vitro bind its 
5’UTR and inhibit its own translation by its RNA re-annealing properties and thus 
stabilizes the secondary structure (Mosner et al. 1995). More recently Takagi et al.
identified two proteins regulating p53 mRNA translation: RPL26 enhanced it whereas 
nucleolin repressed it in response to DNA damage by Ionizing Radiations. These 
proteins are implicated in the folding and the stabilization of 5’UTR secondary 
structures (Takagi et al. 2005). The Polypyrimidine Tract-Binding protein – PTB – a 
well known IRES Trans-Acting Factor – ITAF – is also able to activate both p53 IRESs 
during doxorubicin treatment (Grover et al. 2008).  
Little is known about the 3’UTR of the human p53 mRNA. p53 3’UTR is 1176 
bp long and contains an Alu-like sequence of 470 nt that can inhibit p53 translation. To 
date, only few factors like Defective in Germ Line Development – GLD-1 – the 
C.elegans homolog of the mammalian protein Quaking and Hu antigen R – HuR – a 
RNA binding factor, have an effect on p53 translation (Mazan-Mamczarz et al. 2003; 
Schumacher et al. 2005). Cytoplasmic Polyadenylation Element-Binding protein – 
CPEB – is also able to promote p53 mRNA polyadenylation via its element in the 
P1
P1’
Exon 2 Exon 3
AUG AUG
Exon 4
Intron 4
AUG
Exon 5 Exon 6 Exon 7 Exon 8 Exon 9 Exon 10
Intron 9
Intron 9
STOP
 s.v.
 s.v.
Exon 11
STOP
STOP
[A]
P2
p53 s.v.
133p53 promoter
p53 IRES
The figure is not scaled. Here are represented the three promoters P1, P1’ and P2 in intron 4, The two IRESes, The first 
start codon and its alternative in exon 4 allowing expression of the 40p53 isoforms, 133p53 promoter followed by its
5’UTR and the start codon in exon 5, and EIIp53, p53,  and  splice variants. For references refer to the p53 transcripts
paragraph.
Figure 3. Structure of the human p53 gene
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3’UTR inducing p53 and  promoting thus p53-mediated senescence (Burns and Richter 
2008). We can estimate that more proteins can bind to these elements, as 
Glyceraldehyde 3-Phosphate Dehydrogenase – GAPDH – and Heterogeneous Nuclear 
Ribonucleoprotein – hnRNP – D and A/B. Finally miR-125b is thought to affect DNA 
damage response by inhibition of p53 translation. 
A.I.2.b. p53 translation regulation. 
Fortunately, the 30 theoric mRNAs do not encode for 30 isoforms but 9 – 10 
with the p53 isoform (Hollstein and Hainaut 2010). In this paragraph we only 
succinctly describe the p53 isoforms and the main domains involved – Figure 4. A more 
detailed overview will be done on the next paragraph. As this figure shows us, p53 is 
constituted by an N-terminal transactivation domain – TAD – with a proline rich 
domain, a DNA binding domain – DBD – where are represented in black squares four 
of the five highly conserved domains of p53 and a C-terminal domain composed of the 
Nuclear Localization Signal – NLS – the Nuclear Export Signal – NES – the 
oligomerization domain, and the extreme C-ter domain. The intron 9 spliced isoforms 
do not have an oligomerization domain, 40p53 isoforms lack part of the TAD and the 
133p53 isoforms lack the whole TAD plus a small part of the DBD. 
A.II p53 structure and post translational modifications. 
p53 is a 393 amino acid protein that acts as a tetrameric protein, mostly known 
in a homodimeric fashion but it is also able to form heterodimeric complexes with its 
isoforms. This is thought to modulate strongly its activity in response to different 
stresses. For a review refer to (Kruse and Gu 2009).  
A.II.1 The N-Terminal region.
The N-terminal region of p53 consists first of two acidic unfolded 
Transactivation Domains – TAD1: residues 1 to 40; TAD2: 40-61 – and a proline rich 
p53 encodes for 10 
isoforms, namely  
p53, p53, p53, 
40p53, 40p53, 
40p53, 133p53, 
133p53, 
133p53 and p53. 
From (Hollstein and 
Hainaut 2010)
Figure 4. Structure of the human p53 gene
40p53 
Full length 
p53 
133p53 
p53 
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region. TADs are binding sites for numbers of interacting proteins from the 
transcription initiation complex, the transcription co-factors p300/CREB Binding 
Protein – p300/CBP – and Mouse Double Minute2 and 4 – MDM2/MDM4. 
Competition is also observed between co-factors like the overlap in MDM2 and p300 
binding sites. p300/CBP is a histone acetyltransferase enzyme that loose chromatin 
structure to permit transcription initiation.  
The p53 N-terminal domain is the place of multiple phosphorylation sites – S6-
S9-S15-T18-S20-S33-S36-S37-S46-T55-T81 – Figure 5. These modifications enhance 
the binding affinity of several co-factors like Checkpoint kinase 1 and 2 – ChK1 and 2 – 
p38k, Ataxia-Telangiectasia Mutated protein – ATM – Ataxia-Telangiectasia and Rad3-
related – ATR – DNA-dependent Protein Kinase – DNA-PK – Pin1 and others. 
The proline rich domain is also characterized by numerous protein binding sites. 
It contains five PXXP motifs also known as Src Homology 3 – SH3 – domains. For 
example viruses like SV40 or adenoviruses use respectively their large-T and E1B-55 to 
inactivate p53. However the exact role of this region is not really understood and until 
now it is considered as a linker region between the TAD and the DBD.  
A.II.2 The DNA Binding domain – DBD.
The p53 core domain – p53C – consists of an immunoglobulin like -sandwich 
with three series of loops and short helices that can be divided into two structural motifs 
that bind the minor and the major groove of a target DNA (Cho et al. 1994). Human 
Figure 5. Post-translational modifications of the human p53 protein.
More than 10% of p53 residues are modified after specific inductions, and different modifications can 
occur in a single a.a. Most the modifications observed are present in the N-Ter and the C-Ter which 
are though to modulators of p53 activity. From (Kruse and Gu 2009). 
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p53C is not very stable in comparison to its family proteins like p63. It is possible that 
this less stable structure is an evolution to tighter and more reactive folded-unfolded 
states in response to conditions changes, and also may permit plasticity to DNA binding 
events.  
The p53C binds to a consensus sequence composed of two pairs of head to head 
pentamers forming half site decameric palindromes of 5’-RRRCWWGYYY-3’ – R = A 
or G; W = A or T; Y = C or T – separated by between zero to thirteen base pair linker. 
This specific DNA sequence is also known as the p53 Responsive Element – p53RE – 
(el-Deiry et al. 1992; Bourdon et al. 1997). By ChIP paired-end diTag coupled 
sequencing to the whole genome, around 60% of known p53-responsive genes were 
identified with such consensus sequence without spacer (Wei et al. 2006). p53 protein 
binds DNA as a tetramer with higher affinity for genes involved in cell cycle arrest and 
DNA repair than those for apoptotic response (Weinberg et al. 2005).  
Seven residues in the p53C are essential to bind the DNA half sites: K-120, S-
241, R-248, R-273, A-276, C-277 and R-280 (Kitayner et al. 2006). Like the TAD, the 
DBD is susceptible to posttranslational modifications that enhance or inhibit the binding 
to DNA. Three Lysines in position 120, 164 and 292 can be acetylated. Three serines in 
position 149, 150 end 155 can be phosphorylated and amino-acid 256, 259 and 271 can 
be ADP ribosylated. A tight control of these modifications has been demonstrated as for 
example acetylation of residue 120 by Tat Interactive Protein 60 – TIP60 – after 
induction of an apoptotic stress (Tang et al. 2006).  
A.II.3. The C-terminal domain
The C-terminal domain consists of a short -strand and an -helix. It contains 
the oligomerization domain in which is included a nuclear export sequence – a.a. 340 to 
351 and 305 to 322 respectively – and a nuclear localization sequence, and an arginine 
and lysine rich basic region at the free C-terminal end shown to act as a nonspecific 
nucleotide binding region (Kim and Deppert 2006). The oligomerization domain allows 
p53 to form a homotetramer but also can do heterotetramers in combination with the 
40p53 and 133p53 isoforms. The C-terminus domain of p53 binds non-specifically 
DNA by its Lysine residues with low affinity. In the same time, this region is involved 
in a sliding based mechanism for recognition of specific p53 target genes through the 
DNA molecule (McKinney et al. 2004).  
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The C-terminal domain is the target of multiple posttranslational modifications 
(Kruse and Gu 2009). Besides four phosphorylation sites in Serines 315, 376, 378 and 
392, twelve Lysine residues in position 305, 319, 320, 321, 351, 357, 370, 372, 373, 
381, 382 and 386 are particularly subject to modification like ubiquitination, 
acetylation, methylation, neddylation and sumoylation. These post-translational 
modifications allow uncovering the inhibiting effect of the C-terminus and allowing 
regulating specific binding to target p53 gene promoters (Sauer et al. 2008).    
A.III. p53 Modes of action 
Stress signals like DNA damage fire the sequential scheme of p53 activation that 
can be divided in three time dependent events: First p53 protein is rapidly stabilized 
upon post-translational modifications – phosphorylations, acetylation and inhibition of 
ubiquitination,… – allowing it to bind and induce expression of its target genes. Some 
of p53 target genes regulate p53 protein level – MDM2, Pirh2 – inducing thus a 
negative feedback loop (Levine et al. 2006).  The post-translational modifications 
enables p53 to interact with a larger number of transcription co-factors and thus to 
transactivate a wider range of target genes. Finally when the cell damages are too 
important, multiple and complex modifications lead p53 to activate the programmed 
cell death. 
A.III.1 Input signals for p53 activation
There is a large variety of stress signals that can induce p53 activation. It is 
certainly not the aim of this report to make an exhaustive list of all the factors and 
signals involved in p53 activation, but I considered rather relevant to synthesize and 
describe those which are relevant to my work. These stresses can be divided into groups 
involving different aspects of the cell homeostasis: DNA damage – or alteration – 
cellular starvation, aging, infections and inflammation, heat shocks, incorrect folding of 
proteins or activation of oncogenes (Levine et al. 2006) – Figure 6:  
• Most of all, signals that trigger DNA alteration – gamma and UV irradiations, 
DNA cross linking, Reactive Oxygen Species – ROS – alterations of the 
desoxyribonucleotide or errors in replication – are the main signals of p53 activation. It 
has been thus called “the guardian of the genome” or the “gatekeeper cell growth and 
division” due to his strong ability to maintain the integrity of the genome and to control 
cell cycle progression (Lane 1992; Levine 1997). Each DNA damaging agents has its 
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own hallmark of p53 activation although two common pathways can be designed to 
explain the downstream activation of p53.  
- Single DNA Strand Breaks – SSB – are due to replication stress, UV 
radiation and some chemicals and are recognized by a complex of three proteins Rad9, 
Rad1, Hus1 – not so randomly called 9-1-1 complex – which acts like a sliding clamp 
over DNA and by Rad17 with four Small Replication Factors – RFC – subunits – Rfc 2 
to 5 – forming the RFC-related complex. At DNA damage site, Rad17-Rad2-5 regulates 
the recruitment of the 9-1-1 complex for the loading to the DNA. The 9-1-1-DNA 
complex catalyzes ATR phosphorylation activity and to a less extend the one of ATM 
(Niida and Nakanishi 2006). This mechanism is greatly enhanced by the binding at SSB 
of the Replication Protein A – RPA – which brings ATR and ATR Interacting Protein – 
ATRIP – to phosphorylate the 9-1-1 complex. ATR associates with other multiple 
mediators like Bloom syndrome protein – BLM – Histone H2A – H2AX – and p53 
Binding Protein 1 – 53BP1 – complex to phosphorylate p53 but also MDM2 and chk1 
kinase.  
Figure 6. Upstream regulators and activators of p53 activity.
Input signal are hierarchically organized as a triangle: A consequent set of stimulus can activate 
five different families of mediators which in turn will  modify the dynamics of the core domain in 
favour of p53 accumulation and activation. From (Levine et al. 2006). 
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- Double Strand Breaks – DSB – are DNA damage events caused by IR, 
changes in chromatin structure and chemicals. They can involve the MRN complex – 
MRE11-RAD1-NBS1 – and lead to the activation of ATM. ATM is able to 
phosphorylate itself and other mediators of the DSB response, amplifying its activation 
(Meek 2009). ATM is also potent for the indirect phosphorylation of DNA damage 
response effectors mediated by a complex of four proteins H2AX, Mediator of DNA 
Damage Checkpoint protein 1 – MDC1 – 53BP1, Structural Maintenance of 
Chromosomes protein 1 – SMC1 – or by direct phosphorylation of p53, MDM2 and 
ChK2 kinase (Sengupta and Harris 2005).  
 It is striking to observe that this whole system has been set up to exponentially 
amplify p53 activation by multiple pathways and means. This reinforces the essentiality 
of p53 in DNA damage response.  
• Cell starvation is a wide sense term that enrolls multiples phenomena like 
nutrient or serum deprivation or hypoxia:  
- Nutrient deprivation has been shown to activate AMP Activated Protein 
Kinase – AMPK – and phosphorylate p53 (Jones et al. 2005). Transient activation of 
AMPK pathway leads to G1/S arrest whereas persistent activation leads to senescence 
or apoptosis.  
- The exact molecular link between low oxygen concentration and activation 
of p53 is still not clear, but strong evidence shows that the main actor is the Hypoxia 
Inducible Factor-1α – HIF-1α. In normoxic conditions, HIF-1α is rapidly hydroxylated 
by HIF Prolyl Hydroxylase Domain-containing enzymes – PHD – and leaded by the 
Von Hippel Lindau protein – pVHL – to E3 ubiquitin degradation. When O2 levels does 
not permit hydroxylation of HIF-1α, this later will induce via hypoxia response 
elements transcription of a broad variety of genes involved in cell survival, proliferation 
and angiogenesis but also induces p53 stabilization (Koumenis et al. 2001; Fels and 
Koumenis 2005; Sanchez-Puig et al. 2005). Fels and Koumenis explain that in mild 
hypoxic conditions HIF-1α is stabilized but does not stabilize sufficiently p53 to induce 
a response. In more severe hypoxic conditions or anoxia – 0.2% and 0.02% of 02 – HIF-
1α binds to stabilized p53, which in return starts a negative feedback loop inducing 
HIF-1α degradation mediated by MDM2 (Chen et al. 2003). Further studies in this 
direction showed that HIF-1 binds p53 through two domains, one in the oxygen-
dependent degradation – ODD – domain (Hansson et al. 2002; Sanchez-Puig et al.
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2005). These observations have raised controversies as other studies link p53 activation 
with hypoxia related stress such as acidosis, nutrient depletion or DNA damage 
(Kaluzova et al. 2004). For instance Pan et al. and Ravi et al. did not find p53 activation 
in hypoxic or anoxic conditions “alone” (Ravi et al. 2000; Pan et al. 2004). Regarding 
the formation of the HIF-1-p53 complex, MDM2 plays an important role: MDM2 
increases the expression of HIF-1 in normoxia and hypoxia, independently of p53 
(Bardos et al. 2004; Zhang and Hill 2004). The MDM2 increase of expression in 
hypoxia remains unclear due to opposite results by different groups (Koumenis et al.
2001; Nieminen et al. 2005; Hubert et al. 2006). Other regulators of HIF-1-p53 
complex have been proposed: pVHL has been showed to induce a stabilization of p53 in 
hypoxia, thus avoiding the binding of MDM2 by several post translational 
modifications (Roe et al. 2006). Still, pVHL does not seem to be essential for p53 for 
the binding of HIF-1 (Schmid et al. 2004). Finally p300, known to interact with p53 
and HIF-1 in a transcriptional competitive manner allows p53 transcription activity 
and therefore diminish the HIF-1 one (Blagosklonny et al. 1998; Schmid et al. 2004). 
The involvement of p300 may occur in anoxia because it supposes strong p53 levels. 
This crosstalk allows us to apprehend better the mechanisms underlying the 
different responses to hypoxia. An important balance is p53 and HIF-1 expression 
levels, which bear some common targets regulated in an opposite fashion such as 
VEGF, GLUT-1 and Bcl-2. However this complex regulation is only partially 
conclusive. In the same time a specific pattern in p53 response encountered in hypoxia 
may be explained by Nitric Oxide – NO – levels, a severe-hypoxia-induced factor 
(Hammond and Giaccia 2006). For instance, it has been shown that hypoxia induces NO  
overproduction and overexpression by the Inducible Nitric Oxide Synthase – iNOS. 
This results in the induction of multiple pathways depending on NO concentrations 
(Thomas et al. 2008). From 100 nM to 300 nM NO induces HIF-1α, but in higher 
concentrations corresponding to very low oxygen concentration, NO is able to induce 
Serine 15 phosphorylation of p53 through the activation of ATM and ATR kinases.  To 
note p53 creates a negative feedback loop with NO species: NO induces the 
stabilization of p53 that in consequence inhibit the NO synthase 2 or iNOS. This 
response avoids the stabilization of HIF-1 by NO (Forrester et al. 1996; Ambs et al.
1998). Indeed in strong hypoxic conditions, p53 is activated and binds HIF-1 and then 
directs it to the proteasome. Recently HIF-2α showed to regulate p53 levels in an 
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opposite fashion of HIF-1α (Bertout et al. 2009). As HIF2-α is also accumulated in 
normoxic conditions, in contrary to HIF1-α we can hypothesize that some competition 
between HIF 1 and 2 occurs for the binding of p53 protein. These elements could 
suggest a more complete and complex picture of p53 activation in hypoxic conditions. 
• The immune system is also able to warn the cell from the rupture of homeostasis 
induced by infections or injury. It activates various immune agents like macrophages, 
mast cells, dendritic cells and promotes the release of cyokines, chemokines and ROS 
and Reactive Nitrogen Species – RNS. ROS and RNS – OH
•
, H2O2, NO
•
, O2
•
, OONO
-
 – 
are extremely active DNA damaging agents and thus induce p53 pathways. NO
•
 has a 
major role in inflammation. It is mostly produced by the iNOS and can have opposite 
effects depending on the levels of NO
•
 production. As postulated earlier NO
•
 can induce 
p53 phosphorylation and likewise MDM2 and HIF-1α is subject to a negative feedback 
loop with p53 in which p53 inhibit NO
•
 production by the blockade of iNOS. 
A.III.2. Regulation of p53 protein
 Although transcriptional regulation of p53 has been reviewed in this report, most 
of the p53 protein regulation occurs at the translational level. Indeed, p53 activation 
goes through first posttranslational modification of p53 and interaction with its co-
factors promoting p53 stabilization, resulting in the uncovering of the DBD, then 
increase of its binding ability to specific target sequences by other posttranslational 
modifications and co-factors, and target gene activation by interacting with the general 
transcription machinery. In fact, it would be more relevant to consider also MDM2 to 
assess p53 regulation, because its interaction is a primordial element of p53 activity.  
A.III.2.a. MDM2, the headman.  
  In a wide range of non stressed cells bearing a wild type p53 protein, its half life 
is included between 6 to 20 min, which is very short. This is due principally to its 
interaction with MDM2 and its subsequent poly-ubiquitination and degradation by the 
proteasome. MDM2, also called hdm2, is an E3 ubiquitin ligase of the Really 
Interesting New Gene – RING – finger family. The RING domain permits the direct 
binding of ubiquitin enzymes resulting in mono or poly-ubiquitination of p53 (Itahana 
K et al. 2007). Although MDM2 is the principal E3 ligase that induces p53 degradation 
– underlined by the early lethality of the MDM2-/- mice due to p53 dependent apoptosis 
– other E3 ligase like Caspase Recruitment Domain-Containing Protein 16 – CRDCP16 
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or COP1 – Pirh2 and Arf-BP1 for example have been recently described to have a p53 
ubiquitination activity (Leng et al. 2003; Dornan et al. 2004; Chen et al. 2005). 
Therefore, it is not surprising to found several regulators of the p53-MDM2 interaction, 
such as p19
 ARF
 or HAUSP (Zhang et al. 2003; Dai and Lu 2004; Li et al. 2004). 
Inversely cofactors can act negatively on p53 by promoting the MDM2-p53 interaction. 
In first line MDMX – also named MDM4 – stabilize both MDM2 and p53, increasing 
the ubiquitination and degradation of p53 (Meulmeester et al. 2005).   
  
A.III.1.b. Other p53 regulators 
 Beside cofactors that directly target MDM2 activity and binding to p53, multiple 
cofactors are involved in direct or indirect stabilization of p53. An updated list of p53 
posttranslational modifiers can be found at 
http://www.bnl.gov/biology/People/Anderson.asp. 
As discussed above, four principal kinases phosphorylate p53: ATM, ATR, 
Chk1 and Chk2. However the number of these kinases can be far extended. Most of 
these kinases have the particularity to be able to phosphorylate p53 at multiple sites, 
rising up the complexity of p53 regulation. In order to regulate the activation of p53 by 
phosphorylation, the action of phosphatases has been described. For example, the 
Protein Phosphatase 2 – formerly PP2A – and Protein Phosphatase Magnesium 
Dependant 1 variant 430 – PPM1D430 – carry on the dephosphorylation of Ser46 and 
Ser15 of p53 (Chuman et al. 2009; Mi et al. 2009).  
Histone acetylases are important regulators of p53 stability. Besides acetylation 
of p53 they also are involved in acetylation of the histones in the site of its target genes 
like CNP/300, Tip60 and hMof, thus synergically enhancing transcription (Gu et al.
1997). In addition, p300/CBP Associated Factor – PCAF – is another acetyltransferase 
of lysine 320 of p53 (Sakaguchi K et al. 1998). 
p53 can be deacetylated by Histone Deacetylase – HDAC – complexes 
containing HDAC1 or Sir2α/Sirt1 (Luo et al. 2000; Luo et al. 2001). Deacetylation 
represses p53 dependent transcription activation, and thereby apoptosis and growth 
arrest. In vivo studies showed the importance of Silent Mating-Type Information 
Regulation-2 ortholog 1 – Sirt1 – in mice as Sirt1-/- mice presented hyperacetylated p53 
and hypersensitivity to apoptosis following radiation. This study also suggests that 
acetylations can occur in non stressed cells and that acetylation/deacetylation 
mechanism is a dynamic event. 
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Deacetylation and dephosphorylation are quick-acting mechanisms and require 
little energy for the cells, on the contrary of the transcription mechanism. Therefore they 
are useful tools to stop p53 function when inputs signals are no longer present.  
p53 protein is also modified by less known processes like methylation, 
neddylation and sumoylation. To date, three different methyltransferases have been 
described. Set7/9 monomethylates p53 at Lysine372 and actives it, Smyd2 and Set8/PR-
Set7 act oppositely by monomethylation of lysines 370 and 382 (Chuikov et al. 2004; 
Huang et al. 2006; Shi et al. 2007). Once Lysines 370 and 382 are methylated, 53BP1, 
which is involved in DNA repair, strongly enhance its binding to p53. To note, a 
demethyltransferase has been described, the Amine Oxidase Flavin Containing Domain 
2 – LSD1 – that demethylates one of these lysines (Huang et al. 2007).  
Small Ubiquitin-like Modifier – SUMO – and Neural Precursor Cell Expressed, 
Developmentally Down-regulated 8 – NEDD8 – are ubiquitin-like proteins covalently 
linked to lysines. SUMO is both involved in p53 activation and repression whereas 
neddylation seems to be not completely defined but promotes p53 activity (Xirodimas et 
al. 2004; Abida et al. 2007). 
A.IV. p53 pathways 
There are many different outcomes to p53 induction characterized by hundreds 
of described responsive genes to p53 – for a review of characterized responsive 
elements of target genes and Figure 7 (Harris and Levine 2005; Riley et al. 2008). 
However the authors considered this list only as a partial p53 transcriptome and many 
p53 target genes are still to discover. Cawley et al. and Wei et al. identified between 
500 and 1600 potential target genes by ChIP based techniques, which let us consider a 
Dantesque task to integrate these new regulations to the previously existing p53 
database (Cawley et al. 2004; Wei et al. 2006).     
Once p53 is activated and bound to DNA it is able to activate transcription by 
different main events: The direct recruitment of the transcription machinery proteins: 
the TATA Binding Protein – TBP – and TBP Associated Factors – TAF – 6, 9 which 
will attract the RNA polymerase to the DNA, the recruitment of Chromatin Remodeling 
Factors – CRF – like the SWItch/Sucrose Non Fermentable – SWI/SNF – complex or 
Histone Acetyltransferase – HAT – or Methyltransferases – MT – like mentioned earlier 
and the recruitment of components of the mediator complex.  
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Contrariwise to the so-called p53 transcriptional activity, p53 repress significant 
number of genes. This can occur by three different means: binding site overlap of other 
transcription activators, squelching of transcriptional activators or recruitment of 
Histone Deacetyltransferases – HDACs – Serum Response Factors – SRFs – HATs and 
MTs (Laptenko and Prives 2006). Indeed p53 transcription repression does not 
necessarily require a p53 RE on the contrary to transcriptional activation. Finally, p53 is 
able to repress overall transcription by inhibiting the RNA Pol I, II and III promoters, by 
direct or indirect means (Zhai and Comai 2000; Gridasova and Henry 2005).  
This report will quickly overview principal pathways involved but also will 
described more precisely how p53 can affect angiogenesis.  
A.IV.1. Survival pathways
In vivo and in vitro studies showed that cells devoid of p53 expression are more 
sensitive to DNA damage than cells expressing wild type p53 (Xu et al. 1995; Wahl et 
al. 1996; Cote et al. 1997). This puzzling aspect of p53 has been later solved by 
Figure 7. Target genes of p53 and their related pathways. 
p53 is able to induce many different responses through its target genes. It acts by its transcriptional 
activity and its ability to bind key protein effectors. From (Harris and Levine 2005). 
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uncovering the ability of p53 to favour DNA repair. This with the ability of p53 to stop 
cell cycle progression constitutes the classical survival pathway. 
   
A.IV.1.a.Cell cycle 
Proliferating cells undergo a series of four different phases – G1, S, G2 and 
mitosis – composing the cell cycle during which DNA is duplicated – S phase – and 
cells divide – mitosis. DNA and cells integrity is checked after S phase and mitosis at 
cell cycle arrest – G2 and G1, respectively. The different steps of the cell cycle are 
strongly regulated by Cyclin Dependent Kinases at three checkpoints: G1/S checkpoint, 
S checkpoint and G2/M checkpoint. p53 is induced upon abnormal progression through 
the cell cycle. 
• G1/S transition checkpoint: 
Under normal growth conditions, progression through G1 is promoted by D-type 
and E-type cyclins and their associated Cyclin Dependent Kinases – cdk2, cdk4, and 
cdk6. If DNA is damaged, Chk1 and ChK2 kinases are activated and transfer the signal 
to p53, which induces p21WAF1/CIP1, a Cdk inhibitor (Herold S et al. 2002). p21 
sustains G1 arrest by inhibiting cdk2 and cdk4 activities. While p21 is the primary 
regulator of p53-mediated G1 arrest, other p53 target genes are also involved in 
maintaining G1 arrest, such as B-cell Translocation Gene 2 protein – BTG2 – and 
Growth Arrest and DNA Damage 45 – GADD45.  
• S phase checkpoints: 
When S phase takes place, DNA alterations occur. However this phenomenon is 
in part physiological as replication is imperfect. At least two checkpoints protect the cell 
during this vulnerable time: the intra-S checkpoint and the replication checkpoint. The 
intra-S phase checkpoint is activated when DNA damage occurs during S phase. 
Likewise G1/S checkpoint, ATR-ATRIP heterodimer and ATM are recruited at site of 
DNA lesions, activates Chk1-Chk2 and these kinases induce a halt in DNA replication 
by blocking the binding of Cdc45 to chromatin that normally enhances DNA pol- into 
pre-replication complexes (Lukas et al. 2004). Although p53 is phosphorylated and 
stabilized by ATR and Chk1, p53 does not appear to have a major contribution to S 
phase arrest. 
• G2/M checkpoint: 
The G2/M checkpoint is essential for cell fate because it controls normal 
progression to mitosis. It mainly prevents segregation of damaged chromosomes. In 
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order to sustain G2/M arrest, Cdc2-cyclinB activity must be inhibited. In this respect, 
p53 regulates many target genes that play critical roles during G2/M arrest. For 
example, p53 induces p21 which blocks G2/M progression by binding the Cdc2-cyclinB 
complex and preventing the phosphorylation of Cdc2 at Thr161 by CDK-Activating 
kinase – CAK – (Smits et al. 2000). p53 also induces 14-3-3σ which blocks entry into 
mitosis by promoting Wee1 kinase activity, and sequestering Cdc25C phosphatase in 
the cytoplasm. Moreover, other p53 targets such as GADD45, BTG2, REPRIMO, have 
been implicated in the maintenance of the G2/M checkpoint. 
A.IV.1.b DNA repair 
As there are multiple damaging events that can cause DNA to be altered, and 
multiple consequences in term of DNA alteration, DNA repair involves a broad range of 
elaborated mechanisms to recover DNA integrity. Five principal pathways are required: 
the Nucleotide Excision Repair – NER – the Base-Excision Repair – BER – and the 
Mismatch Repair – MMR – that consecutive of SSBs and the Non-Homologous End-
Joining – NHEJ – and the Homologous Recombination – HR – that follows DSBs. p53 
inhibits HR on the contrary to the four others – for complete reviews see (Sengupta and 
Harris 2005; Helton and Chen 2007). Interestingly p53 is a general activator of DNA 
repair by increasing the chromatin accessibility to DNA Repair involved proteins 
(Rubbi and Milner 2003). 
A.IV.2. Cell death pathways
The two best described pathways in which p53 is involved are cell cycle arrest 
and apoptosis. It is widely accepted that induction of cell death pathways are consequent 
to a threshold in p53 activation following stress signals. 
  A.IV.2.a. Apoptosis 
As well as cell cycle arrest, apoptosis implies the induction of a large set of 
genes that are responsive to p53 induction: p53 Upregulated Modulator of Apoptosis – 
PUMA – Noxa – latin for damage – Bcl-2-Associated X protein – BAX. Apoptosis can 
be divided by two sub-pathways both involving p53: the intrinsic and the extrinsic 
pathways. 
The intrinsic pathway is induced by transcription activation of BH3-only 
proapoptotic like PUMA, NOXA and BH3 Interacting Domain Death Agonist – BID – 
B-cell Lymphoma 2 – BCL-2 – family proteins like BAX protein or Actin Filament-
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Associated Protein-1 – AFAP-1. PUMA and NOXA sequester the antiapoptotic 
associated proteins BCL-2 or BCL-XL and thus release the pro-apoptotic proteins BAX 
and BAK. BAX and BAK can oligomerize and form a pore in the mitochondrial outer 
membrane releasing among others the cytochrome c from interstitial membrane 
compartment. Once in the cytoplasm, cytochrome c forms a complex with several 
monomers of APAF-1 and procaspase-9 to constitute the apoptosome. Activated by 
ATP, the apoptosome cleaves and activate procaspase-3, 6 and 7 leading to DNA 
fragmentation and generation of apoptotic bodies – for a review see (Fridman and Lowe 
2003; Danial and Korsmeyer 2004). 
In addition to its transcriptional activity, p53 uses transcription independent 
activation for its ability to bind directly BCL-2 and BCL-XL proteins in mitochondria.  
The extrinsic apoptosis pathway involves the activation of transmembrane 
receptors, the well named Death Receptors – DR4 or DR5. Their intracellular death 
domain clusterizes with other death receptors and recruits the adaptator Fas-Associated 
Death Domain – FADD – and procaspase 8 and 10 – initiator caspases – forming the 
Death Inducting Signaling Complex – DISC. Procaspases 8 and 10 are cleaved and 
activated which in turn activate the caspase 3, 6 and 7. Although the main ligand of 
these DR is the p53 independent ligand Apo2L/TRAIL, p53 can induce the transcription 
of the Fas ligand gene TNF Ligand Superfamily member 6 – TNFSF6 – the DR 5 and 
Fas/CD95 death receptor genes. Therefore, p53 sensitize the extrinsic pathway, 
enhancing the susceptibility to the environment.   
A.V. p53 family  
In addition to the p53 gene, two other genes with a similar structure and 
phylogenetically conserved have been discovered: p63 and p73 genes (Kaghad et al.
1997; Yang et al. 1998). In invertebrates only one p53 gene exists, suggesting a 
triplication of the gene during evolution (Yang et al. 2002). Despite the genetic 
redundancy between p53, p63 and p73 sequences, each one of these gene have specific 
patterns of target genes. The profile of p63 and p73 isoform expression has been 
predominant to reconsider the p53 isoform expression.   
A.V.1. p63 and p73 family genes.
A.V.1.a. p63 gene. 
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In 1998 Yang described the p63 gene which bears strong homology with p53 
and p73 genes – Figure 8 (Yang et al. 1998). Osada et al. discovered it in the same time 
and named it p51 but only p63 lasted (Osada et al. 1998). This last group found p63 
able to transactivates p21 and induce cell arrest and apoptosis. Present in human and 
mouse tissues, p63 encodes multiples isotypes that can interplay with p53 modulating 
its transcriptional activity. N-truncated isoforms seem to be predominant in epithelial 
cells. Human p63 consists in three different C-terminal splicings – // – and an 
internal promoter in the intron three – respectively TAp63 and Np63 for full length 
and truncated p63 isoforms. If TAp63 isoforms have transactivating activity, Np63
which is the most expressed isoform between truncated spliced isoforms, contains a 
specific short transactivating domain in N-terminal which can inhibit cell proliferation, 
induce cell death, and up-regulate GADD45, p21 and others (Helton et al. 2006).  
A.V.1.b. p73 gene. 
In 1997, Kaghad discovered a p53 related gene: p73 – Figure 9 (Kaghad et al. 1997). 
The p73 locus is also frequently deleted – but barely mutated – in cancer and 
particularly in neuroblastoma. They showed that p73 transactivates some p53 target 
gene such as p21 and is able to bind p53. The pattern of isoform is conserved in p73 
gene, although the number of resulting isoforms is much bigger, giving a more complex 
map. The p73 gene expresses at least 7 alternatively spliced C-terminal isoforms – , , 
Figure 8. Structure of p63 gene and its isoforms. 
Scheme of the human p63 gene – A - and proteins – B. From (Murray-Zmijewski et al. 2006). 



Np63
TAp63
A. 
B.
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, , ,  and  – and at least 4 alternatively spliced N-terminal isoforms, which contain 
different parts of the TAD. Altogether, the p73 gene expresses at least 35 mRNA 
variants which can encode theoretically 29 different p73 protein isoforms. An additional 
sterile alpha motif – SAM – within the C-terminal region, which is not present in p53, is 
also required for p63 and p73 transcription factor activity. SAM-containing-proteins are 
involved in regulation of development and in differentiation. The exact molecular 
partners are consequences of this regulation are largely reviewed in Zawacka-Pankau et 
al. (Zawacka-Pankau et al. 2010). 
  
A.V.2. p53 isoforms
Until 2005 the structure of p53 gene was quite simple. In 1993 Chow identified 
an alternative splicing in the exon 9 by PCR amplification in a lymphoblastic leukemia 
cell line. This splicing was resulting from a deletion upstream the donor site to the exon 
9, creating a novel donor site (Chow et al. 1993). Many mutations and deletions modify 
significantly p53 gene structure leading to expression of abnormally spliced p53 
mRNAs in human cancers. 
The first alternative splicing of p53 in human was identified in 1987. 
Matlashewski et al. showed an alternative splicing at the acceptor site in intron 2 
TAp73
Ex2p73 
Ex2/3p73 
N’p73 







Figure 9. Structure of p73 gene and its isoforms. 
Schema of the human p73 gene – A - and proteins – B. From (Murray -Zmijewski et al. 2006).
A. 
B.
Ex2p73 
Ex2/3p73 
Np73 
Sche e of the human p73 gene – A - and proteins – B. From (Murray-Zmijewski et al. 2006). 
27 
resulting in an altered 5' end coding region named EIIp53 (Matlashewski et al. 1987). 
They did not however associate it with the expression of an alternative isoform.  
 Indeed the first isoform has been described in 1996, Flaman et al. showed that 
p53 gene was submitted to an alternative splicing in the exon 9 in lymphoblastic cells 
(Flaman et al. 1996). The resulting new mRNA contained an additional 133 bp exon 
which is translated into an isoform lacking the p53 tetramerization domain and failed to 
bind DNA. This isoform was upregulated in quiescent cells.  
In 2002 Yin et al. found that in response to DNA damage treatment, mdm2 
induces the expression of an isoform of p53 of 47 kDa (Yin et al. 2002). This isoform 
called p53/47 comes from the alternative initiation of translation in the exon 4 does not 
contain the mdm2 binding site and thus is not sensitive to mdm2 proteasomal induction. 
In the same year Courtois et al. described the same isoform – called DNp53 – and found 
the same characteristic regarding mdm2 binding and showed that this isoform 
negatively regulates p53 transcriptional activities (Courtois et al. 2002). They also 
demonstrated that DNp53 is accumulating in serum starved conditions and phase S but 
not in response to DNA damage, suggesting a cell cycle regulator of p53. Another 
group further characterized this isoform demonstrating it shuttles between cytoplasm 
and nucleus during cell cycle (Ghosh et al. 2004). 
In 2005 our group discovered and characterized nine isoforms of p53 (Bourdon 
et al. 2005). The presence of alternative splicings was already pointed out in the 
precedent studies but also in the studies concerning p63 and p73. However no internal 
promoter was found yet in human p53. In the same year, Chen et al. in collaboration 
with our group showed that the zebrafish p53 gene contained an internal promoter 
allowing the expression of the 113p53 isoforms and possessed the same gene structure 
(Chen et al. 2005). The work of our group revealed the presence by mRNA Capped 
specific RT-PCR of several new isoforms which structure was present as well in 
Drosophila. In fact, p53 has a similar gene structure to its homologs p63 and p73. It has 
two alternative splicings in the exon 9 that allow the expression of ,  and  isoforms, 
and an internal promoter in intron 4 that defines the expression of the 133p53 
isoforms. Importantly p53 isoforms are differentially expressed in human normal 
tissues. Finally we confirmed the presence of an alternative initiation of translation site 
in exon 4, 40 codons after the first start codon. This latter isoforms named 40p53 
isoforms are the one characterized by Courtois and Ghosh groups – named p53/47 or 
DNp53. These 9 nine isoforms are schematically represented in Figure 3. Rohaly at al. 
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described another isoform resulting from skipping exon 8 and expressing the p53 
isoform (Rohaly et al. 2005). This isoform is also expressed in normal human tissue and 
activated following UV treatment. They also showed p53 was able to induce p21 and 
14-3-3	 but not MDM2 nor BAX and did not tetramerize with p53. However the results 
found by this group were not confirmed by others (Chan and Poon 2007; Garcia-Alai et 
al. 2008). We did not  detect it neither in normal tissues, nor in couples of tumour 
tissues, as well as other groups (Anensen et al. 2006; Goldschneider et al. 2006; 
Boldrup et al. 2007; Bourdon 2007)  
A.V.2.a. 40p53 isoforms 
Since its discovery 40p53 is the subject of much interest because it has been 
shown to modulate significantly and depending strongly on cell cycle and specific 
stresses. Indeed p53/47 – or 40p53 – translation is controlled by an alternative 
mechanism of initiation of translation called IRES (Candeias et al. 2006; Yang et al.
2006). Through cytotoxic agents such as platinum derived complex LA-12 this isoform 
is able to induce apoptosis (Hrstka et al. 2008). They also showed that this isoform can 
enhance p53 transcriptional activity – to p21 for instance – by forming tetramer 
insensitive to MDM2 binding (Powell et al. 2008). Finally they showed that 40p53 is 
translationally activated by endoplasmic reticulum stress and induces G2 cell cycle 
arrest (Bourougaa et al. 2010). An interesting review focuses on the role of translation 
mechanisms on p53 and its isoform 40p53 (Grover et al. 2009) 
 A.V.2.b. Full length p53 spliced isoforms.  
This paragraph will mainly focus on the p53 isoform as little is still known 
about the p53. It is maybe due to its lack of stability, as we observed experimentally – 
unpublished data.  
Our group has shown that endogenous p53 bind preferentially BAX promoter 
and poorly MDM2 promoter and has partial pro-apoptotic activity. p53 is able also to 
form complexes with p53 and modulates p53 activity. Further more, we raised a specific 
antibody specific to p53 – KJC8.  Another study by our collaborators Fujita et al.
confirmed this first work (Fujita et al. 2009). It showed the implication of p53 in 
senescence as its expression level increased with the number of cell passages – at 
replicative senescence – in normal human fibroblast strains – MRC-5 and WI-38. When 
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overexpressed, p53 inhibited cell proliferation and induced cell senescence probably 
by increasing p21 and miR34 expression.  
 A.V.2.c. 133p53 isoforms 
133p53 isoforms are expressed as three different splices – 133p53, 
133p53β and 133p53. 133p53 is expressed in a wide range of normal human 
tissues, while 133p53β and 133p53 are expressed in few normal human tissues 
(Bourdon et al. 2005). Thus when I will term 133p53 I will refer mainly to 133p53
although in most cases segregating between them is still not technically possible. One 
important aspect of 133p53 has been revealed by our work in 2005: overexpression of 
133p53 inhibits p53 mediated apoptosis after co-transfection in a p53 null cell line. So 
this protein is considered as negative dominant to p53. Consistently our collaborators 
Fujita et al. showed that 133p53 is able to inhibit senescence and is downmodulated in 
senescent human fibroblasts (Fujita et al. 2009). 113p53, the counterpart in zebrafish 
of 133p53 in humans, bears interestingly activities that could help us to understand 
133p53 ones. Indeed, 113p53 depletion by morpholinos injection in zebrafish 
embryos sensitizes embryos to p53 dependent apoptosis after ionizing radiation (Chen 
et al. 2009). More importantly this work reinforced our first hypothesis of a dominant 
negative effect and also suggested a role as a modulator of p53 response. They showed 
that 113p53 has its own intrinsic activity and transactivates BCL-XL gene in a mutant 
p53 context.  
 A.V.2.d. p53 isoforms in tumourigenesis 
One thing is to characterize p53 isoform in cell line models and in vitro but 
revealing the importance of these isoforms in the development of cancer is truly 
essential. In breast cancer, p53 gene is mutated only in 25% of the cases; suggesting that 
p53 is inactivated by alternative pathways. Consequently, we first identified strong 
differences in the p53 isoform expression profile between normal breast tissue and 
tumour tissue. We showed that there was a loss of p53 expression – 60% of the cases – 
and an overexpression of 133p53 forms – 40% of the cases – in breast cancer. These 
results strongly suggest that abnormal expression of p53 isoforms explain the low 
percentage of p53 mutation in breast cancers. 
Anensen et al. analysed the modifications in p53 expression profile in acute 
myeloid leukemia – AML – and showed a strong expression of an unidentified p53 C-
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terminal truncated isoform – more important than the full length p53 – in AML 
(Anensen et al. 2006). After 4 hours treatment of chemotherapy the ratio between p53 
and this isoform increased drastically.  
 Boldrup et al. investigated the p53 expression profile in human head and neck 
tumours (Boldrup et al. 2007). They found strong variations between tumour samples, 
non tumour samples surrounding the tumour and non tumour samples. Marabese et al.
analysed by quantitative PCR the levels of expression of 133p53, 40p53 and p53 in 
phase I and phase III ovarian cancer. They first found comparable levels between each 
set of isoforms and no differences between phase I and phase III cancers.  
 In melanoma cells and primary tumours, Avery-Kiejda et al. investigated the 
p53 expression profile and found expression of p53 and 40p53 in tumour cells but 
not in normal cells (Avery-Kiejda et al. 2008). They also found a variation of 133p53 
expression between normal and tumour cell lines, and a general change in p53 
expression profile suggesting an involvement of p53 isoforms in melanoma malignancy. 
 Renal cell carcinoma – RCC – has been also the subject of investigations. Song 
et al. analysed quite exhaustively the p53 expression profile in normal and tumour 
samples and cells (Song et al. 2009). They found that RCC and normal renal cells 
expressed all p53 isoforms apart from the 133p53 which is not expressed in normal 
cells. They also found an overexpression of p53 in cancer suggesting a role for this 
protein.  
 Fujita et al, besides their approach in senescence modulation by 133p53 and 
p53 isoforms, analyzed the expression of these proteins in colon adenomas and 
carcinomas and correlated a senescent phenotype with increased 133p53 and 
decreased p53, indicating the overcome of this latter phenotype.
 The few reports we have just looked upon show us two main informations 
regarding p53 expression profile in cancer – For a summary of p53 isoform expression, 
see Table 1. First the profile can vary depending on the tumour type and stage. Second, 
the scientific tools available to investigate the p53 isoforms are not sufficient enough to 
specifically analyse p53 isoforms expression in relation to clinical markers and clinical 
outcome. For instance by nested PCR we are able to identify specifically the presence of 
each p53 isoforms. However, it would be much more informative to quantify 
specifically the expression level of each isoform. Nevertheless, we can definitely 
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confirm the importance of the p53 isoforms regarding the present clinical data in several 
cancer tissues.  
Likewise, Chen et al. investigated the p53 isoforms activities during embryogenesis in 
zebrafish. They determine that p53 isoforms play an important role during development 
by inhibiting p53 mediated apoptosis. These findings suggest that p53 isoforms have 
biological activities beyond carcinogenesis. Therefore, Prives and Manfredi had the best 
word to summarise in what the discovery of these isoforms had contributed to the entire 
p53 world: “more sleepless nights ahead” (Prives and Manfredi 2005). 
--+/-+/-++ (Boldrup et al. 2007)Higher statistical p53
expression
Normal tissue from
head and neck
+-ND++ND(+)Stomac
+-ND++ND(+)Tyroid gland
+-ND++ND(+)Intestine
--ND--ND(+)Fetal liver
+--+-+Squeletal muscle
+--+-+Prostate
(Bourdon et al. 2005)Expression of 133p53 and 
loss of p53
---+++Breast
+--+++Uterus
NDND+NDND+Thymus
NDND+NDND+Adrenal gland
NDND+NDND+Placenta
--+-++Spleen
--+--+Lung
+-+--+Spinal chord
--++++Salivary gland
--++++Heart
+++-++Fetal brain
--++-+Brain
(Song et al. 2009)Overexpression of p53 and 
Expression of 133p53
+-++++Kidney
+++-++Testis
++++++Bone Marrow
(Fujita et al. 2009)Overexpression of 133p53
and downregulation of p53
in transition from adenoma to 
carcinoma
++++++Colon
ReferenceCancerTissue
133p53p53
From (Bourdon et 
al. 2005)
Table 1. Expression of p53 and its isoforms in normal tissues and cancers. 
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B. Angiogenesis  
Angiogenesis is a physiological process involving the growth of new blood 
vessels –BVs – from a pre-existing network. In contrast vasculogenesis describes the 
formation of new BVs from the differentiation of circulating endothelial progenitors 
known as angioblasts. Vasculogenesis mainly occurs in the embryo resulting in the 
formation of the primordial systemic complex of vasculature which has to be effective 
before the start of heartbeats. On the contrary angiogenic processes only occur after 
vasculogenesis and consist in remodeling of vasculature to readapt the blood circulation 
system to the constant and enormous changes that will occur until maturity. 
B.I. Circulatory system 
The circulatory system is a unique organ system composed by the cardiovascular 
system which includes the heart, arteries, capillaries and veins, and the lymphatic 
system which carries lymphatic vessels, nodes and the thoracic duct.  
B.I.1. Structure and functions of the blood vessels. 
The cardiovascular system is a typical asymmetric organ devoted to supply 
effectively and continuously the tissues with oxygen and nutrients throughout the body 
and to collect the metabolic waste like carbon dioxide. The arteries are the efferent BVs 
from the heart whereas the veins are the afferent ones.  
B.I.1.a. Arteries and Veins 
This implies that arteries must be extremely resistant to the variations of blood 
pressure and flow induced by the contraction of the heart. To overcome this pressure 
arteries adjacent to the heart possess a thick wall containing elastin – 40% – and Smooth 
Muscle Cells – SMC – in the tunica media. Consequently to the decrease of blood 
pressure arteries – elastic arteries – give rise to thinner walls devoid of elastin – 
muscular arteries –arterioles and finally capillaries. They make a bridge between 
arteries and veins. Similar in structure, veins are however characterized by thinner walls 
containing only few elastin and SMCs. In order to avoid backflow due to gravity and 
lack of pressure, veins contain bileafvalves in the lumen. 
Since arteries and veins are subject to different constraints and differ in their 
functions, molecular pathways have been elucidated to understand the underlying 
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mechanism of arterio-vascular identification – Figure 10. Principally, arterial cells 
specifically express the gap junction proteins Connexin-37 and 40 – Cx37 and Cx40 – 
components of the Notch pathway – Dll4 – Vascular Endothelial Growth Factor – 
VEGF – co-receptor Neuropilin-1 – NRP1. On the other hand, venous cells specifically 
– or at least predominantly – express the co-receptor Neuropilin-2 – NRP2 – receptor 
VEGFR3, COUP Transcription Factor 2 – COUP-TFII – that negatively regulates the 
Notch pathway, and the Apelin receptor (Rocha and Adams 2009). 
Although arteries and veins show some structural, molecular and functional 
differences, they are both composed of three tunicae containing endothelial cells – ECs 
– SMCs and fibroblasts – Figure 11. 
B.I.1.a.. The tunica intima and endothelial cells.  
This is the internal and thinner tunica. It is composed of a monolayer of ECs 
recovered by a vascular basal membrane – subendothelial layer.  
- The endothelial cell layer is polarized. On the contrary to the apical side in 
contact with the blood stream, the basal side in contact with the basal membrane is pro-
thrombogenic and secretes procoagulating molecules: Collagen IV and the Von Hippel 
Factor – pVHL. Tumour cells are thought to enhance a pro-coagulation stage that 
favours metastasis in certain types of tumours (Maragoudakis et al. 2000). 
  - The endothelium regulates the arterial vasomotricity by vasodilatating 
molecules like endothelin or thromboxane A2 or vasoconstricting factors like NO. 
These components act upon the internal parts of the artery and principally to the SMCs. 
 - It allows blood cells and components to penetrate and reach the internal layers 
of the artery, to ensure the nutrition and the defence of these cells. 
Figure 10. Arteries, veins, capillaries and thier specific markers.
A. Arteries are represented in red, veins in blue and EC of the capillary bed in grey. Pericytes 
partially covering the capillaries are colored in yellow. Structure of SMCs in blue and red show a 
strong difference in morphology. B. Markers of arteries and veins can either be specifically 
expressed in one compartiment or be differentially expressed. From (Rocha and Adams 2009). 
B.A.
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The endothelium has a strategic localisation in vessel wall due to its functions of 
communication between the blood and the circulatory system and the other parts of the 
vessel wall. Finally, the endothelium maintains the blood vessel in a vasodilatation, non 
proliferating state and block inflammatory cells to adhere. Upon activation ECs induce 
vasoconstriction, blood platelet and monocytes adhesion and proliferation of SMCs.   
B.I.1.a.. The tunica media and the smooth muscle cells. 
The media is constituted by concentric layers of SMCs forming the thick internal 
part of the artery, lined by an internal and an external elastin layer. Each layer is 
surrounded by an extracellular matrix containing fibrous proteins and – in elastic 
arteries – elastin. Arterioles display only one layer of SMCs. While elastic arteries dilate 
and passively shrink on each blood pulse from the heart, muscular arteries function to 
respond to their afferent tissue demands.  
Figure 11. Structure and organization of Arteries, Veins and Capillaries
This schema drows differences and similarities between arteries and veins. Both bear sequently a 
layer of ECs, a basal membrane, the tunica media consistuted of SMCs and elastin and the  tunica 
externa – or adventitia – constituted of fibroblasts in majority. From (Tortora and Grabowski 2003).
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B.I.1.a.. The tunica adventitia and the fibroblasts. 
Although the adventitia is composed of a majority of fibroblasts within a 
connective tissue rich in collagen and elastic fibers, many different cell types are 
encountered in this external layer. Recent experimental evidence has identified fetal and 
adult arterial and venous vessel walls as niches for stem and progenitor cells such as 
endothelial and smooth muscle progenitor cells, hematopoietic stem cells and 
mesenchymal stem cells (Tilki et al. 2009) and adipocytes. The adventitia and the media 
are irrigated by the vasa vasorum. 
   B.I.1.b. The capillary network 
This latter only exhibits ECs, a basal membrane and sparse pericytes partially 
covering the endothelial cell vessel. Pericytes and SMCs can be distinguished by several 
markers like -actin, desmin and Platelet Derived Growth Factors – PDGFR- – 
(Gerhardt and Betsholtz 2003). Pericytes are closely linked to the endothelial basal 
membrane and to several ECs by gap and “peg-socket” junctions and synergize EC 
communication (Caruso et al. 2009). Besides to capillaries, pericytes are located in the 
pre-capillar arterioles, the veinules gathering points and the post-capillar veinules.  
The second population of cells in capillaries exhibits also different morphology 
depending on the organ. Three different types of endothelial cell walls can be 
encountered:  
- Continuous capillaries constituted by firm lining of strands of tight junctions 
with rare intercellular clefts. They are found in skeletal muscles, lungs, gonads, and 
skin. A more sophisticated version includes specific transporters for glucose, amino 
acids, and other substances. These latter capillaries are found in central nervous system 
and form the brain-blood-barrier.  
- Fenestrated capillaries: ECs of endocrine glands, pancreas, intestine, kidney 
glomeruli and liver sinusoids contain small – 60-70 nm in diameter – but densely 
clustered pore-like openings permitting only small molecules and limited amount of 
proteins to diffuse.  
- Sinusoidal or discontinuous capillaries are present for instance in the liver, 
spleen, bone marrow and the lymph nodes. They are constituted by larger pores – 30-40 

m in diameter – that allow red and white blood cells to cross over as well as some 
serum proteins.  This structure helps the transfer of metabolites between blood vessels 
and tissues. 
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B.I.2. The lymphatic system
B.I.2.a. Role of the lymphatic network  
In contrast to the blood system the lymphatic system is a one way system that 
drains the excess of liquids – lymph – antigens and macromolecules like fatty acids 
from every tissue in the whole body to the lymphatic tissue and nodes, to finally be 
rejected into the left and right subclavian veins. This draining is an important task that 
ensures oncotic equilibrium of the interstitial space. The lymphocytes are also 
transported in the lymphatic system and produced by the lymphoid organs like the 
thymus, the spleen and the bone marrow. The lymph is a vector for immune cells to 
amplify their response in the lymph nodes and then get back to the blood system. The 
lymphatic system is primal target for metastasis dissemination because first of its 
intrinsic collecting function and also by the leaky structure of the blind-ended lymphatic 
endothelial capillaries. 
The Lymphatic ECs – LECs – constitute a monolayer of ECs that are not 
wrapped by any pericytes nor SMCs and does scarcely or not have basement membrane. 
The structure features of the lymphatic capillaries i.e. discontinuous junctions and 
interjunctional gaps makes it highly permeable and enables leukocytes entry (Tammela 
and Alitalo 2010).  
As well as blood vessel veins, lymphatic vessels contains bileaflat intraluminal 
valves to prevent lymphatic backflow. Besides the monolayer of ECs and the basal 
membrane, collecting lymphatic vessels possess a layer of SMCs and also an adventitia 
that contains connective tissue and fibroblasts. On the contrary of the common belief, 
lymphatic vessels demonstrate regular, strong, fast phasic contractions implying both 
lymphatic pumping and flow resistance (Muthuchamy and Zawieja 2008).  
B.I.2.b. Tumour Lymphangiogenesis 
Lymphangiogenesis, the growth of new lymph vessels, is involved in the adult in 
tissue inflammation, wound healing, and tumour metastasis – Figure 12. Tumour cells  
disseminate first through the lymphatic system via sentinel lymph nodes in various 
types of cancer like breast, colon and prostate carcinomas. It is thought that even prior 
to tumour metastasis dissemination to the whole body, tumour cells engage their 
remodeling and their settlement in the sentinel lymph nodes (Qian CN et al. 2006). It is 
currently discussed to know whether this step of dissemination is just a hallmark of 
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tumour transit towards the next organs or if it plays a role in amplification for systemic 
metastasis (Joyce and Pollard 2009). 
B.II. Physiologic and pathologic angiogenesis. 
In healthy adults, angiogenesis occurs in physiological changes such as the hairy 
skin and the female reproductive system, e.g. in the ovary, in the uterus, in the placenta 
and development of the mammary gland during pregnancy. Otherwise, vascular 
development in the adult is linked to tissue repair and clinical disorders like wound 
healing and tumour growth, rheumatoid arthritis, diabetic retinopathy and psoriasis 
(Folkman 1971; Folkman 1995; Plendl et al. 1999; Plendl 2000; Tamanini and De 
Ambrogi 2004; Nagy et al. 2007; Schenone et al. 2007). The formation of these BVs is 
mastered by a sophisticated balance of numerous pro and antiangiogenic molecules that 
non solely inhibit or activate angiogenesis but prime a set of various processes that will 
lead to a mature and efficient new blood organization, or lead to the regression of the 
overall vasculature. 
 B.II.1 The angiogenic switch
 In normal conditions, the maintenance of steady blood and lymphatic vessels is 
provided by the balance of proangiogenic and antiangiogenic factors released by the 
microenvironment. In fact, antiangiogenic factors are thought to be responsible of the 
quiescent state of the ECs whereas proangiogenic factors can activate ECs. In some 
pathological conditions like in cancer, the overall balance is modified – irreversibly – to 
Figure 12. Dissemination and metastasis through blood and lymphatic vessels.
While blood vessels expand their network towards the tumour, lymphatic vessels also develop new 
vessels that will help the draining of the microenvironment and the dissemination of cancer cells. 
Indeed in priority to invasion of blood vessels, cancer cells evade the tumour niche by the lymph and 
can cause lymph node metastasis and secondly to other organs. From (Avraamides et al. 2008). 
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obtain an induction of blood vessel formation. Many growth factors, cytokines and 
other extracellular matrix components like the VEGF, Fibroblast Growth Factor 2 – 
FGF-2 – angiopoïetins, Platelet Derived Growth Factor - PDGF - and Transforming 
growth factor – TGF - are involved in this process. They and others will be discussed 
further in this essay. Besides these molecular modulations, metabolic stresses – 
hypoxia, hypoglycemia or acidosis for instance – mechanical stress and shear stress or 
inflammatory response can induce an angiogenic switch (Carmeliet and Jain 2000). 
 Yet this angiogenic switch is a paramount step of tumour progression and 
transformation. If a tumour raises a certain size – 1 to 2 mm3 – and does not have 
sufficient oxygen and nutrient supply, it becomes quiescent or necrotic and even 
apoptotic (Holmgren et al. 1995; Parangi et al. 1996). In fact, some of these tumours – 
also called micrometastases because of their size – that are not malignant enter either a 
dormant state in which their mutagenic capacity is blocked or have a division/death 
ratio that does not permit the tumour to grow. These tumours can be present all over the 
body and do not induce cancer until they escape dormancy by stimuli like genetic 
mutations, hypoxia and other metabolic stresses, mechanical stress, and the 
immune/inflammatory response (Carmeliet and Jain 2000). Unfortunately, surgical 
removal of the primary tumour in breast is often correlated with shortening of dormancy 
and promotes the growth of micrometastasis (Demicheli et al. 2008). These data are 
reinforced by the fact that only a local burst of angiogenic factor is able to irreversibly 
switch on the dormant tumour leading to tumour growth and metastasis (Indraccolo S et 
al. 2006).  
B.II.2. Steps of blood vessel formation.
Various mechanisms involve the remodeling and the neovascularization of BVs 
commanded by the microenvironment in response to physiological activities or 
pathological stresses, followed by a step of maturation – also called resolution step - and 
recruitment of peripheral blood cells such as smooth muscle cells  Here are presented 
the common mechanisms observed in angiogenesis. 
B.II.2.a. Sprouting angiogenesis 
Sprouting angiogenesis is described as the prevalent event and best characterized 
event of angiogenesis – Figure 13 (Gordon et al. 2009). The release of proangiogenic 
factors like VEGF into the surrounding stroma causes the activation of the remodeling 
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the vasculature prior to the formation of new BVs. Indeed the multi-layered structure of 
blood vessels is disrupted by the detachment of pericytes and SMCs from the ECs, 
dilatation of blood vessel wall, increase of vascular permeability by the redistribution of 
adhesion molecules like Platelet Endothelial Cell Adhesion Molecule-1 – PECAM-1 – 
and Vascular Endothelial-cadherin – VE-cadherin – and loosening of the extracellular 
matrix. Proteases embedded in the extra cellular matrix – ECM – such as Urokinase 
plasminogen activator – uPA – heparanases, metalloproteases or growth factors like 
FGF-2 are released and now able to degrade the basal membrane of the endothelial layer 
and create permissive intercellular space for circulating ECs. In the same time, 
plasmatic proteins – Angiopoïetin-1, FGF-2, and VEGF – guide EC through out the 
interstitial matrix. One of them is activated and will guide the growing sprout by 
making filopodia and lengthen itself in the direction of the stimulus: it is the capillary 
tip cell. It migrates and forms a cone with a layer of EC underneath – the stalk cells – 
the whole forming a cavity and a lumen. In physiological angiogenesis, selection of tip 
cells and hierarchy between tip and stalk cells is achieved by a cunning Notch-DLL4 
regulatory pathway and by ECs crosstalks. On the contrary tumours models cause 
Notch-DLL4 inactivation and induce excessive sprouting and branching of BVs 
(Suchting et al. 2007). Maturation of the blood vessel is achieved by mural cells and 
synthesis of the ECM.  
  
Figure 13. Steps of sprouting angiogenesis
Upon angiogenic stimuli via 
proangiogenic factors like 
VEGF and FGF-2 certain 
ECs activate their sprouting 
program and lead the for-
mation of new blood ves-
sels. These “tip cells” extra-
vasate, form filopodia to 
allow motility, lengthen 
them and pull other ECs 
with them. These are the 
stalk cells and have the 
ability to keep vessel inte-
grity and expend to form the 
lumen of the new vessel. Tip 
cells can meet and form a 
bridge, finalize the new 
blood vessel while new tip 
cells arise. From (Adams 
and Eichmann 2010).
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B.II.2.b. Intussusception. 
Intussusceptive angiogenesis is an alternative angiogenic phenomenon firstly 
described by scanning electron microscopy – Figure 14 (Caduff et al. 1986). Contrarily 
to sprouting angiogenesis it does not requires a large number of EC divisions and 
permits a fast remodeling of the environment. Preexisting vessels split into two new 
vessels by formation of a transvascular tissue pillar into the lumen of the vessel. This 
process can be divided into four steps: Opposite ECs make a “kissing contact”, 
reorganize to form a cavity between the EC layers, surrounding pericytes and SMCs 
migrate and cover the newly interstitial pillar. Finally the pillar extends its own 
diameter and allows separating the new vessels.  
Intussusception in tumour angiogenesis could explain the rapid BV remodeling 
(Djonov et al. 2001). This phenomenon relies on molecular events that are still not 
clearly understood but it has been noticed that shear stress – sensed by PECAM-1 – and 
blood pressure are key stimuli triggering intussusception. 
B.II.2.c. Recruitment of endothelial progenitor cells – EPC. 
Since the finding in 1997 of well characterized EPC in the blood stream and 
their implication in angiogenesis (Asahara et al. 1997), a lot of controversy is ongoing 
about the importance or predominance of the recruitment of EPC in relation to sprouting 
angiogenesis. A core aspect for the assessment of progenitor’s recruitment is the current 
availability of specific markers for each specific study and subtype of cells (Tilki et al.
2009). 
A. B. C. D.
Figure 14. Steps of intussusceptive angiogenesis
3D diagram illustrates steps of intussusceptive angiogenesis. Following stimuli like shear stress or 
mechanical pressure, blood vessels begin vessel division called intussusception – A. Opposite 
walls approach each other via protrusions of ECs towards the lumen – B. When each side meets 
they tighten the contact – C, which is followed by central perforations, where fibroblasts, pericytes 
and connective proteins such as collagens will lock and finalize the separation of vessels parts. 
From (Djonov et al. 2003). 
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The recruitment and the mobilization of EPCs from the bone marrow – 
compared to other origins – seem to be the prevalent and best described mechanism. In 
summary bone marrow endothelial progenitors are activated by VEGF, Placental 
Growth Factor – PlGF – Stroma Cell-Derived Factor-1 – SDF-1 – and angiopoïetin-1 
(Hillen and Griffioen 2007).  The recruitment and integration of EPCs implicates 
chemoattraction, anchoring, and homing within the angiogenic site, integration into the 
new vessel and differentiation into mature ECs. 
B.III. Tumour Angiogenesis. 
The growth of solid tumours is extremely dependent on nutrient supplies from 
the environment: they only grow until a size of 100 µm3 – around 4 to 7 layers of cells, 
depending of the type, from the closest blood vessel – using efficiently passive transport 
of nutrients and oxygen between cells. Beyond this size, tumours must start to trigger 
gradients of angiogenic stimuli pulling BVs towards the tumour spot. Without this new 
inflow, tumours can not overcome 1 to 2 mm3.  
 The principal difference between a physiologic angiogenic process – including 
wound healing – and tumour angiogenesis is the tight regulation of each factor that 
permit the elaboration of a functional, structured and matured BVs network. In contrast, 
the vasculature pointing at the tumour is under constant and overwhelming induction, 
conferring it a tortuous, extorted and dilated phenotype with dead ends. This vasculature 
is known to be poorly efficient, leaky and hemorrhagic (Bergers and Benjamin 2003). 
B.III.1. Tumour-related angiogenesis
The mechanisms described below perfectly underline the plasticity of some 
types of cancer cells in their capacity to resist and adapt to the lack of oxygen and 
nutrient supply. They are even able to redefine their nature and functions in order to 
keep on going or to resume the metastasis process despite the extremely challenging 
microenvironment. This rises up deep concerns on the strategy of antiangiogenic 
therapies and their efficiency in aggressive tumour models. More than all, strong 
knowledge and smart profiling of the tumour from each patient will be one solution for 
successful treatment. 
B.III.1.a. Vasculogenic mimicry – VM. 
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Firstly discovered in 1999 by Maniotis et al., it describes the capability of 
tumours cells to dedifferentiate and to form tube-like structures without a clear 
endothelial phenotype. Revealed by Periodic Acid-Shiff’s reagent – PAS – staining and 
negative CD34 ECs staining, VM has also been observed in many cancers (Shirakawa 
et al. 2002; Sharma N et al. 2002; Sood et al. 2000; Sun et al. 2004; El Hallani et al.
2010). Typical aggressive tumours show a reversion to a more undifferentiated 
embryonic-like phenotype expressing endothelial associated genes such as VE-cadherin, 
Ephrin A2 and tissue factor pathway inhibitors, tyrosine kinase receptor 1, neuropilin 1, 
E-selectin and endoglin (Hendrix et al. 2001; Hendrix et al. 2003). However the 
mechanism leading to formation of endothelial like tubes is still not understood.  
VM was shown to be an alternative mean in aggressive tumours to escape 
insufficient blood supply and to be stimulated by antiangiogenic strategies. 
Interestingly, canonical growth factors like VEGF, FGF-2 or Transforming Growth 
Factor  – TGF- – are not implicated in this phenomenon as they do not induce VM in 
non aggressive melanoma cell lines OCM-1A and UMEL-1 (Maniotis AJ et al. 1999). 
B.III.1.b. Cooption. 
Figure 15. Tumour angiogenesis mechanisms.
Principal mechanisms involved in tumour angiogenesis. If sprouting angiogenesis is considered as 
the main event, other mechanisms take part considerably in this phenomenon, depending on the 
tumour type. From (Hillen and Griffioen) 
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In highly vascularized tissues, tumour grows and cancer cells migrate next to 
blood vessels in order to be correctly supplied (Holash et al. 1999). By switching from 
the Ang-1 to the Ang-2/Tie-2 pathway tumour cells can induce regression of blood 
vessels and reduced blood perfusion. This mechanism induces necrosis of blood vessels 
that allows the tumour to grow furthermore, and hypoxia that will exacerbate the 
production of angiogenic factors like VEGF by tumour cells and facilitate the formation 
of new vessels. This type of angiogenesis underlies the heterogeneity of tumour samples 
: in the center the tumour is devoid of nutrient supply and is often necrotic (Holash et al.
1999) whereas the periphery of the tumour is responsible for the angiogenic activity.  
B.III.1.b. Mosaic vessels. 
Firstly described in 2000, Chang et al. baptized mosaic BVs as heterogenic BVs 
constituted by EC and tumour cells activated by natural killer cells, in colon carcinoma 
xenografts (Chang et al. 2000). It resulted in their study that 15% of vessels were 
mosaic vessels, forming 4% of the whole vasculature. However, the presence of tumour 
cells within the vascular network seems to be transient as it is consequent of tumour cell 
intravasation in the lumen that will stay briefly in the capillary wall. FGF-2 and VEGF-
A induced tumour cells intravasation (Folkman J. 2001)   
B.IV. Molecular signaling in tumour angiogenesis 
 B.IV.1. VEGFs
The VEGF family is composed of five mammalian cytokines, VEGF-A, VEGF-
B, VEGF-C, VEGF-D, and Placenta Growth Factor – PIGF – plus two viral VEGFs: 
VEGF-E and VEGF-F. VEGFs are homodimeric disulfide bonded glycoproteins that 
bind Heparan Sulphate Proteoglycan – HSPG – and three Tyrosine Kinase Receptors – 
TKR – VEGFR-1, VEGFR-2 and VEGFR-3 plus two co-receptors lacking the 
intracellular tyrosine kinase activity, NRP-1 and NRP-2 and an alternatively spliced 
VEGFR-1, soluble receptor VEGFR-1. To activate the transduction pathway VEGF 
dimers binds to TKRs that will dimerize and autophosphorylate. TKRs activation can 
induce angiogenesis, vasculogenesis or lymphangiogenesis. Each VEGF ligand has its 
own specificity with its respective TKR: VEGF-A, prominent amongst VEGF ligands 
and thus also called VEGF, induces angiogenesis and vasculogenesis through VEGR-2, 
which is ECs specific, whereas VEGF-C mainly induces lymphangiogenesis through 
VEGR-3 (Neufeld et al. 1999; Grothey and Galanis 2009).  
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B.IV.1.a. VEGF-A 
The splicing of the eight exons of the VEGF-A gene resulted in several isoforms 
with different angiogenic potentials. Alternative splicing of exon 6 – a and b – 7, 8 and 
proteolytic cleavage rise to anti and proangiogenic isoforms varying in their ability to 
bind HSPG and consequently to be present in ECM – Figure 16. In basal conditions 
overall VEGF-A expression is dominated by VEGF-Axxxb isoforms whereas their 
expression strongly decrease in pathological context (Harper and Bates 2008). VEGF-
Axxxb isoforms compete equally with VEGF-Axxx ones in the binding of VEGFRs but 
does not induce sufficient transduction activation and rather induce degradation of is 
VEGFRs.  
In human VEGF 165, 121 and VEGF 189 mainly constitute VEGF-Axxx isoforms 
and the ability to bind HSPG distinguishes them. From highly diffusible to completely 
bound are VEGF121, 165 and 189. The interest of sequestered VEGFs is to have a pull 
of available factors in situ that will be quickly functionally maturated either by uPA or 
plasmin is response to various aggressions.  
B.IV.1.a.. VEGF-A expression 
VEGF-A is constitutively expressed at low levels in normal adult tissues 
whereas it is recurrently overexpressed in several cancer types and constitutes one of the 
strongest diagnostic markers for evaluation of tumour gravity. This overexpression is 
the result of an adaptive behavior of the tumour in a stringent environment. Indeed, 
hypoxia is one important setting for VEGF overexpression. Under low level of oxygen, 
Figure 16. VEGF-A and VEGF-Axxx isoforms.  
All VEGF-A and VEGF-Axxx isoforms are synthesized from alternative splicings of exon 6, 7 and 8 
resulting in 12 isoforms. The most studied isoform up to now are the VEGF-A189, VEFGF-A165 and 
VEGF-A121, due to their proangiogenic potential and their differences in secretion, VEGF-A121 being 
the most secreted. VEGF-AXXX isoforms have opposite effects and generally counteract the VEGF-
A isoforms. Ratio of them is proposed to be an important determinant for angiogenic switch. From 
(Harper and Bates 2008)
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pVHL no longer targets HIF-1 to proteasomal degradation and induces its dimerization 
with HIF-1 counterpart, which will translocate to the nucleus and activate transcription 
of various genes such as VEGF-A. In a second hand, hypoxia favours VEGF mRNA 
stability probably by interaction with HuR (Ciais et al. 2004; Ido et al. 2008). Low pH, 
another characteristic of tumour microenvironment, induces VEGF-A independently of 
HIF-1 (Fukumura D et al. 2001).  
In tumours VEGF-A is expressed in high levels even if there is no patent 
hypoxia. Actually this upregulation can be achieved by several mechanisms such 
oncogene activation, tumour suppressor inactivation or by induction from growth 
factors. For instance src ,c-myc or Ras activation are known to increase VEGF-A 
mRNA and protein, similarly as pVHL inactivation, p53 and p73 mutation (Nagy et al.
2007).  
In addition several cytokines have shown to be able to induce VEGF expression 
like PDGF, Tumour Necrosis Factor  – TNF- – TGF-, IGF and Interleukin 6 – IL-6 
– and IL-1 (reviewed in Dvorak HF. 2002). All these cytokines are directly or 
indirectly regulated by the NF-B and Activated Protein-1 – AP-1 (Pradeep et al. 2005). 
B.IV.1.a.. VEGF-A pathways. 
Due to the VEGF-A pivotal role in angiogenesis this report will only restrict its 
observation to a general view. VEGF-A triggers a cascade of signaling events: VEGFR2 
Receptor dimerization and autophosphorylation, downstream phosphorylation of 
various proteins such as PKC, PLC- and PI3K. Detailed overview of the pathway 
involved is discussed in the following reviews – Figure 18 (Olsson et al. 2006; Rahimi 
2006; Shibuya 2008). 
If VEGF-A binds equally to VEGFR-1 and -2, VEGFR-1 has a poor tyrosine 
kinase activity which indicates that VEGFR-1 could act by ligand trapping or 
heterodimerization. NRP-1 and -2 enhance VEGF-A binding to VEGFR-2.
B.IV.1.a.. Biological Effects of VEGF-A. 
VEGF-A has been first described in 1983 as a vascular permeabilizing factor 
from tumour ascites fluids (Senger et al. 1983). Actually as an immediate action, 
VEGF-A induces vasodilatation through NO synthesis, microvascular permeability and 
extravasation of plasmatic proteins (Dvorak et al. 1979; Horowitz et al. 1997).  
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All other activities of VEGF are consequent of gene expression regulation. 
Indeed, VEGF is able to activate migration and proliferation of arterial and venal ECs 
and lymphatic cells in vitro. In this purpose it regulates proteins related to blood clotting 
and fibrinolysis i.e. Tissue Factor – TF – uPA, tissue Plasminogen Activator – tPA – 
Plasminogen Activator Inhibitor-1 – PAI-1 – etc, proteases i.e. Matrix Metalloproteases 
– MMPs – glucose transporters, NO synthase and numerous mitogens. It is also able to 
inhibit cell death via apoptosis in vitro and in vivo by several antiapoptotic factors i.e. 
BCL-2, survivin, X-linked Inhibitor of Apoptosis – XIAP (Gerber et al. 1999). VEGF-
A acts upon cell to cell recognition and cell to matrix interaction regulating adhesion 
molecules like E-selectin, Inter-Cellular Adhesion Molecule – ICAM-1 – and Vascular 
Cell Adhesion Molecule – VCAM (Olsson et al. 2006; Rahimi 2006; Shibuya 2008).  
Besides its role in angiogenesis VEGF can have some relevant role in 
inflammation as it can recruit monocytes and induce the formation of granulocytes and 
Figure 18. VEGF-A signalling
Upon dimerization and activation on VEGF-Receptor – here VEGF-R2 – multiple pathways are triggered 
such as the MAP kinase pahtwaypathway, the phospholipase ? - PLC? - pathway, the focal adhesion kinase 
– FAK – pathway, the Src and the Phosphatidyl inositol 3 phosphate pathway – PI3K. This allows couples of 
cellular responses which activate the cell to an angiogenic phenotype. Numbers represent the 
phosphorylation site of the tyrosine. From (Olsson et al. 2006).
Src: sarcoma; TSAd: T-cell-specific adapter protein; Shb: Src homology 2 domain containing adaptor protein 
B; AKT/PKB: serine/threonine protein kinase B; eNOS: endothelial NO synthase; Rac: Rho GTPase protein; 
IQGAP1: IQ motif containing GTPase activating protein 1; MAPK: Mitogen activating protein kinase; MEK: 
MAPK Kinase; PKC: Protein kinase C; DAG: Diacylglycerol; HSP27: Heat shock protein 27
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macrophages (Clauss et al. 1990; Broxmeyer et al. 1995). In return, these cells as well 
as lymphocytes T produce proangiogenic factors like PDGF and MMP-9 that will 
contribute maturation of newly formed vessels (Freeman et al. 1995; Rafii et al. 2002).  
B.IV.1.b. Other VEGF members 
• VEGF-B exists as two isoforms of 167 and 186 a.a. from a single gene. 
VEGF-B 167 and 186 do not bind VEGFR2 but rather VEGFR1 and VEGF-B 167 
binds also to HSPG. VEGF-B is expressed embryonically, in some adult tissues and in 
cancer. However VEGF-B does not support strong activity apart from cardiac function 
and uPA proteolytic activation (Olofsson et al. 1998; Roskoski 2007).
• VEGF-C is highly expressed in adult heart, ovary, placenta, skeletal 
muscle, and small intestine, but is present also in kidney, lung, pancreas, prostate, 
spleen, and testis (Joukov et al. 1996). By its binding to VEGFR-3 and in a weaker 
manner to VEGFR-2 VEGF-C is a potent activator of lymphangiogenesis in embryo 
and in tumour associated lymphangiogenesis. VEGF-C is required for the migration and 
survival of lymphatic ECs. VEGF-C is expressed by a significant fraction of human 
tumours including those of breast, cervix, colon, lung, prostate and stomach (Siegfried 
et al. 2003; Onogawa et al. 2005; Su et al. 2006). VEGF-C KO mice die at embryonic 
state E15.5 to E17.5 due to impairment of lymphatic vascular development.
 Also involved in lymphangiogenesis and binding to VEGFR3 and VEFGR2, 
VEGF-D is less described maybe because effects on VEGF-D KO mice are normal 
despite its upregulation in several types of cancers.  
• Placental growth factor is expressed as four isoforms primarily in the 
placenta but also in diverse human tissues. PlGF null mice are viable and fertile despite 
diminished vascularization of the retina and the corpus luteum. PlGF enhances 
expression of VEGF. 
  
 B.IV.2. FGF-2
FGF-2 – a.k.a. bFGF – is a member of the super family of FGFs which consists 
of 23 members for 18 ligands – FGF11 to 14 do not function as ligands and FGF15 gene 
does not exist. FGF family contains numerous members divided in seven subfamilies 
but particularly two members, FGF-1 and FGF-2 are well investigated and show 
relevant activities. All FGF members have affinity to HSPG which is essential to the 
subsequential binding of the TKR type FGFRs. Ligands of FGF family encompass 
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various activities on different types of cells, such as mitogens, induce cell migration, 
cell survival and differentiation. They also act upon different times in development, 
adult physiology and pathology, from embryo steps to wound healing and cancer 
promotion. 
   
  B.IV.2.a. FGF-2 Biosynthesis 
   B.IV.a.. FGF-2 gene expression 
FGF-2 is transcripted from a single gene FGF2 in chromosome 4 and contains 
only three exons (Mergia et al. 1986; Shibata et al. 1991). FGF-2 promoter has only one 
+1 transcription site, no TATA or CAAT box, five Sp1 binding sites in the 5’ of exon 1 
and one AP1 site in position -243. A large number of transcription factors regulate the 
FGF-2 promoter activity. Homeobox protein Hox-B7 – HOXB7 – IL-1, and EGF, 
PDGF and FGF-2 itself through Early Grown Related protein – EGR-1 – upregulate 
FGF-2 transcription whereas cell confluency and interferon  and  inhibit FGF-2 
transcription (Biesiada et al. 1996; Care et al. 1996; Moffett et al. 1996; Wang et al.
1997). Additionally Regulator of FGF-2 Transcription – RTF – and p53 have been 
identified as inhibitors of FGF-2 transcription (Ueba et al. 1994; Ueba et al. 1999). 
Interestingly thalidomide, a potent and controversial drug that bears antiangiogenic 
activity binds to the G-rich FGF-2 promoter as well as the coding region giving another 
step to understanding of thalidomide modes of activity (Mei and Wu 2008). Finally a 
small mRNA from antisense transcription of FGF2 gene is able to destabilize FGF-2 
RNA (Li and Murphy 2000).  
B.IV.2.a.. FGF-2 translation regulation 
Matured FGF-2 RNA is constituted by a 5’UTR of 484 nt particularly rich in GC 
bases, a 468 nt coding region and an extremely long 3’UTR of 5823 nt which contains 
several polyadenylation sites, destabilization sequences and translation activation (Prats 
et al. 1989; Touriol et al. 1999; Touriol et al. 2000). 
The 5’UTR of FGF-2 RNA is extremely rich in GC bases which makes it highly 
structured. Indeed it contains cis regulatory elements called IRES involved in alternative 
translation initiation which drives translation from four different non canonical codons 
CUG and a canonical AUG upstream the IRES driving cap-dependent translation   
(Prats et al. 1992).  
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Firstly described in virus, mammalian IRESs are now well described in multiple 
factors involved in different IRESs such as C-Myc, the chaperone Bacterial Intravenous 
Protein – BiP – HIF-1 VEGF-A, FGF-1 and others – for a detailed list of mammalian 
IRES database: http://ifr31w3.toulouse.inserm.fr/iresdatabase/ or http://iresite.org/
(Nanbru et al. 1997; Kim et al. 2002; Lang et al. 2002; Martineau et al. 2004). These 
specific structures give fundamental advantage in some selective stimuli because IRES 
dependent translation is not sensitive to stress related translation blockade. If no 
consensus sequences between IRESs have been identified, some general features are 
sometimes observable.  
The FGF-2 IRES is one of particular importance amongst IRESs. Indeed FGF-2 
IRES activation is tissue-specific and condition dependant such as hyperglycemia, heat 
shock, hypoxia or oxidative stress (Vagner et al. 1996; Creancier et al. 2000; Teshima-
Kondo et al. 2004; Conte et al. 2008). FGF-2 IRES activity is also involved in brain 
development and testis maturation (Gonzalez-Herrera et al. 2006; Audigier et al. 2008). 
Cellular factors can bind to IRESs and regulate internal ribosome entry – they are called 
IRES Trans Acting Factors – like Heteronuclear Ribonucleoprotein A1 – hnRNPA1 – 
and p53 (Galy et al. 2001; Galy et al. 2001; Bonnal et al. 2005).  
B.IV.2.b. FGF-2 isoforms  
Due to five start codons in humans in one mRNA, FGF-2 is able to produce five 
different isoforms of 18 – a.k.a. LMW form for low molecular weight form – 22, 22.5, 
24 and 34 kDa – HMW for High Molecular Weight – Figure 19 (Florkiewicz and 
Sommer 1989; Prats et al. 1989). These differences in size come with differences in 
function, localization and fate. The 18 kDa isoform is localized in the cytoplasm 
whereas the HMW are mainly located in nucleus in vitro, due to the presence in these 
isoforms of NLS (Renko et al. 1990; Bugler et al. 1991; Arnaud et al. 1999). HMW 
isoforms expression negatively correlates with cell density in human primary fibroblasts 
and augments with transformation due to a modulation of the use of alternative start 
codons (Galy et al. 1999). Overexpresssing HMW isoforms induce a cell cycle arrest at 
G2M, by inhibition of 4E-BP1 phosphorylation in glioma cell line, and inhibited in vivo 
tumour growth (Lemiere et al. 2008) 
Contrarily to the HMW isoforms that only are present in cytoplasm and nucleus, 
LMW FGF-2 isoform trafficking is extended from cytoplasmic, secreted by a non 
conventional RE/Golgi independent mechanism allowing it to bear paracrine or 
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autocrine activity, and nuclear. Indeed, following binding to its FGFR receptors, FGF-2 
18 kDa can either induce signal transduction or be translocated to the nucleus and 
activate its mitogenic capacities through transcription induction. 
   
   
  B.IV.2.c. FGF-2 Molecular interactions 
B.IV.2.c.. Interactions with ECM and Receptors 
Within the ECM are present a multiplicity of HSPGs that are secreted from cells, 
or these HSPG can be bound to the cell surface. FGFs are extremely affine to HSPGs so 
once in the extracellular domain they generally bind to HSPGs. This binding has two 
main significances: to protect FGF-2 from proteases and to constitute a stock. FGF-2 
can be activated following specific protease activity like heparanases and MMPs or by 
binding to FGF-2 Binding Protein – FGF-2 BP (Bashkin et al. 1992; Czubayko et al.
1994). There is thus a modulation of activation FGF-2 signaling through the overall 
composition of HSPGs and the expression of FGF-BP. 
HSPGs bound to cell membrane have a different signification as they have a role 
of low affinity binding receptors that will display FGF-2 to high affinity receptor 
FGFRs. Due to their variety, the role of HSPGs-FGF-2 complexes regarding the 
activation of FGF-2 signaling through FGFRs has still some controversy since perlecan 
activate the binding and fibroglycan and syndecan inhibit it (Aviezer et al. 1994). It is 
however commonly accepted that HSPG enhance FGF-2 binding to FGFRs by 
Figure 19. Human FGF-2 isoforms 
All 5 FGF-3 isoforms 
come from the same 
mRNA thanks to the 
presence of an IRES 
and alternative start 
codons. The 
extremely long 
3’UTR contains 
regulatory elements 
for its stability. The 
low molecular weight 
isoform is the major 
isoform and is 
secreted, mean while 
are upregulated in 
cancer and are present 
mainly  in the nucleus. 
Shema from 
(Sorensen et al. 2006) 
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stabilizing ligand-receptor complex (Raman et al. 2003). As well as VEGFRs, 
dimerization of FGFRs is essential to TKR activity, autophosphorylation and signal 
transduction.  
FGF Receptors constitute a family of five tyrosine kinase members – 1 to 5 – in 
which each receptor possesses different splicing isoforms in the N-terminal extracellular 
domain – Table 1. Splicing is an essential mechanism that drives the specificity of 
FGFR to each FGF. Together with ligand specificity, FGFRs are prone to be expressed 
in defined conditions and tissues, during development, proliferation and cell 
differentiation. For instance FGFR2b is only expressed in epithelial cells whereas 
FGFR2c is in mesenchymal cells. Besides these forms and similarly as VEGFRs, 
FGFRs exist in soluble forms and membrane bound defective TKR – like FGF-5 – that 
could show a dominant negative role towards FGFRs (Kim et al. 2001).  
B.IV.2.c.. FGF-2 transduction pathways. 
FGFR-1, IIIb; FGFR-3, IIIc; FGFR-4 FGF-23 
FGFR-2, IIIb FGF-22 
FGFR-1, IIIb; FGFR-3, IIIc; FGF-21 
FGFR-1, IIIc; FGFR-2, IIIb;  XFGF-20 FGF-20 
FGFR-1, IIIc; FGFR-2, IIIc; FGFR-3, IIIc; FGFR-4 FGFs 17–
19
FGFR-1, IIIc; FGFR-2, IIIb; FGFR-4 FGF-16 
FGFR-1, IIIb; FGFR-2, IIIb§ KGF-2 FGF-10 
FGFR-2, IIIc; FGFR-3, IIIb & IIIc; FGFR-4 GAF FGF-9 
FGFR-2, IIIc; FGFR-3, IIIc; FGFR-4 AIGF FGF-8 
FGFR-2, IIIb KGF FGF-7 
FGFR-1, IIIc; FGFR-2, IIIc, FGFR-4 hst-2 FGF-6 
FGFR-1, IIIc; FGFR-2, IIIc FGF-5 
FGFR-1, IIIc; FGFR-2, IIIc; FGFR-3, IIIc; FGFR-4 kFGF, kaposi 
FGF, hst-1 
FGF-4 
FGFR-1, IIIb; FGFR-2, IIIb Int-2 FGF-3 
FGFR-1, IIIb & IIIc; FGFR-2, IIIc; 4 FGFR-3, IIIc; FGFR-4 Basic FGF, bFGFFGF-2 
FGFR-1, IIIb & IIIc; FGFR-2, IIIb & IIIc; FGFR-3, IIIb & IIIc; 
FGFR-4 
Acidic FGF, 
aFGF 
FGF-1 
Signaling through high-affinity receptorsSynonymsName
List of the 22 FGF-2 members and their affilliate recpetors. From (Powers et al. ; Schwertfeger) 
Table 1. List of FGF members and thier related recpetors 
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Following dimerization occurs autophosphorylation in different tyrosine 
residues. This allows the recruitment of signaling molecules such as Src – short for 
sarcoma – via the Src Homology domain 2 – SH2. The subsequent transduction cascade 
involves many factors reviewed in the following journals (Schlessinger et al. 2000; 
Dailey et al. 2005). Four main pathways are induced downstream FGFRs 
phosphorylation: FGF Receptor Substrate 2 – FRS2 – Phospholipase C  – PLC – Src 
and Phosphatydil Inositol 3 kinase – PI3K.  
FRS2 protein, anchored thanks to a specific juxtamembrane domain in the FGFR 
is phosphorylated and recruits the Growth Factor Receptor Bound protein 2 – Grb2 – 
and Son Of Sevenless – SOS – which is a guanine exchanger. SOS activates then Ras 
and Mitogen Activated Protein Kinase – MAPK – pathway: Raf, Erk, p38 and JNK. 
This pathway transcriptionnally activates proliferation genes like c-jun, c-myc and c-
fos. As a negative feedback loop FGF-2 induced MAPK inhibits FRS2, induces MAPK 
phosphatase 3 – MKP3 – Sprouty proteins – SPRY – and Similar Expression to FGF 
Genes – SEF – family members that modulate receptor signaling at several points in the 
signal transduction cascade (Lax et al. 2002; Turner and Grose 2010).  
PLC binds FGF-2 TKR through another tyrosine phosphorylated site. This 
interaction leads to PLC activation, Phosphatidyl Inositol Biphosphate – PIP2 – 
hydrolysis and generation of Diacylglycerol – DAG – and Inositol Triphosphate – IP3. 
These two messengers induce calcium liberation from endoplasmic reticulum and 
Protein Kinase C – PKC which in return induces cytoskeleton reorganization. This 
pathway is responsible for the migratory and cellular differentiation effects of FGF-2 
(Gu et al. 1996; Gu and Kay 1998).  
As well as PLC, Src phosphorylates the actin filament bound protein cortactine 
and may induce migration and differentiation (Tsuda et al. 2002). 
PI3K interacts either directly with FGFRs or indirectly through GRB2-
associated binding protein 1 – GAB1 – resulting in phosphorylation of 3-
Phosphoinositide Dependent Protein Kinase-1 – PDK – and then AKT. PI3K activation 
affects a number of apoptotic factors like Glycogen synthase kinase 3 – GSK3 – Bcl-2-
associated death promoter protein – BAD – which contribute to the antiapoptotic and 
pro-survival mechanism of FGF-2 – Figure 20 (Turner and Grose 2010). 
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B.IV.2.c.. Intracellular protein partners. 
 FGF-2 is internalized through FGF TKRs and HSPG in endosomes and can 
translocate to the nucleus or is degraded through internalization by lysosomes. Once in 
the cytoplasm FGF-2 is able to interact with Casein Kinase II – CK2 – in proliferating 
cells which induce translocation and transcription of ribosomal genes, typoisomerases 
and RNA polymerase II (Bouche et al. 1994; Bailly et al. 2000). For instance nuclear 
FGF-2 interacts with Upstream Binding Factor – UBF – in order to engage 
transcription. Translokin interacts with the 18 kDa FGF-2 and is essential to its 
translocation into the nucleus and its mitogenic properties (Bossard et al. 2003). FGF-2 
interacts also with Ribosomal Protein S19 – RPS19 – in the cytoplasm, Nuclear 
Ribosomal Protein S6 Kinase 2 – RSK2 – in S1 phase of cell cycle and ribosomal 
protein L6/TAXREB107, in the nucleus (Shen et al. 1998; Sheng et al. 2005).  These 
latter interactions play also a role in the metabolism of the RNA and cell growth. HMW 
FGF-2 have been found to interact with the nuclear 66 kDa Subunit of Splicing Factor 3  
– SF3a66 – and Survival Of Motor Neuron 1 – SMN – indicating roles in RNA splicing, 
as well as FGF-2 Interacting Factor – FIF – resulting in increased cell survival (Van den 
Berghe et al. 2000; Claus et al. 2003; Gringel et al. 2004). 
Figure 20. FGF-2 signal transduction pathways 
Principal cell types involved in FGF-2 signalling are related to angiogenesis or neuronal 
development. FGF-2 activate its tyrosine kinase receptors and trigger three main pathways such as 
PI3Kinase AKT/PKB, PLC/PKC and MAPKinases. From (Cao et al. 2008).  
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B.IV.2.d. FGF-2 biological activities in tumour angiogenesis 
Firstly identified as a murine fibroblast mitogenic factor, FGF-2 is identified as a 
strong inducer of angiogenesis – mediated by stroma, inflammatory and ECs or tumour 
cells – and cell transformation but also in embryonic development. This report will only 
focus on the pathological events in which FGF-2 is involved. 
   B.IV.2.d.. FGF-2 and angiogenesis 
 FGF-2 has a broad range of actions in tumour angiogenesis. FGF-2 is involved 
in each step of vascular remodeling leading the synthesis of new BVs.  
Indeed, it has been shown to activate ECs (Kandel et al. 1991). In contrast to 
VEGF, FGF-2 activation relies significantly more on pericytes and vascular SMCs 
which finally confers a much more equilibrated and efficient vasculature (Cao et al.
2008). Angiogenesis can be “switched on” also by the pool of FGF-2 present in the 
ECM.  
FGF-2 has a potent role in the degradation of the ECM because it is able to 
activate uPA, its receptor the Urokinase receptor – UR – and some MMPs (Mignatti et 
al. 1991; Gualandris and Presta 1995). This mechanism creates a positive feedback loop 
involving the sequestered FGF-2 in ECM that will be freed and thus activates migration 
and proliferation of cells. FGF-2 is also able to induce integrin V3, initiating MAPK 
signaling. This pathway is thought to enhance EC migration (Shono et al. 2001).  
   B.IV.2.d.. FGF-2 and transformation 
FGF-2 is considered a powerful activator of cell proliferation. This aspect of 
FGF-2 is applicable both to ECs and tumour cells because they express FGFRs and 
trigger proliferation pathway . However to note, in cancer this signal transduction is 
altered and exacerbated by FGFR constitutive activation or amplification, ligand 
independent signaling, etc. 
   
 B.IV.3. PDGF 
 PDGF is an important angiogenic factor involved in the biology of the 
mesenchymal cells such as proliferation of fibroblasts and other connective tissue cell 
types (Alvarez, 2006). PDGF has pleiotropic effects and has roles in embryonic 
development, CNS development, the vascular system, tissue homeostasis, and wound 
healing(Dunn, 2000). In mice, targeted disruption of PDGF-B or the PDGF receptor 
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ablated the microvascular pericytes that normally form part of the capillary 
wall(Lindahl, 1997). Due to a wide spectrum of activies – not mentioned here – 
overexpression of PDGF signaling can cause various diseases like liver cirrhosis, 
pulmonary fibrosis, atherosclerosis, etc…  
  B.IV.3.a. PDGF Ligands and receptors 
PDGF ligands are mainly represented by with two different types of 
polypeptides A or B – in a family which comptises also PDGF C and D - which act in a 
mature form as sulfide bound dimers like PDGF-AA, -AB or –BB. Theses angiogenic 
factors are principally paracrine factors, but also can act as autocrine factors in tumors. 
To be secreted, PDGF-A and B are cleaved at their amino terminal domain. In many 
tymor types such as glioblastomas, PDGF-BB is overexpressed and lead to 
hypervascularization (Cao, 2008). PDGF expression is responsive to various simuli 
such as hypoxia, thrombin, cytokines, and growth factors, including PDGF itself 
(Andrae, 2008). Likewise FGF-2, Diffusion of PDGF in the tissue interstitium is 
regulated by binding to extracellular matrix components like HSPG.  
PDGF ligands bind tyrosine kinase receptors, the PDGF- and PDGF-
receptors - which chains can as well homo or heterodimerize. Both receptors can 
activate many of the same major signal transduction pathways, including PI3K, Ras 
MAPKinase and PLC pathways, but have a different pattern of activation depending 
on cell types. PI3K is essential for cell migration, actin remodeling and survival. Ras 
pathway on the contrary lead to cell proliferation. As VEGF and FGF-2 receptors PDGF 
receptors undergo dimerization and autophosphorylation to activated the subsequent 
transduction signal pathways. They are expressed in fibroblasts, pericytes, Vascular 
SMCs, platelets, neurons, mammary epithelial cells, macrophages, myoblasts and 
others. 
 B.IV.4. TGF-
Transforming growth factor  family is constituted by 35 members in humans in 
which the typical member is TGF-1. In this respect, depending on the context,  TGF-
induce an extreme variety of effect ranging from stimulation and inhibition of cell 
growth, extracellular matrix elaboration, EC migration incduction but also maturation of 
mural cells and regulation of immune. TGF- signaling is of first importance in cell 
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biology and angiogenesis a it is responsible for many diseases such as cancers, 
pulmonary and liver fibrosis and vascular disorders (Bertolino, 2005). 
  B.IV.4.a. TGF- pathways 
TGF- members exert their effect by binding to couples of specific 
serine/threonine kinase type I – also termed activin receptor-like kinase – ALK - and 
type II receptor complexes. TGF- has high affinity for the TGF- type II receptor - 
TRII - and on binding a specific TGF- type I receptor - TRI - is recruited and 
phosphorylated  by TRII. This reaction triggers the the TGF- signal transduction 
mediated by smads proteins – R-smads like  Smad 2/3, Smad 1/5/8 and Co-smad like 
smad4 – which translocate to the nuleus and with co-factors activate gene transcription.  
TGF- is of first importance in angiogenesis as studies have shown that loss 
TGF- signaling induce abnormal differenciation and maturation of the primitive 
vascular plexus, resulting in fragile vessels with decreased integrity of the vessel wall 
(Goumans, 2003). the vessels of the TGF-1 mutant embryos have decreased wall 
integrity, which is caused by a defect in endothelial cells differentiating into 
capillarylike tubules. 
The main difficulty for the understanding of TGF- role in angiogenesis is that it 
is able to have opposite effect depending on the context. In physiological conditions 
TGF- is though to induce the proliferation of ECs during the activation step of 
angiogenesis and also participate in tube vessel formation by inhibition cell proliferation 
in the resolution step. This bipolar effect is reinforced by observations that low doses of 
TGF- induce cell proliferation whereas high doses inhibit it (Pepper, 1993). Otherwise 
TFG- is ale to induce MMP-2 and MMP-9 expression, matrix remodeling and release 
of proangiogenic factors by monocytes.  
B.V. p53 and angiogenesis 
Because of its implications in other mechanism of cell defense against 
aggressions and all aspects of tumour progression, assuming a direct role of p53 in 
angiogenesis has been more difficult to prove. In 1998 Holmgren et al. showed that 
independently of its anti-proliferative and proapoptosis role p53 is able to induce 
dormancy by inhibiting angiogenesis (Holmgren et al. 1998). However p53 plays a key 
role in the inhibition of angiogenesis by interacting with HIF-1 under hypoxic 
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conditions, inhibiting antiangiogenesis targets and activating proangiogenic ones and 
also acting directly upon regulation of proliferation and migration of ECs. Likewise, 
other tumour suppressors such as retinoblastoma and pVHL do have antiangiogenic 
properties, frequently inactivated in tumour cells.
B.V.1. Correlations between angiogenic behavior and p53 status. 
p53 status is an important prognosis marker for tumour growth, aggressiveness 
and metastasis potential, due to its classical implication towards the different 
mechanisms of response to cellular stresses. Regarding the evaluation of tumour 
angiogenicity linked with p53 status, several studies have revealed strong correlation in 
various types of cancers such as colon cancer, head and neck cancers, breast cancers and 
NSCLC cancers (Linderholm et al. 2000; Yuan et al. 2002; Perrone et al. 2004). Two 
independent studies in human prostate cancers have shown that tumours expressing 
mutated p53 have significantly greater microvessel density – MVD – than tumours 
expressing wild-type p53 (Yu et al. 1997; Takahashi et al. 1998). These clinical 
observations have constituted the first steps towards the understanding of p53 
antiangiogenesis in cancer – Figure 21. 
Figure 21. p53 involvement in angiogenesis and consequences of its loss.  
Diagram showing the innate balance of pro and antiangiogenic genes in p53 target genes in 
neoplasms – A, and the consequences of p53 activation – B. Target genes shown here will be 
discuss more in details in this report. When p53 is inactivated or mutated, tumour can escape 
dormancy and activate their angiogenic program – C. Shown here important proangiogenic genes. 
A.
B. 
C. 
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 B.V.2. p53 and hypoxia.
Under strong hypoxic conditions near anoxia – around 0.2 % of O2 – p53 
response possesses a unique pattern. Contrarily to other p53 dependent stresses, p53 
interferes in angiogenesis with the hypoxia inducible factor HIF-1 as explained earlier 
on (Ravi et al. 2000). This crosstalk allows us to better apprehend the mechanisms 
underlying the different responses to hypoxia. This important balance bears some 
common targets genes regulated in an opposite fashion such as VEGF, GLUT-1 and 
Bcl-2 that would explain the radical changes in response from cell survival to cell death 
(Ebert et al. 1995; Forsythe et al. 1996; Zhang et al. 2000; Wu et al. 2001; 
Schwartzenberg-Bar-Yoseph et al. 2004; Zhang and Hill 2004). In the same time a 
specific pattern in p53 response encountered in hypoxia may be explained by NO levels, 
and phosphorylation in p53 S15, as explained earlier on. Additionally, some groups 
have demonstrated that hypoxic stress does not induce both p21 nor MDM2 target genes 
and fails to induce the acetylation of Lys382 of p53 which is known to be important for 
p53-p300/CBP interaction (Koumenis et al. 2001; Hammond et al. 2006). However 
hypoxic activation of p53 results in increase of mSin3A affinity, a p53 transcriptional 
corepressor (Murphy et al. 1999). Another factor involved is the BNIP3L, a p53 target 
gene induced as well in hypoxia (Fei et al. 2004). Yamakuchi et al. identified a miRNA 
– miR-107 – regulated by p53, which inhibits hypoxia signaling by suppressing HIF-1
expression (Yamakuchi et al. 2010). They showed a miR-107 induction by p53 with 
etoposide treatment. Interestingly loss of ATM induces the upregulation of HIF-1
through oxidative stress (Ousset, 2010 #964). Concomitantly with p53 activation, ATM 
by this mechanism controls tightly two major factors in angiogenesis and tumour 
suppression. 
 In conclusion, mild hypoxia result in stabilization of HIF-1 but not p53, 
allowing the cell to trigger survival and a proangiogenic response. But when the 
conditions of hypoxia are too severe, p53 is also stabilized through formation of a 
complex containing HIF-1 and other factors like MDM2, pVHL or p300 and p53 S15 
phosphorylation by NO. p53 is activated but does not induce cycle arrest and rather an 
inhibition of its target genes. However lack of evidence in these conditions remains to 
define p53 target genes involved in hypoxia-induced apoptosis. On must note that 
Hammond and Giaccia localized p53 in the cytoplasm after induction by the hypoxia-
mimetic deferroxamine (Hammond and Giaccia 2005). The remaining uncertainties rely 
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also on the definition of hypoxic and anoxic conditions which may vary between 
studies. For instance, Kamat et al. compared acute and chronic hypoxia – 4 and 72 
hours – and showed that the apoptotic response triggered in the cells in chronic hypoxia 
was caused by p53 (Kamat et al. 2007). 
 B.V.3. Regulation of proangiogenic targets.
One of the principal target of p53 towards proangiogenic factors is VEGF-A. 
Indeed this latter is a p53 target gene through competitive binding of the transcriptional 
VEGF-A co-activator SP1 (Zhang et al. 2000; Pal et al. 2001). 
Similarly p53 is able to inhibit the FGF-2 transcription through binding to its 
basal promoter (Ueba et al. 1994). Our lab has shown that p53 is also able to bind the 
5’UTR IRES region of the FGF-2 mRNA and to inhibit its translation by a modification 
of the mRNA secondary conformation (Galy et al. 2001; Galy et al. 2001). Adding a 
layer to p53 control upon FGF-2 biosynthesis and metabolism, p53 downregulates the 
expression of the FGF binding protein – FGF-BP (Sherif et al. 2001). This protein is 
involved in the activation of FGF-2 particularly when bound to HSPG in the ECM. 
Finally p53 is able to repress heparanase, a cleaving enzyme which frees VEGF-A and 
FGF-2 (Baraz et al. 2006 626).  
p53 downmodulates COX-2 expression by competing DNA binding with TATA 
binding protein (Subbaramaiah et al. 1999). COX-2 is an inducible enzyme that 
converts arachadonic acid to prostaglandin H2, a progenitor of prostanoids, which are 
key players in inflammation and actually also promote the expression of proangiogenic 
factors (Subbaramaiah et al. 1999; Iniguez et al. 2003).  
Cysteine-rich 61 – Cyr61 – and p53 status have been strongly and negatively 
correlated in prostate cancer (Lv et al. 2009). Cyr61 is a member of the CCN protein 
family that has been implicated in diverse biological processes, promoting for example 
cell adhesion and proliferation, angiogenesis, and tumourigenesis. In this study authors 
also showed that overexpression of wildtype and mutant p53 in various cancer cell lines 
confirmed that p53 tightly regulate Cyr61 expression.  
 B.V.4. Regulation of antiangiogenic targets. 
The involvement of p53 in the angiogenic switch non solely implies inhibition of 
proangiogenic genes but also enhancement of antiangiogenic ones. Interestingly, 
antiangiogenic genes have double actions through the ECs. First, they inhibit EC 
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proliferation, migration and rearrangement but also induce EC apoptosis. One would 
argue that this induction by p53 is merely differentiable to the classical p53 apoptosis 
pathway. Interestingly p53 antiangiogenic target genes are almost presents in the ECM 
– Table 2. 
Thrombospondin-1 – TSP-1 – is the first antiangiogenic factor identified as a 
p53 target gene and one of the first p53 target genes (Dameron et al. 1994). TSP-1 is a 
450 kDa glycoprotein, in the ECM, which inhibit angiogenesis by ECs inhibition of 
proliferation and migration via its receptor CD36 (Ren et al. 2006). Dameron et al.
showed that its expression is strongly correlated with the dormancy state of the tumour 
and thus is an essential factor regulated by p53. This work has been confirmed by two 
groups showing similar effects of p53 on TSP-1 in a p53 null context (Giuriato et al.
2006; Su et al. 2010).  
Semaphorin-3F – SEMA-3F – when overexpressed inhibits cell growth and 
tumour related angiogenesis. Futamura et al. identified it as a direct p53 target gene and 
showed strong correlation between p53 status, SEMA-3F and its receptor neuropilin 2 – 
NRP2 – levels (Futamura et al. 2007). Overexpression of SEMA-3F leaded to inhibition 
of tumour growth and decrease of MVD levels in colon cancer xenografts. 
Brain-specific angiogenesis inhibitor-1 – BAI-1 – is a large transmembrane 
protein of the B family of G-protein coupled receptors which was originally identified 
(Futamura et al. 2007)SEMA-3F
(Lv et al. 2009)Cyr61
(Teodoro et al. 2006)P4HA2 [(II) 4-prolyl hydroxylase]
(Wei et al. 2006)1 collagen 4 – COL4A1
(Miled et al. 2005)1 collagen 18 – COL18A1
(Dohn et al. 2001)ephrin-A1 – EFNA1 
(Dohn et al. 2001)EPHA2
(Nishimori et al. 1997)BAI1
(Dameron et al. 1994)TSP-1
p53-upregulated genes
(Subbaramaiah et al. 1999)COX-2
(Sherif et al. 2001)bFGF-BP
(Ueba et al. 1994)bFGF
(Pal et al. 2001)VEGF-A
p53-downregulated genes
ReferenceTable 2. p53 target genes in angiogenesis
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in a screen for p53-induced genes in glioblastoma cells (Van Meir et al. 1994; 
Nishimori et al. 1997; Nishizaki et al. 1999). The first group to identify BAI-1 was Van 
Meir in 1994, who found an antiangiogenic factor secreted in condition mediums, 
following overexpression of p53. Still, they were not able to characterize it. BAI-1 
contains TSP-1 repeats – TSR – and is processed into an antiangiogenic fragment called 
vasculostatin present in the ECM – and responsible for the effects observed by Van 
Meir (Kaur et al. 2005). 
Ephrin receptor A2 – EPHA2 – and its ligand ephrin A1 – EFNA1 – are also 
transcriptionally induced by p53 (Brantley et al. 2002; Kaur et al. 2005). EPHA2 is a 
part of the tyrosine kinase receptor family ephrin receptors and plays important roles in 
angiogenesis, but also in cancer progression. EPHA2 signaling is a complex mechanism 
where the preservation of the ligand-receptor ratio is determinant for antiangiogenic 
induction. p53, promoting concomitantly EPHA2 and EFNA1, uses the ephrin pathway 
to induce antiangiogenesis. 
Finally miR-34a, a p53 target miRNA, has been shown to induce senescence of 
EPC (Zhao et al. 2010). This would give another important role in angiogenesis besides 
its effects on cell cycle arrest, apoptosis and senescence.  
 B.V.5. Activation of collagen derived antiangiogenic factors.
Collagens, principal component of the ECM, greatly contribute to the vessel 
remodeling during the basal membrane breakdown. In their mature form i.e. a triple 
helix composed of members amongst a family of 29 ones, cross-linked and assembled 
together, collagens are generally though to be scaffolds for the surrounding vessels – 
Figure 22. Simple chains of collagens are proline hydroxylated by (I) and (II) prolyl 
4-hydroxylases – (I)PH and (II)PH – enabling hydroxide bound between filaments 
and strongly enhancing stability of the helix. Their overexpression induces EC stability, 
adhesion and migration (Form et al. 1986). Under certain circumstances, they are 
processed by different proteases to deliver antiangiogenic fragments present in the non 
collagenous C-terminal domain of these chains.  
During collagen biosynthesis and metabolism, p53 acts directly and indirectly 
upon several steps, from the transcription upregulation of collagen members to the 
cleavage of the C-terminal antiangiogenic fragments.  
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Among the large family of collagen genes and 
isoforms, p53 is able to transcriptionally activate 
COL4A1, COL4A3 and COL18A1 (Miled et al. 2005; 
Teodoro et al. 2006; Wei et al. 2006). COL18A1 
following cleavage by MMP-9, elastase or cathepsin L 
frees endostatin, a well-known antiangiogenic fragment 
(Wen et al. 1999; Felbor et al. 2000).  
p53 contributes to the formation of the collagen 
triple helix by enhancing the hydroxylation of proline 
residues – 9% of total residues – of collagens chains. It 
enhances the transcription of one rate-limiting enzyme, 
(II)PH (Teodoro et al. 2006). Surprisingly 
overexpression of this enzyme did not lead to an increase 
in the amount of stable triple helix chains in the ECM but 
rather a diminution caused by a strong activity in collagen C-terminal cleavage. 
Consequently Teodoro et al. found an increase of tumbstatin and endostatin fragments. 
This study limited its investigations to these two collagen chains although their 
involvement in angiogenesis is predominant. The protease enzymes involved in this 
activity remain to be elucidated, but authors hypothesize the involvement of MMPs 
such as MMP-2, a p53 target gene (Bian and Sun 1997). This work may open the gate 
of some important findings regarding the antiangiogenic potential of p53, through 
collagen derived antiangiogenic fragment stimulation.  
If p53 has been shown to be an essential antiangiogenic factor, growing evidence 
tends to explain that mutant p53 not only passively fails to be active, but takes part in 
complexes that induce angiogenesis. For instance formation of a complex containing 
mutant p53 and ESAF1 shows transcriptional activity towards the inhibitor of DNA 
Binding 4 – ID4 – which consequently increases IL8 and GRO- proangiogenic factors 
(Fontemaggi et al. 2009).  
B.VI. Models of angiogenesis. 
Since many years angiogenesis assays are considered of prime importance for 
understanding and predicting the effects of specific molecules on angiogenesis. 
Figure 22. Unravelling 
collagen. Julian Voss-
Andreae's sculpture. 
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Consequently a considerable list of assays is nowadays available for studying the 
different aspects of angiogenesis. 
 B.VI.1. In vitro models
There are several advantages of in vitro studies: They are highly reproducible, 
quick, easy to perform and in some extend, cheap. However some would argue that they 
are oversimplified, as they do not consider the high complexity and heterogeneity of 
ECs – ECs from fenestrated, sinusoid or BBB capillaries, from capillaries or arteries, 
from venous or arteries or from various regions of the body. Moreover, despite the 
existence of co-cultured ECs with pericytes, in vitro studies can not reproduce the 
whole blood vessel and stroma, including all the cell types it normally has. In vitro 
models are proliferation assays, migration assays, tubulogenesis and co-cultures.  
Endothelial cell proliferation assays are common in investigation. However 
some care for EC handling is important and precise settings must be respected for 
proper experiments i.e. cell density, number of passage and induction of a quiescent 
state. Proliferation assessment can be achieved by cell counting, MTT – [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide], cleaved by a mitochondrial 
deshydrogenase enzyme to produce purple/blue formazan crystals – and DNA synthesis 
by measuring the incorporation of [
3
H]Thymidine or bromodeoxyuridine – BrdU 
(Denizot and Lang 1986; Gomez and Reich 2003; Yu et al. 2004). Cell cycle analysis 
assays can also be undertaken in this purpose. 
Migration assays involve mainly the Boyden chamber assay and the wound 
healing assay. The Boyden chamber is highly sensitive to angiogenic agents and this 
experiment has the advantage not to last long time – few hours – but setting up the 
Boyden chamber requires some attention. On the contrary, the wound healing assay 
does not require the mounting of a chamber and two compartments but just needs a 
scraping into the Petri dish containing ECs. However, “wound repair” in this model is a 
multi-step process involving spreading, proliferation and migration events, and it has to 
be considered that the scraping constitutes a stress for the cells (Wong and Gotlieb 
1988).  
Endothelial cell differentiation constitutes the late step of angiogenesis and is 
represented by capillary like tubule formation. This assay involves plating a layer of 
ECs onto ECM like matrix – pig matrigel, fibronectin, etc. Compounds or conditioned 
64 
media are then added to the cells and tubule formation is assessed within few hours. 
This assay is widely used for measuring the potency of anti- or proangiogenic molecule.  
Co-culture assays are mainly used for studying the interactions between ECs and 
mural cells. In summary, ECs are first coated then usually pericytes are added and 
several measurements can be done such as proliferation, and cell to cell interactions.  
 B.IV.2. Ex vivo models
Contrary to in vitro, ex vivo models allow inclusion of an entire organ in the 
experiment. Generally all cell types are represented as well as the surrounding stroma 
and in vivo angiogenesis is observed.  
Discs – like aortic, vena cava and lymphatic rings – or sections of the specific 
tissue type are cultured in a matrix and are monitored for microvessel outgrowths for 
two weeks. Number and length of outgrowths, the area covered by outgrowths and the 
number of branches are used for quantification of angiogenesis – or lymphangiogenesis 
(Nicosia et al. 1997).  In these models ECs are not altered by successive passages and 
are quiescent. However one discrepancy is the absence of different factors – and in the 
case of vascular rings the absence of circulating cells. A similar assay is the chick aortic 
arch model which is collected from embryonic aortic arch at D17.  
 B.VI.3. In vivo models
• The corneal angiogenesis assay. The cornea is a non vascularized and 
transparent tissue easily available for experiment. These properties make it a model of 
choice for angiogenesis in vivo assays as angiogenesis is easily visible and quantifiable 
(Gimbrone et al. 1974). As almost all types of corneal injury induce neovascularization, 
implantation of micropocket intracorneally next to the limbal epithelium containing 
substances, tumour cells or extracts in order to evaluate their angiogenic potential, or to 
test systemic injection or antiangiogenic compounds. Vascularization is visualized and 
quantification by adding fluorescent dye or India ink in flattened corneas onto slides. In 
this model, angiogenesis is quite atypical, as cornea is normally avascular and does not 
sense oxygen. This model raises however some ethical concerns.  
• Sponges and polymers. Many materials can be implanted into animals 
such as stainless steel mesh chambers, hollow chambers with porous walls, synthetic 
sponge matrix – polyvinyl alcohol, polyester and polyurethane – implants or Matrigel 
plugs. The matrigel – liquid at 4 °C and solid at 37 °C – is composed of different 
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proteins of ECM and the basal membrane, plus growth factors, although now these 
matrigels are reduced in growth factors. Compounds or cells can be suspended with it 
prior to subcutaneous injection into mice. Angiogenesis is measured by CD-31 positive 
vessel by IHC, hemoglobin content, FITC-dextran injections in mice, etc. 
• The dorsal air sac model. First proposed by Oikawa in 1997, this model 
consists in a chamber ring loaded with tumour cells on the murine skin – in the dorsal 
part (Oikawa et al. 1997). Quantification of angiogenesis is possible in five days by 
injection of Evan blue into the mice, staining only pre-existing vessels. Blood volume 
can be measured by circulating Cr51-labelled erythrocytes.  
 B.VI.4. The chick embryo chorio-allantoic membrane – CAM
  B.VI.4.a. Function and structure in embryonic development.  
 The CAM is a transitory extra-embryonic organ resulting from fusion of the 
chorion and the allantoidic layers at day 4 post fertilization and contains an extremely 
dense capillary network devoted to supply the embryo of oxygen, calcium from the 
shell and other nutrients, and carries carbon dioxide excretion. From day 5 and until 
hatching – day 21 – the CAM undergoes several steps of angiogenic development and 
reduction: During three days the angiogenic network grows very rapidly by sprouting 
with immature BVs lacking basal lamina and SMCs, setting up the first capillary plexus. 
From then the capillary network attaches to the basal membrane of the epithelial layer 
of the ectoderm part of the CAM adjacent to the shell membrane. It continues to expand 
its capillary network until day 12 by intussusceptive angiogenesis. Thereafter, EC 
proliferation quickly declines, network architecture is mature but will adopt its final 
arrangement on day 18 (Ausprunk et al. 1974). Javerzat et al. have investigated the 
molecular regulations during CAM development and found specific patterns of 
expression correlating to the above mentioned steps such as BMP4 and FGFR2 
upregulation from days 7 to 10 (Javerzat et al. 2009)  
A dense lymphatic network also exists on the CAM. This allows the draining of 
metabolites but it may not have the same functions as in human adults because immune 
system is not mature. Indeed it enables the implantation of biopsies, xenografts of 
tumour cells, molecules and different sterile objects onto the CAM without conferring 
immune response.  
   B.VI.4.b. The CAM as a tool. 
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The CAM has been developed since more than one century and has greatly 
proven its usefulness for the studies of angiogenic compounds and tumour growth, 
dissemination and metastasis – Table 3. Generally studying the effects of a molecule on 
angiogenesis takes only two or three days whereas the effects of tumour cell can be 
studied over two to seven days. Compared to other in vivo assays this gain of time is 
valuable. Observations and experimental manipulations at different times are easily 
manageable. Several types of tumour and tumour cell types but also  non tumoural cells 
and compounds have been successfully implanted onto CAM  – Table 3 (Ribatti 2008). 
CAM development can be monitored through in ovo or ex ovo follow-up. This 
latter consists in discarding the shell to observe the embryo development in a Petri dish. 
It confers the advantage of a larger window of observation for the CAM and also the 
possibility of multiple grafting onto the CAM, but this step lowers the proportion of 
Table 3. Tumours inducing angiogenesis in CAM model 
AuthorsTumour Cell type
(Klagsbrun et al. 1976)Walker 256 carcinoma
(Ribatti et al. 2002)Neuroblastoma
(Klagsbrun et al. 1976)Meningioma
(Auerbach et al. 1976)Melanoma
(Lucarelli et al. 1999)Lipoma
(Marzullo et al. 1998)Hepatocellular carcinoma
(Petruzzelli et al. 1993)Head and neck squamous cell carcinoma
(Klagsbrun et al. 1976)Glioblastoma
(Ribatti et al. 1990)B-cell non-Hodgkin's lymphoma
(Palczak and Splawinski 1989)Adenocarcinoma of the endometrium
AuthorsTumour               
Tumours and tumour cell types successfully implanted in Chicken CAM. From (Ribatti 2008) 
(Klagsbrun et al. 1976) Walker carcinoma 256 cells 
(Ribatti et al. 2003) Plasma cells from patients with multiple myeloma 
(Ribatti et al. 2002) Neuroblastoma 
(Ribatti et al. 2001) Mammary tumour cells transfected with VEGF 
(Vacca et al. 1998) Lymphoblastoid cells 
(Vacca et al. 2003) Ecs isolated from patients with multiple myeloma 
(Takigawa et al. 1990) B- Melanoma cells
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viable and alive embryos throughout the experiment. The quantification of angiogenesis 
can be performed by several counting means, such as number of vessels, number of 
branches, scoring the angiogenic net changes, microvessel density, uptake of H3 
Thymidine, etc. However angiogenesis must be segregated from vasodilatation which is 
not in all counting methods, possible. SNA-lectin or LCA-lectin for ECs staining, 
desmin for pericytes, -SMA for SMCs; all these cell markers are available for CAM 
immunohistochemistry and immunofluorescence.   
Depending on the cell type, CAM can be used for studying the dissemination of 
tumour cells into internal organs of the embryo such as lung, liver and brain. Indeed 
within five to seven days aggressive tumour cells develop to sizable tumours, escape the 
primary site, invade surrounding stroma, intravasate into BVs and reach distal part of 
the and embryo organs, summering spontaneous metastasis in a very short period of 
time. Fluorescent tagged cells can be followed for distal dissemination as well as 
quantification of Alu DNA repeats, specific of primate genome (Deryugina and Quigley 
2008). 
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C. Glioblastomas
C.I. Introduction to glioblastomas 
Primary brain tumours from the central and peripherical nervous systems – CNS 
and PNS – are derived from cells of neuro-ectodermic origin and constitute, with brain 
tumour metastases, a relatively rare tumour type – 2% of all types of tumours. Their 
recognition and characterization are funded upon morphologic and immunohistologic 
bases (Dracopoli et al. 1985; Kleihues et al. 2002). There are twelve main categories of 
brain tumours and up to one hundred sub-categories. The most frequent tumours in the 
CNS are grouped into the generic term gliomas but are astrocytomas, 
oligodendrogliomas, oligoastrocytomas or mixed gliomas. As showed in Table 4 
gliomas can correspond to very different types of tumours. This term is often confused 
with the most prevalent type of brain tumours glioblastomas or glioblastoma multiform 
– GBM – which represent 40% of primary malignant brain tumours.  
  
Unfortunately, GBM and other primary tumours are going increasingly these last 
years (Brandes et al. 2003). GBM is of bad prognosis with a 5% survival rate after five 
years.  
On a histopathologic view, glioblastomas are highly cellular, anaplastic, with 
undifferentiated, round, atypic and pleiomorph astrocytes. GBM are highly proliferative 
and characterized by important vascular glomeruloid proliferations and/or 
GIV Neuroblastoma
GIV Meduloblastoma
Embryonic tumours
GII Ependynoma
GIII Ependynoma
EpendymocyteEpendynomas
GII o ligo-astrocytoma
GIII Anaplasic oligo-astrocytoma
Astrocyte or 
o ligodendrocyte
Mixed gliomas
GII Oligodendroglioma
GIII Anaplasic Oligodendroglioma
OligodendrocyteOligodendro-gliomas
Anaplasic astrocytoma
GII d iffuse astrocytoma
GIII Anaplasic astrocytomas
GIV Glioblastoma
AstrocyteGliomas
Tumour grade – from WHOType of originTumours
Table 3. Different types of brain tumours
WHO classification of brain tumours. From (Kleihues and Sobin, 2000) 
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pseudopalisading shaped necrosis with marginal tumour cells in the surrounding 
forming a palisade. Ki-67 index is generally superior to 20%. Various symptoms are 
caused by GBM: head aches, nauseas, vomiting which traduce intracranial 
hypertension, focal neurological defaults due tumour infiltration and troubles in the 
behavior (Grossman and Batara). These tumours are extremely aggressive and invasive 
but they do not disseminate systemically and death is the consequence of local 
expansion.  
Various favorable prognostic factors include age, KPS – Karnofsly performance 
status – histology, absence of extended necrosis, and the size of the residual tumour 
following chirurgical resection – debulking (DeAngelis). However GBM is still 
extremely deadly (Grossman and Batara).  
There are two sub-types of GBM: primary GBM and secondary GBM whether 
the genetic and clinical characteristics. Primary GBM develops extremely rapidly – in 
six months – from glial cells and is the spreadest in elder patients. The secondary GBM 
is developed in months or years after diagnosis of low grade astrocytomas and affects 
mainly younger people. Primary GBM oncogenesis is a genetic multistep mechanism 
such as EGF amplification, loss of chromosome 10, amplification of MDM2 gene and 
deletion and mutation of PTEN gene (Ohgaki 2005). On the contrary secondary GBM 
oncogenesis involves p53 inactivation and overexpression of EGF and PDGF pathways. 
Due to their high tumour grade and their capacity to become resistant from classical 
methods, targeting the microenvironmental cells and in particular ECs that are more 
genetically stable is a well suited strategy.  
C.II. Angiogenesis in glioblastomas. 
One important and unique pattern in the brain vascular organization is the 
presence of a merely impermeable barrier between blood and stoma called brain-blood 
barrier – BBB. This barrier is constituted of ECs, pericytes and astrocytes and 
constitutes a strong obstacle to drug delivery. In brain tumours this barrier loses its 
integrity allowing tumours cells to induce neoangiogenesis. Disruption of BBB, 
increase of tumour vessel permeability and accumulation of fluids in the surrounding 
brain induce vasogenic edema, the major cause of morbidity. In the case of gliomas, 
vascularization is strongly correlated with tumour grade and prognosis (Leon et al.
1996). Consequently, antiangiogenic treatment in brain tumour hampers non-solely 
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tumour development but also the above mentioned related complications of BBB 
loosening. Hispathologically, GBMs are characterized by microvascular proliferation of 
12.5 % of total ECs, which is 40 fold the proliferation index of normal vessels. Newly 
formed tumour ECs have thicker cell wall due to hyperplasia, vascular permeability, 
abnormal pericyte layer distribution and thinner basal membrane.   
If glioblastomas can display strong vascular networks, they still have hypoxic 
regions resulting from the hyperproliferation of these tumour cells and microthrombosis 
phenomenons. The low levels in oxygen is responsible for the VEGF overexpression  
and stabilisation of HIF-1 at these juxta-necrotic regions, in the palisading 
glioblastomas cells (Plate et al.). Constantly proangiogenic factors such as EGF, TGF
and HGF induce VEGF expression in vitro (Goldman et al. 1993; Moriyama et al.
1998; Valter et al. 1999). Loss of PTEN, p53 and pVHL and activation of the 
oncogenes ras and src induce also VEGF expression (Jain et al. 2007). 
Interest in anti-VEGF therapies has been rekindled by preclinical data showing 
that, when used judiciously, these agents can transiently ‘normalize’ the tumour 
vasculature and potentially reduce the risk of haemorrhage, enhance the penetration of 
concurrently administered chemotherapeutics and improve the efficacy of cytotoxic 
drugs. Increased oxygenation could also reduce the invasive potential of cancer cells. 
C.III. Treatment of glioblastomas. 
Glioblastoma is one of the most lethal tumours, despite intensive research for 
many years. The proportion of patient curing from it is very low, under 10%. However 
research has permitted to considerably lengthen overall survival. Common treatments of 
glioblastomas involve repetitive surgery, local irradiations and systemic 
chemotherapies.  
Surgical excision is still the most prevalent treatment for brain tumours. 
However the beneficial aspects of local surgery have somehow raised some doubts 
concerning their efficacy to lengthen survival. Some of the reasons are the extreme 
difficulty to entirely resect GBM because of their extensive three dimensional structures 
and sometimes surrounding benign tumours can be activated by surgery. For these 
reasons surgery is followed by radiotherapy or chemotherapy to avoid recurrence.  
Radiotherapy is considered as a basic treatment for selected gliomas. Particularly 
gamma rays are well suited for profound tissues and adapted for brain tumours. Fourty 
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five to sixty Gy radiotherapy treatment for six week can enhance median survival from 
twenty weeks to one year.  
Chemotherapy is also a good alternative as it ameliorates survival and saves the 
functionality of the surrounding replacing totally or partially the local treatment. The 
BBB only allows small molecules like alkylant agents and platinum derivates. 
Irradiations with alkylant agent temozolomide orally have become one of the standard 
treatments for newly diagnosed GBM. This latter have little impact on outcome as 
median survival is 2.5 months more than surgery and radiotherapy without 
chemotherapy which is of 12.1 months (Stupp et al. 2005).  
C.III.1. Antiangiogenic therapy
The main issues concerning radio and chemotherapies in glioblastomas come 
from the ability of these cells to overcome aggressions that are lethal in many tumours 
types, the heterogeneity of cells within a tumour and between patients, GBM 
localization underneath the BBB and into the brain, render difficult to obtain full 
efficiency of these treatments. Likewise, although some consensus have risen in the 
conditions of radio and chemotherapy treatment, defining the best conditions that give 
maximum tumour cell death and minimum secondary effects depending on the different 
GBM sets is still an ongoing task. Contrarily to it, antiangiogenic therapy targets ECs 
and pericytes from the surrounding of the tumour, cells that are more genetically stable 
and are less prone to develop a resistant phenotype to treatment. Another important 
aspect of antiangiogenic therapy has been recently revealed. In hyperangiogenic tumour 
environment, BVs are only partially functional. The decrease of angiogenic potential by 
antiangiogenic agents induces renormalization of the vessel network and restoration of 
the blood flow, if the treatment is not too strong. This normalization regained helps 
other cytotoxic agents to reach properly the tumour and thus give full potential of 
treatment (Kim and Lee 2009).  
As we have seen it earlier on in this report, VEGF plays a principal role in 
angiogenesis and tumour related angiogenesis. Thus many approaches intend to disrupt 
VEGF or down and upstream actors. Bevacizumab, a humanized mouse antibody 
targeting VEGF-A in combination with a chemotherapeutic agent is already in use for 
colon, lung and breast cancer. Sorafenib, vatalanib/PTK787 and Sunitinib are VEGFR 
tyrosine kinase activity inhibitors in RCC. Soluble receptors trapping VEGF – VEGF 
Trap – show also interesting properties. In brain tumour these compounds are still in 
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clinical trial phases. Phase II trials showed improvement of apparent median 
progression-free survival but phase III trials are still ongoing. Bevacizumab received 
accelerated FDA approval in May 2009 for treatment of high grade astrocytomas. For 
better understanding in extend the different open or recent clinical trial  – refer to table 
X (Vredenburgh, 2007 #442;Winkler, 2004 #446;Batchelor, 2007 #448;Kim, 2009 
#972). Both Vredenburgh et al. and Batchelor et al. showed better therapeutic results 
with antiangiogenic agents in combination with chemotherapeutic ones. These results 
are supported by several preclinical models of primary and secondary brain tumours 
(Yuan et al. 1996; Jain et al. 1998; Tong et al. 2004). However the normalization 
induced by the antiangiogenic agents seems to be only transient and finally reverses, 
providing a limited time window for chemotoxic agent action. Another hypothesis is 
that renormalization of blood vessel blow and structure first allow increasing the 
efficacy of chemotherapeutic penetration, but then brain tumours BVs come back to a 
more physiological phenotype i.e. tightening of BBB, the chemotherapeutic agents no 
longer reach the tumour spot. 
MGI,II
GBM, Gliosarc, MetaI,IITubulin (microvessel)CY997
OG, OA, MB, NB, I,II BBBSodiumthiosulfate/Man
GBMI,IIMicrotubule MPC-6827
GBMI,IIPKCEnzastaurin (SKI)
OligodendrogliomaIPI3K/mTORXL765 (SKI)
GB, Astrocytoma, I,IIPDGFRTandutinib (TKI)
GBMImTORTemsirolimus (SKI)
AstrocytomaIIImTORRAD001 (SKI)
GBM, MGII,IIIIntegrinCilengitude (Peptide)
GBMII
FKBP-12/mTOR Everolimus/Sirolimus
Meningioma, GBMIIPotential Valproic Acid
GBMI,IIVEGFBevacizumab (mAb)
GBMI,IIVEGFRCT-322 (Peptide)
GBMI,IIVEGFRZD6474 (TKI)
GBMI,II,IIIVEGFRCeradinib (TKI)
MGIIVEGFVEGF Trap (Peptide)
GBM, MetaI,IIVEGF/bFGF/TNFThalidomide/Lenalidom
GBM, MetaI,IIVEGFR, PDGFRSunitinib (TKI)
GBM, Meta, GSI,IIVEGFR, PDGFR/RafSorafenib
Glioma, MetaIIVEGFR, PDGFR/c-Pazopanib (TKI)
MGI,IIVEGFR, PDGFRZK222584 (TKI)
GBMIIVEGFR, METXL 184 (TKI)
Tumours Phase Target Drug 
Table X. Ongoing clinical Trials with antiangiogenic agents targeting brain tumours. 
Jan 2009 
From (Kim and Lee 2009). GS: gliosarcoma; MG: Malignant Glioma; OG: Oligoglyoma; OA: 
Oligoastrocytoma; MB Medulloblastoma; NB: Neuroblastoma; Meta: Metastasized secondary brain 
tumors; mAb: monoclonal antibody; PDGFR; Platelet derived growth factor recpeptor; SKI: Serine-
Threonine kinase Inhibitor; FKBP-12: FK506 binding protein 1A-12 kDa. 
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Association of radiotherapy with antiangiogenic treatment looks also promising 
for clinical trials as some interesting findings show that VEGF inhibition enhanced the 
cytotoxic effect of radiotherapy and also induce ECs apoptosis (Gorski et al. 1999; 
Garcia-Barros et al. 2003). Interestingly radiotherapy induces HIF-1 and thus its 
downstream target VEGF, essential for ECs survival.  
Other angiogenic pathways have been investigated in clinical trials: Inhibitors of 
PKC and PKC – Tamoxifen, Enzastaurin - Integrins antagonists – Cilengitide – HIF-1a 
inhibitors – Panzem – and Cyclooxygenase 2 inhibitors – Celecoxib (Reardon et al.
2005; Reardon et al. 2005; Penas-Prado and Gilbert 2007).   
C.III.2. Current limitations of antiangiogenic therapy in glioblastomas
Despite the complementarity of antiangiogenic and chemoactive treatments 
antiangiogenic therapeutic agents have one major disadvantage for the treatment of 
GBMs. These agents are only able to induce a cytostatic state within the tumour, 
meaning it induces tumour cells to stop their growth and enter dormancy. They are not 
suitable for the suppression of malignant tumours. This also means that for 
antiangiogenic treatments patients will be always clinically followed since their 
treatment. Patients with cardiovascular and cerebrovascular ischemia could undergo 
severe secondary effects (Folkman 2006). Another aspect of importance, related to all 
therapies targeting a specific molecule, is the activation of parallel pathways inducing 
angiogenesis after the blockade of a selected one. To overcome this matter, the use of 
drugs that have several targets, or the use of a combination of different antiangiogenic 
drugs could permit to optimize the efficiency.  
Another issue is the correct evaluation of antiangiogenic treatment with current 
means of GBM observation. Gadolinium-DTPA – Gd-DTPA – uptake observed by MRI 
in brain tumours is strongly affected by antiangiogenic agents. However this does not 
correctly fit with tumour regression. To palliate the imperfection of these technologies, 
new imaging modalities have been developed but need to be confirmed (Verhoeff et al.
2009). Antiangiogenic treatment induces instead of a shift from highly proliferative 
tumours to necrosis and apoptosis, a shift to invasive and angiogenesis-independent 
phenotype.  
Viable and proliferative GBM cells are often encountered in the surrounding of a 
blood vessel, and also within the vessel ring. As shown previously GBM cells are able 
to do co-option in order to increase metabolic income. The newly formed co-opted 
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vessels are not sensitive to antiangiogenic treatment (Leenders et al. 2004; Martens et 
al. 2008). GBM can still migrate and invade proximal or distal part of the cerebrum 
even during antiangiogenic treatment. These clinical observations are confirmed by 
preclinical studies in GBM tumours for example (Du et al. 2008; Ebos et al. 2009; 
Paez-Ribes et al. 2009).  
 Finally some strong differences are observed concerning the measurement of 
brain blood flow by MRI settings in humans, i.e. significant decrease of blood flow, and 
the normalization hypothesis of brain blood flow which normally would lead to an 
increase of selected intracranial regions where antiangiogenic agents counteract 
angiogenic stimuli by brain tumours.  
C.IV. Glioblastomas and experimental models. 
 C.IV.1. Mouse models
In vivo models for gliomagenesis consist mainly in tumour cells xenografts 
injected subcutaneously or orthotopically in immunodefiscient mice. In my following 
experiments we chose the U87 cells because it is a predominant cell model for 
glioblastoma, it is also well characterized in the CAM models and it is wild type p53. 
These cells come from GBM of a 44 years old women with less chromosomic 
aberrations than other glioblastoma cell lines (Mulholland et al. 2006). Spontaneous 
glial tumours can be obtained in genetically modified mice overexpression src gene in 
astrocytes, or mice heterozygous for p53 and NF1. However these models presents 
several counterparts such as time of experiment, lack of appropriate mean for measuring 
all the aspects of angiogenic and size evolution and differences between experimental 
GBMs and human GBMs.  
 C.IV.2. CAM model of glioblastoma.
   Pretreatment of GBM cells by doxorubicin inhibited U87 MG tumour formation 
in a CAM assay up to 50% (Stan et al. 1999). Similarly amyloid beta peptide avoided 
tumour angiogenesis in this in vivo model (Paris et al. 2004). The INSERM team U920 
uses U87 MG cell line in CAM as predilection model from brain tumour experiments. 
They demonstrated strong similarities between experimental gliomas tumour growth in 
U87cells onto CAM and normal features of GBMs in humans (Hagedorn et al. 2005). 
They also put into CAM human biopsies for further tumour characterizations. They 
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showed that combined IL-6 and VEGF-A inhibition by SiRNA inhibited tumour 
growth, angiogenesis and invasiveness, whereas one these factors solely inhibited 
induce tumours regression but increase of invasiveness (Saidi et al. 2009). Inhibition of 
VEGFA by siRNA was further investigated and correlation with markers of poor 
survival and prognosis such as CHI3L1 and PI3/elafin was demonstrated (Lemiere et al.
2008).  
  In consequence, this model bears many advantages like established and know 
cell line for implantation, quickness, cost and feasibility, less ethical concerns compared 
to mice models, and use of many experimental procedures for investigation of 
angiogenesis and tumour progression parameters that pushed me to develop this model 
in my team in Toulouse.   
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PROBLEM 
Since its discovery in 2005, the 133p53 isoform has revealed important aspects 
of its activity and its strong interaction with p53. Acting like a dominant negative 
towards p53, its presence reduces considerably the transcriptional activity of p53 for its 
target genes such as p21 and BAX (Bourdon et al. 2005). It has been shown that this 
isoform, the 40p53 isoforms and the zebrafish isoform 113p53 corresponding to 
133p53 in human, are able to considerably modify the activity of its big brother p53 
(Chen et al. 2009; Grover et al. 2009). On the other hand, p53 is implicated in many 
processes such as the ones explained above – cell cycle arrest, apoptosis, DNA repair 
and angiogenesis – and others I didn’t get into details in this report – for instance 
autophagy (Crighton et al. 2006). Although the effect of p53 in angiogenesis is 
somehow shrunken by its role in tumour suppression and inhibition, p53 greatly 
participates in angiogenesis inhibition, resulting in tumour inhibition. Thanks to the 
respective expertises in p53 isoforms and angiogenesis from the European associated 
laboratory, we decided to investigate further in the role of the 133p53 in angiogenesis. 
The idea of an effect of 133p53 isoforms has been triggered in the first times by a 
collaboration with Pierre Roux’s laboratory in Montpellier who showed us an increase 
in migration – and potently invasion – in cells overexpresssing 133p53 isoforms – 
unpublished data, and by preliminary clinical data concerning 133p53 isoforms 
correlated with the survival rate. 
Further characterization of the 133p53 isoform was however an essential task 
to undertake. Chen et al. contributed greatly to the understanding of this latter isoform 
thanks to their study in zebrafish. They established that it not only binds and blocks p53 
activity, but rather contributes to qualify p53 activity and induce BCL2L gene 
independently of p53. They showed also that 113p53 expression is induced 
dependently to p53 in the embryo development – at 24 hours post fertilization – and in 
DNA damaging stresses such as -rays, camptothecin, and roscovitine. Furthermore 
they found two cis regulatory regions, namely −1041 to −1991 bp and −1 to −239 bp 
crucial for the 113p53 expression. This regulation by p53 has a deep impact on p53 
mediated apoptosis as overexpression of 113p53 reduces drastically apoptosis in 
zebrafish. We concomitantly to these studies investigated the molecular aspects 
underlying 133p53 expression in humans.  
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We also wanted to investigate new and innovative aspects of p53 activity. p53 is well 
known for its transcriptional activity controlling the cell fate but it controls the 
expression of several protein through translation regulation, or direct binding, leading to 
proteasomal degradation (Ewen et al. 1995; Mosner et al. 1995; Galy et al. 2001). Our 
laboratory showed that p53 inhibits the FGF-2 expression through a mechanism of 
translational initiation blockade involving binding to the 5’UTR of FGF-2 and loss of 
mRNA conformation (Galy et al. 2001; Galy et al. 2001). Consequently, p53 is able to 
regulate FGF-2 by two distinct mechanisms. Many questions have risen from these 
observations: What is the purpose of such double layers regulation? Is this translation 
regulation extendable to other structured 5’UTR mRNAs? Do p53 isoforms have the 
same effect? 
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MATERIAL AND METHODS 
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A. Cells and embryos.
HUVECs – Promocell – were cultured in endothelial growth medium – EGM-2 
– containing 2% foetal bovine serum – Cambrex/Lonza – U87-MG human glioblastoma 
astrocytoma – n° ATCC : HTB-14, provided by LGC promochem, Molsheim, France – 
and fertilized chicken eggs – E.A.R.L. Morizeau, Dangers, France – were handled as 
described (Hagedorn et al. 2005). ABAE cells were grown in DMEM 10% Foetal 
bovine serum – FBS – with 2.5 mM L-Glutamine – From either Invitrogen, Paisley, UK 
or Lonza, Levallois- Perret, France – and FGF-2 at 2 ng/ml – From personal production. 
U2OS human osteosarcoma cell line  – ATCC no. HTB-96 provided by LGC 
promochem, Molsheim, France – were grown in DMEM serum supplemented with 10% 
FBS and 2.5 mM L-Glutamine. 
B. Transfections, transductions, drugs treatment and western blotting. 
 B.I. SiRNA and plasmid transfections in cells 
Small interfering RNAs – siRNAs – were purchased from Eurogentec – Liege, 
Belgium – and Sigma-Aldrich – Saint-Quentin Fallavier, France. Sequences are 
provided in Sup Table II. SiNON served as a negative control. SiTAp53 targets the full 
TAD of p53 and Si133p53 1 and 2 target the 5’ untranslated region of 133p53. U87 
and U2OS cells were transfected with the different siRNAs using InterferIN – Polyplus 
transfection, New York, USA – or with for plasmid transfection of p53 isoforms, using 
FuGENE reagent – Roche, Meylan, France. 
B.II. Transductions 
Following standard operating procedures, U2OS cell were transduced with 
replicating defective adenoviruses expressing p53 or the Green Fluorescent Protein – 
GFP at different multiplicities of infection. After six hours of treatment media were 
changed for fresh virus free medium. Transfection assessment was done by culture 
photos.
B.III. Drugs treatment and Western Blot 
Actinomycin D and Doxorubicin – Sigma-Aldrich, York, UK – were at indicated 
titrations and for the time mentioned in the figure legends. When recovering cells for 
drug treatment, above mentioned media were used. 
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Western blots were performed as previously described (Bourdon et al. 2005). 
Primary antibodies were CM-1 and Sapu (Bourdon et al. 2005) for p53 and 133p53, 
respectively, 2A10 – Abcam, Cambridge, UK – for mdm2, TUB2.1 – Sigma-aldrich – 
for -Tubulin and AC-15 – Sigma-aldrich – for -Actin. Horseradish peroxidase-
conjugated goat antibodies – Jackson ImmunoResearch, Baltimore – were used as 
secondary antibodies in immunoblots. Quantitative analysis of the immunoblot data was 
performed using the ImageJ 1.40g software. 
C. Endothelial cell migration, tube formation and proliferation. 
 C.I. Wound Healing Assay 
HUVEC and ABAE migrations in the “wounding assay” was performed 
respectively after eight and eighteen hours treatment with conditioned media from in 
siRNA-transfected U87 cells as described previously, i.e. after forty eight hours of 
siRNA treatment, cell media was changed to serum free medium for more twenty four 
hours (Bossard et al. 2004). Then newly formed conditioned media were transferred 
into the endothelial cell petri dishes.  
C.II. Boyden Chamber assay 
375 
L of U87 cells – 50 × 10
3
/well – were seeded in 12 well plates and 
submitted to siRNA treatment as descrived above. One day after media were changed to 
serum free medium for one more day. Following manufacter’s instructions inserts were 
added and 125 
L of ABAE cells – 100 × 10
3
/insert – in DMEM with 2% FBS were 
deposited in the inserts allowing them to migrate for six hours. Staining with 1% Trypan 
Blue for thirty minutes was processed after removing the upper layer of ABAE cells 
with a cotton bud and fixation of the lower layer – migrating cells – with 4% 
formaldehyde for 15 minutes. Photos were taken with a stereomicroscope and cells 
counted with a software.
C.III. Matrigel 
To assess the ability of cultured HUVECs to form vessel-like structures in 
culture – tube formation - Matrigel – BD Biosciences – was added to the wells of a 24-
well plate in a volume of 300 µl and allowed to solidify at 37°C for 30 min. After the 
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Matrigel solidified, HUVECs – 50 × 10
3
/well – were plated in 100 µl of media EGM-2 
with 0.5 % serum and 300 µl of siRNA tumour cells transfected supernatant containing 
20 ng/ml FGF2 final. Cultures were photographed and the mean number of branch 
points – SEM – per microscopic field was determined. Studies were performed in 
triplicate. 
C.IV. Cell proliferation assay 
Cell proliferation was determined by using the MTT [3-(4,5-dimethylthiaxol-2-
yl)-2,5-diphenyltetrazolium bromide] assay. HUVECs – 2 × 10
3
/well – were incubated 
with EBM-2 medium with 2 % FBS in 96-well plates. ABAE cells – 15 × 10
3
/well – 
were incubated with DMEM medium with 2 % FBS in 96-well plates. U87 cells – 5 × 
10
3
/well – were incubated as described above. HUVECs and ABAE were serum starved 
overnight and incubated in 50 µl of rerspectively media EGM-2 with 2 % serum or 
DMEM with 2 % serum and 150 µl of siRNA tumour cells transfected supernatant 
containing 3 ng/ml FGF2 final. The medium then was aspirated and MTT was added to 
each well – 0.25 mg/ml. Cells then were incubated for a further 4 h at 37°C. The 
medium then was aspirated and the cells were lysed with DMSO and absorbance at 540 
nm was measured.  
  
 C.V. ELISA 
 FGF-2 ELISA kits were purchased at Biolegends, supplier Ozyme, Saint 
Quentin Yvelines, France. Conditioned media from SiRNA treated U87 cells were used 
to assess FGF-2 secretion. Manufacturer’s procedures were followed and experiment 
repeated twice. 
C. Tumour in CAM and xenografts in mouse. 
SiRNA transfected U87 cells were deposited on CAM as described (Hagedorn et 
al. 2005). 18 Digital photos were taken on Day 4 using a stereomicroscope – Nikon 
SMZ800. 
For xenografts, were injected subcutaneously into nude background – n=8. 
Animals were sacrificed ten days later. Six-week-old nude mice were purchased from 
Janvier. Mice were injected with 10
6
 siRNA transfected U87 cells subcutaneously into 
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the mid-back region. The tumour size was measured in three dimensions with calipers 
one time a week starting at Day 7. Mice were observed for any change in behavior, 
appearance or weight. At the end of the experiment at Day 10 and Day 44, mice were 
killed and xenograft specimens were harvested for further analyses.
Tumours were considered as oblate half spheroids for the estimation of the 
volume using a stereomiscroscope and abode Photoshop software. 
D. Histology and immunochemistry. 
Tumours from CAM xenografts were fixed and cryo-sectioned as described 
(Saidi et al. 2008). Ten micrometer sections were stained with haematoxylin and eosin. 
For immunohistology studies, the following primary antibodies were used: Ab-2 – clone 
V9, NeoMarkers Ab, Montluçon, France – for Vimentin, Anti Ki-67 – AnaSpec Inc., 
Fremont, CA – for Ki-67, Fluorescein-coupled SNA-1 – AbCys, Paris, France – for 
Sambucus Nigra Lectin (SNA-lectin). Cell nuclei were visualized by DAPI dye. 
Corresponding secondary antibodies were from Molecular Probes – Invitrogen. SNA-
lectin staining allowed quantification of the capillary network invading the tumour by 
counting the number of green pixels on each field with Adobe Photoshop software. The 
whole surface of tumours has been counted because of capillary staining heterogeneity – 
at least 5 tumours / group.
For mice tumour xenografts, five thick cryosections of tissues were prepared 
using a Leica cryostat CM3050. Slides were fixed in ice cold acetone for two minutes, 
permeabilized in 0.1% Triton X-100 in phosphate buffered saline – PBS – blocked in 
5% bovine serum albumin in PBS for 1 hour at room temperature and then incubated 
with 5 µg/ml primary antibodies for 1 hour at room temperature. Blood vessels were 
detected with 5 µg/ml anti-CD31 – BD Pharmingen – antibody. After extensive 
washing, slides were incubated with 1-2 µg/ml cross-absorbed goat anti-rat DyLight 
549 – Tebu-bio – secondary antibody for 1 hour at room temperature. Slides were 
counterstained with DAPI – Tebu-bio. Coverslips were mounted with Dako Cytomation 
fluorescent mounting medium – Dako. For quantification, number of blood vessels in 5-
10 microscopic fields per cryosection – per animal – was quantified and the mean 
number of vessels +/- s.e.m. for the entire treatment group determined. 
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E. RNA extraction, nested RT PCR, real time qRT-PCR and TLDA.  
Total RNA was isolated from U87 cells using Nucleospin RNA II kit – 
Macherey Nagel, Hoerdt, France – assessed and nested RT PCR was performed as 
described previously (Bourdon et al. 2005). 
Quantitative PCR was performed on StepOne+ – Applied Biosystems – using 10 
to 100 ng of cDNA and Power SYBER Green or Taqman Universal PCR master mix – 
Applied Biosystems – for detection of FLp53, 133p53 and 18S.  
Taqman low density array – Applied Biosystems – was performed following 
manufacturer instructions with 50 ng of cDNA. The results were treated with the 
StepOne Software v2.0 – Applied Biosystems. Primers sequences are provided in Sup 
Table II. 
F. Plasmid constructions 
133p53, 133p53 and 133p53 plasmids for cloning experiments were 
obtained from Heiley Moore, SuMO laboratory, Dundee and the pTRIP-TRE-Tight-
MCS plasmid was obtained form the A. Delluc, BiViC platform, Toulouse. Restriction 
enzymes and ligases were from New England Biolabs, suppier Ozyme, Saint Quentin 
Yvelines, France. Fragment and Plasmid purification kits were from Macherey Nagel, 
Hoerdt, France. 
G. Luminoter assays 
Luminoter experiments were done following Promega’s procedures. 100 
L/well  
of 1X Passive lysis Buffer were added to the U2OS stable cell lines for 15 minutes and 
homogenized and transferred to plain white 96 well/plates. Luciferases – dual 
luciferases, Promega, Charbonnières-les-Bains, France – addition and measurement – 
30 
L/luciferase for 10 sec – were done by a Berthold Luminometer – Berthold, Thoiry, 
France. 
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H. Statistical analysis 
All statistical determination was performed with GraphPad Prism, version 4.0 – 
GraphPad, San Diego, CA. All data are presented as the mean ± SEM. One-way and 
two-way analysis of variance was used to evaluate the significance of differences 
between groups. All statistical analyses were performed with a two-tailed Student's t-
test. A p value of less than 0.05 was considered statistically significant. 
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RESULTS 
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Résumé de la partie résultats 
Suite à la découverte et la caractérisation de 9 nouvelles isoformes du gène de 
p53, J’ai focalisé mon travail sur les isoformes dépourvues du domaine de 
transactivation : les isoformes 133p53. Plus particulièrement j’ai étudié l’implication 
de ces isoformes lors de l’angiogenèse et la progression tumorale, qui m’ont permis de 
mettre en évidence leu rôle activateur prépondérant. En effet par une approche d’ARNi 
j’ai pu démontrer que lorsque l’on inhibait l’expression des 133p53 dans des 
glioblastomes humains possédant une p53 sauvage, les tumeurs présentaient une 
absence de réseau angiogénique in vivo dans un modèle de CAM. De la même manière 
j’ai démontré dans un modèle murin immunodéficient xénogréffé une diminution nette 
du nombre de vaisseaux, ainsi qu’une croissance tumorale plus lente. Ce mécanisme 
vis-à-vis de l’angiogenèse résulte d’une inhibition de la migration et la tubulogenèse des 
cellules endothéliales, et non de leur prolifération. Au contraire les cellules tumorales 
traitées par les Si133p53 prolifèrent beaucoup moins rapidement que les mêmes 
cellules contrôles. Grace à une étude large spectre de la transcription de facteurs 
impliqués dans l’angiogenèse, J’ai identifié plusieurs cibles, l’Angiogenine, la midkine, 
IL-12, ANGPTL4 et HGF régulées par 133p53. Cette étude nous a également permis 
d’identifier des cibles spécifiques de 133p53, ce qui n’a jamais été encore démontré, et 
de nouveaux gènes cibles de p53 comme la pléiotrophine et le VEGF-C. Enfin des 
lentivecteurs exprimant des isoformes 133p53 que j’ai construit sont produits afin 
d’étudier finement l’impact de leur surexpression. 
Je me suis également penché sur le mode de régulation du FGF-2 par p53. Les 
études précédentes dans notre laboratoire et ailleurs montrent un système complexe de 
régulation. Sur une lignée d’ostéosarcome humain, par approche ARNi, j’ai pu 
démontrer que la p53 endogène était capable d’inhiber l’activité IRES du FGF-2 et de 
C-myc. Au contraire j’ai constaté que p53 ne modifiait pas l’expression de l’ARNm du 
FGF-2, ni sa présence dans le milieu extracellulaire. A la suite de stress génotoxique tel 
que la doxorubicine, j’ai montré que le FGF-2 endogène subissait une diminution 
transitoire de sa présence protéique sans subir de variation de son expression de son 
messager. En revanche une forte surexpression de p53 par adénovirus ne modifie par 
l’expression du FGF-2, suggérant une modification post-traductionnelle spécifique de 
p53. 
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Pour finir, j’ai participé aux travaux de Moustapha Aoubala sur l’étude de la 
surexpression de l’isoforme 133p53 en réponse au traitement à la doxorubicine, dans 
des lignées de glioblastomes humains (Aoubala et al. 2010). 
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CHAPTER 1:    
Involvement of the 133p53 isoforms in angiogenesis and 
tumour progression in a glioblastoma model
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133p53 isoforms which include in this nomination ,  and  isoforms – 
respectively bearing 261, 209 and 214 a.a. – do not contain the p53 TAD in the N-
terminus domain. They even lack a part of the first of five well conserved DBDs. For 
this reason, it is widely suggested that 133p53 isoforms do not have transcriptional 
activity and modulate p53 activity through the binding of p53 when associating in a 
tetramer form. The  and  spliced isoforms do not contain the C-terminal 
oligomerization domain and in exchange possess 11 and 16 a.a. sequences. Our study 
showed that the full length p53 isoform does bind p53 indicating that the  splice still 
may confer the ability to tetramerize (Bourdon et al. 2005). Additionally, it is however 
reasonable to question the efficiency of inhibition regarding the quantity of bound N-
truncated isoforms to p53. Indeed, Chan et al. established that only one N-truncated 
molecule of p53 is needed to inhibit the transcriptional activity of a tetramer and DNA 
binding is not necessary for these isoforms to inhibit p53 (Chan et al. 2004). 
Surprisingly, three molecules of mutant p53 are necessary to inhibit the p53 tetramer. 
Consequently, even if these truncated isoforms are less expressed than the full length 
p53, they still conserve the ability to totally inhibit p53. 
133p53 isoforms unlike full length p53 are not expressed in all normal tissues. 
133p53 is expressed in 14 tissues over 18 tested, 133p53 in 6 and 133p53 in 10. 
For instance in breast tissues none of the short isoforms are expressed; in colon, bone 
marrow, spleen and testis all isoforms are expressed. Although we did not elucidate the 
reason of these differences, it would explain in part why p53 does not respond equally 
and does not trigger a response with same amplitude in different tissues (Lindsay et al.
2007). 
So far, 133p53 is considered as dominant negative of p53 through binding of p53 
and inhibiting its transcriptional activity. Based on the studies mentioned above, an 
alteration of 133p53 expression would result on an inhibition of p53 related induction 
of apoptosis and senescence. Particularly, and because of the localisation of 133p53 in 
the nucleus and the cytoplasm, the short isoform would be able to inhibit this pathway 
and would block interaction of p53 and its cytoplasmic partners – Bcl-2 for instance – 
for mitochondrial associated apoptosis.  
Another important aspect of 133p53 isoforms is their expression in abnormal 
cells like cancer cells. As we first showed 133p53 isoforms are differentially 
expressed in cancer cells and overexpressed in breast cancer (Bourdon et al. 2005). 
These observations have been confirmed in other cancer types I have previously 
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mentioned in this report: colon cancer, melanoma and renal cancer. These studies 
highlight the importance of two isoforms mainly, 133p53 and p53. To note Horikawa 
et al. in 1995 discovered a p53 mutant isoform in human choriocarcinoma cell line CC1 
resulting from mRNA lacking exon 2, 3 and 4… and starting at codon 133! 
Nevertheless, they didn’t compare it with normal cell lines (Horikawa et al. 1995).  
Shorty after the discovery of the p53 isoforms, I investigated different aspects of 
133p53. Among them I wanted to see whether these isoforms are able to modulate the 
migration of cancer cells that are wildtype for p53. The laboratory of Pierre Roux has 
strong expertise in mechanisms involving p53 related migration of cancer cells (Roger 
et al. 2006). They did some preliminary experiments in MEF cell line overexpresssing 
each 133p53 and found that these isoforms were able to induce the motility of the cells 
– data not shown. As invasion and angiogenesis are strongly related through different 
molecular events such as remodelling of the extra-cellular matrix –ECM – and 
loosening of cell to cell interaction, these results encouraged us to start a new project 
involving the role of 133p53 isoforms in angiogenesis.  
The choice of the glioblastoma model U87 – also known as U87 MG – was 
directed by the features of this cell line: we needed a wild type p53 cancerous cell line, a 
cell line that induces strong angiogenic response, a model that would allow to separate 
tumour growth and angiogenesis and in which this cell line has been properly studied. 
Consequently, the chorioallantoic membrane model became clearly the one of interest 
and the p53 wildtype U87 MG – U87 – cell line appeared to be the most convenient of 
these studies. 
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The well-known tumour suppressor p53 qualified of "the guardian of the 
genome" is mainly described as a single protein. However we have shown that the p53 
gene exhibits a complex pattern of expression leading to synthesis of nine isoforms 
(Bourdon et al. 2005; Bourdon 2007). Alternative splicing of intron 9 generates p53 
isoforms bearing different C-terminal domains – α, β and γ – Figure 23A. Initiation of 
translation at an alternative AUG codon leads to ∆40p53 isoforms devoid of part of the 
TAD, whereas the presence of an alternative promoter in intron 4 generates ∆133p53 
isoforms lacking the TAD and part of the DNA-binding domain (Yin et al. 2002; 
Bourdon et al. 2005). P53 isoforms are conserved from Drosophila and zebrafish to 
human, but little is known about their functions (Bourdon et al. 2005; Chen et al. 2009). 
Overexpression of ∆133p53 in human breast tumours versus normal breast tissue 
suggests a protumoural involvement of these isoforms, contrasting with the tumour 
suppressor activity of p53 (Bourdon et al. 2005). Indeed, human ∆133p53 as well as its 
zebrafish ortholog is able to antagonize wild-type p53 pro-apoptotic function (Chen et 
al. 2009). Furthermore, increased expression of ∆133p53 is associated with a loss of 
senescence (Fujita et al. 2009).   
In addition to its ability to control DNA repair, cell cycle arrest and apoptosis, 
p53 is involved in inhibition of angiogenesis, a critical mechanism in tumour 
progression and metastatic dissemination (Teodoro et al. 2007). This process is induced 
in most solid tumours, whose centers become hypoxic following an increase of the 
diffusion distance between the nutritive blood vessels and tumour cells. Hypoxia is one 
of the principal angiogenic stimuli leading to synthesis of angiogenic growth factors and 
inducing formation of new blood vessels (Pouyssegur et al. 2006; Fraisl et al. 2009). 
Such vessels, in addition to their ability to feed tumour cells, provide a way for cells to 
disseminate and form metastases. p53 inhibits angiogenesis by at least three 
mechanisms:  
1) by interacting with the central regulator of hypoxia, the hypoxia-induced 
transcription factor HIF1-α,  
2) by inhibiting production of pro-angiogenic factors such as vascular 
endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF2), and  
92 
3) by increasing production of anti-angiogenic factors (Dameron et al. 1994; 
Ueba et al. 1994; Ravi et al. 2000; Galy et al. 2001; Pal et al. 2001; Folkman 2006; 
Teodoro et al. 2007).  
p53 is able to induce tumour dormancy, and to block or reverse the tumour 
switch from dormant non-angiogenic state to angiogenic invasive phenotype (Giuriato 
et al. 2006; Naumov et al. 2006). Clinical data also suggest that p53 plays a crucial role 
in controlling tumour vascularization. However, nothing is known about the role of 
∆133 isoforms in this process. 
Among all solid tumours, glioblastoma multiform – GBM – are the most 
angiogenic by displaying the highest degree of vascular proliferation and endothelial 
cell hyperplasia (for review (Wong et al. 2009)). Such intense vascularization plays a 
critical role in the pathological features of GBM, including peritumoural oedema 
resulting from the defective blood brain barrier – BBB – in the newly formed 
vasculature. Thus, human glioblastoma U87, expressing wild type p53, has been chosen 
here to address the role of ∆133p53 in angiogenesis and tumour progression. 
In the present study we show by a knockdown approach that ∆133p53, in 
contrast to p53, is necessary for endothelial cells migration and tube formation in vitro, 
whereas it allows angiogenesis and tumour progression in vivo. Taqman Low 
Angiogenesis Array analysis showed that ∆133p53 pro-angiogenic activity is associated 
with a specific modulation of the angiogenic balance. 
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Α. ∆133P53 knockdown activates p53 expression.  
p53 isoforms expression was analysed by nested RT PCR in U87 human 
glioblastoma, known to exhibit a wild type p53 genotype – Figure 23B. This allowed us 
to detect p53, p53γ, ∆133p53 and ∆133p53β, but not p53β and ∆133p53γ. To note, In 
comparison with human normal brain tissue, U87 cell lines express the ∆133p53β
isoform (Bourdon et al. 2005). Also of important and maybe relevant for embryo 
development, human foetal brain tissues express all p53 isoforms evaluated but 
not ∆133p53α.  
U87 cells were treated by siRNAs targeting either p53 or ∆133p53, named 
SiTAp53 and Si∆133p53, respectively – Figure 23A. Knockdown efficiency was 
analysed by qRT-PCR – Figure 23C. Results showed that SiTAp53 and Si∆133p53 
generate specific knockdown of the targeted isoforms compared to the control SiNON.  
This was confirmed by Western blot – Figure 23D and E. Unexpectedly, ∆133p53 
knockdown generated an increase of p53 expression visible at both protein and mRNA 
levels, also reflected by up-regulation of the p53 target mdm2 Figure 23C and D. 
These data validated SiTAp53 and Si∆133p53 as efficient tools to knockdown 
p53 and ∆133p53, respectively. In addition, they also suggest that ∆133p53 might 
inhibit p53 expression. 
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A.\ Human p53 gene structure. Full length – TA – and N-terminal truncated – ∆133
– protein isoforms result from splicing in exon 9 – // – and/or transcription from 
the internal promoter in intron 4 – TA/133, respectively (Bourdon et al. 2005). 
SiTAp53 and Si133p53 are positioned underneath their target sites. p53 features 
are shown: TADs, proline rich domain – PR – DBD, NLS and oligomerization 
domain – OD. B.\ Gel electrophoresis – 1% agarose – of p53 isoform mRNAs 
detected by nested RT-PCR in U87 cells.   
Figure 23. Expression and knockdown of p53 isoforms in U87 cells. 
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C.\ 133p53 – left – and p53 mRNAs – right – relative expression following siRNA 
treatment – qRT-PCR. Experiments were repeated twice in duplicate and mean is 
represented. Sample quantity is normalized with 18S rRNA using the 2
-Ct
 method 
and set to percentage of control.  
Figure 23. Expression and knockdown of p53 isoforms in U87 cells. 
D.\ p53 and mdm2 – p53 
target – expression analysed 
by Western blot following 
siRNA treatments – β-
tubulin used as a control. 
Experiments were repeated 
four times for p53 detection 
and twice for mdm2. The 
histogram shows p53 signal 
quantification from Western 
blot – 4 independent 
experiments.*, p<0.05. vs 
SiNON control group.  
Statistics done sith Student 
test. p53 immunostaining 
with Sapu antibody, mdm2 
is with 2A10 antibody and 
-tub with -tubulin 
antibody 
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Figure 23. Expression and knockdown of p53 isoforms in U87 cells. 
97 
Β. ∆133P53 knockdown blocks endothelial cell migration and tubulogenesis.  
Anti-angiogenic features reported for p53 prompted us to look at the effect of 
∆133P53 in this process. This issue was first addressed in vitro, using human umbilical 
vein endothelial cells – HUVECs. HUVECs were treated with conditioned media 
produced by siRNA-transfected U87 cells, and their ability to migrate was analysed by 
the classical wound assay – Figure 24A and B. Data clearly showed that Si∆133P53 
inhibits HUVECs migration. Tube formation in matrigel was also significantly inhibited 
by Si∆133P53 treatment – Figure 24C and D – whereas HUVECS proliferation was not 
affected – Figure 24E. The blockade of HUVEC migration and tube formation was 
abolished in the double knockdown by SiTAp53 + Si∆133P53 – Figure 24B and D – 
indicating that ∆133P53 is employed in normal endothelial cell migration and tube 
formation by a mechanism that might involve a dominant-negative effect on p53 
activity. 
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A-E.\ Conditioned medium from knocked-down U87 were used to assess HUVEC 
migration, tube formation and proliferation. A.\ Micrographs of scratch wound 
healing assay of HUVEC in the presence 10ng/mL FGF2-contatining supernatants 
of U87 cells transfected with siRNAs as indicated. B.\ Quantification of HUVEC 
migration in scratch wound area.Asterisk indicates statistical significance. *, P < 
0.05 vs the control SiNON-treated group. Statistics done with Student test. 
Figure 24. ∆133P53 knockdown blocks HUVEC migration and tube formation, 
but not proliferation. 
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C.\ Micrographs of tube formation by HUVEC in Matrigel containing 10 ng/mL 
FGF2 in the presence of U87 cells supernatants. D.\ Quantification of the number of 
branch points formed. Asterisk indicates statistical significance. *, P < 0.05 vs the 
control siNON-treated group. Statistics done sith Student test. 
Figure 24. ∆133P53 knockdown blocks HUVEC migration and tube formation, 
but not proliferation. 
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E.\ Effects of siRNA-transfected U87 cells supernatants containing 3ng/mL FGF2 
on HUVEC proliferation. HUVECs were incubated with supernatants for 24, 48 and 
72 h. Cell proliferation was determined by the MTT assay. 
Figure 24. ∆133P53 knockdown blocks HUVEC migration and tube formation, 
but not proliferation. 
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C. 133P53 knockdown is anti-angiogenic and prevents tumour growth in CAM.  
∆133P53 effect on angiogenesis and tumour growth was addressed in vivo using 
the experimental glioma assay developed on the chicken chorio-allantoic membrane – 
CAM – as described previously (Hagedorn et al. 2005). This experimental glioma 
recapitulates hallmarks of human GBM and allows following the first steps of tumoural 
angiogenesis. SiRNA-transfected U87 cells were deposited on the CAM of fertilized 
eggs and tumours were analysed 4 days later – Figure 25A. SiTAp53 and Si∆133P53 
exhibited opposite effects on tumour angiogenesis: p53 knockdown resulted in increase 
of tumour vascularization, whereas ∆133p53 knockdown generated avascular tumours, 
showing that it strongly inhibited angiogenesis – Figure 25B and C. Angiogenesis 
inhibition by Si∆133P53 was confirmed by SNA-lectin quantification of vessels – 
Figure 25D. Such anti-angiogenic effect of Si∆133P53 was also correlated with smaller 
size of tumours at day 4 – Figure 25E. Western blot confirmed that siRNAs were still 
efficient in tumours – Figure 25, F and G. Interestingly, tumours resulting from the 
double knockdown by SiTAp53 and Si∆133p53 were similar to the control, as observed 
in vitro.
These results strongly suggested that ∆133p53 might exhibit pro-angiogenic and 
tumour accelerating activities, indicating that p53 and ∆133p53 might antagonize each 
other in the angiogenic conversion of glioblastoma.
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Figure 25. ∆133P53 knockdown prevents tumour growth and angiogenesis in 
CAM. 
U87 tumours were analysed in CAM following knockdown of p53 and/or 133p53. 
A.\ Experimental protocol. B.\ Histological analysis of p53 and 133p53 
knockdown in U87 tumours 4 days after implantation. I, II, III and IV.\ Tumour
growth was assessed by biomicroscopy – ×3 magnification, 
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Figure 25. ∆133P53 knockdown prevents tumour growth and angiogenesis in 
CAM. 
Histological analysis of p53 and 133p53 knockdown in U87 tumours 4 days after 
implantation. V, VI, VII and VIII.\ immunohistology – x20 magnification – and IX, 
X, XI and XII.\ H&E histology – x20 magnification. Images were taken in the 
center of the tumour. Tumour undifferentiated state and pro-invasive potential was 
checked by Vimentin staining. Numerous irregular and dilated capillaries are 
visible in histology photos of all tumours V, VI and VIII.\ except for 133p53
siRNA tumours VI.\. 
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Figure 25. ∆133P53 knockdown prevents tumour growth and angiogenesis in 
CAM. 
C.\ Angiogenic appearance presented as the percentage of absent – no visible 
tumour, vascular or avascular tumours following treatments with the different 
siRNAs – 10-18 tumours for each siRNA treatment. D.\ SNA-lectin staining 
allowed quantification of the capillary network invading the tumour by counting 
the number of green pixels on each field with Adobe Photoshop software. The 
whole surface of tumours has been counted because of capillary staining 
heterogeneity – at least 5 tumours / group. *, P < 0.05 vs the control siNON-treated 
group. Statistics done sith Student test. 
C
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Figure 25. ∆133P53 knockdown prevents tumour growth and angiogenesis in 
CAM. 
E.\ Tumour volume quantification – 11 to 16 tumours / condition. F.\ P53 protein 
expression in tumours analysed 4 days after implantation. Western blot is a merge 
of two different blots with 4 tumours for each condition. G.\ Quantification of p53 
signal from Western blots from at least three tumours after normalization with -
actin. *, P < 0.05 vs the control siNON-treated group. Statistics done with Test 
Student. p53 immunostaining with Sapu antibody and -Actin with -Actin
antibody 
* * 
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D. ∆133P53 knockdown prevents tumour angiogenesis and growth in mouse.  
To study ∆133P53 involvement in tumour progression, siRNA-treated 
glioblastoma U87 cells were subcutaneously implanted in nude mice, and followed 
during 44 days – Figure 26. At day 7 after xenografts implantation, ∆133p53 
knockdown resulted in significantly smaller tumours, an effect that was abolished in the 
double knockdown by SiTAp53 and Si∆133p53 – Figure 26A. In addition, tumour sizes 
measured at day 44 confirmed the anti-tumoural effect of Si∆133p53, whereas p53 
knockdown had no significant effect. In contrast to the data obtained at day 7, the 
double knockdown did not abolish the anti-tumoural effect of Si∆133p53 at day 44 – 
Figure 26B. Angiogenesis was quantified at day 7 by CD31 staining and showed that 
the Si∆133p53-treated tumours were significantly less angiogenic at day 7 – Figure 26C 
and D.
These data, fully consistent with that obtained in CAM, revealed that ∆133p53 
might be a pro-angiogenic activator of tumour growth, contrasting with the well-known 
tumour suppressor feature of p53. They also suggested the existence of two 
mechanisms: a short term effect where ∆133p53 would antagonize p53 activity, and a 
long term activity on tumour progression resulting from ∆133p53 intrinsic activity. 
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Figure 26. ∆133P53 knockdown prevents U87 tumour growth and angiogenesis 
in mouse xenografts. 
Knocked-down U87 were xenografted in nude mice. A.\ Tumour volumes were 
quantified at day 7 – 8 tumours / condition. B.\ Quantification of number of blood 
vessels/field. Asterisk indicates statistical significance. *, P < 0.05 vs the SiNON-
treated group.Statistics done with Student test. 
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Figure 26. ∆133P53 knockdown prevents U87 tumour growth and angiogenesis 
in mouse xenografts. 
Knocked-down U87 were xenografted in nude mice. C.\ Immunostaining to detect 
blood vessels in glioblastoma. Cryosections of murine xerographs of U87 cells were 
immunostained using anti-CD31 antibody. Nuclei were stained with DAPI – blue. 
Magnification x200. D.\ Evolution of tumour sizes until day 44. * = p<0,05 vs the 
SiNON-treated group.Statistics done with Student test.
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E. ∆133p53 modulates the angiogenic balance towards angiogenesis.  
The mechanism responsible for the pro-angiogenic activity of ∆133p53 was 
addressed by Taqman Low Density Array – TLDA – analysis of gene expression by 
siRNA-treated U87 cells. We used a Taqman human angiogenesis array providing a 
panel of 96 angiogenesis-related genes. In the control, expression of 14/39 anti-
angiogenic genes – 35% – and 20/28 pro-angiogenic genes – 71% – was detected, 
confirming the strong angiogenic basal state of U87 glioblastoma – Figure 27A.  
As regards anti-angiogenic factors, ∆133p53 knockdown resulted in induction of 
interleukin 12A – IL12A – and matrix metallopeptidase 2 – MMP2 – and repression of 
COL4A2 collagen – Figure 27B and Suppl data, Table I. MMP2 induction, also 
observed with p53 knockdown, was not specific of ∆133p53. In contrast, IL12A was 
repressed by p53 knockdown, but remained induced in the double knockdown, 
suggesting that its regulation by ∆133p53 is not dependent of p53. 
Several pro-angiogenic factors were down-regulated by ∆133p53 knockdown, a 
profile drastically different from that obtained with p53 knockdown – Figure 27C – 
Angiogenin – ANG, Midkine – MDK – and hepatocyte growth factor – HGF. 
Interestingly, the main angiogenic growth factor VEGF is downregulated almost two 
times folowing ∆133p53 knockdown, which is a strong variation for such important 
facotr. This suggests that ∆133p53 could play a role in the regulation of VEGF levels. 
However, to prove that VEGF levels is deeply modified, further studies should be 
undertaken. On the contrary, other main proangiogenic factors like FGF1 and FGF2, 
remained unaffected. Regulation of MDK and HGF was abolished by the double 
knockdown, indicating a p53-dependent activity of ∆133p53. In contrast, ANG 
regulation was maintained in the double knockdown and thus probably corresponds to 
an intrinsic activity of ∆133p53. ∆133p53 knockdown also downregulated the 
angiogenic marker Angiopoietin-like 4 – ANGPTL4 – a regulation that is only partially 
removed by the double knockdown – Figure 27D.  
The present study thus reveals that ∆133p53 is of first importance in the 
angiogenic balance and could be responsible for a strong angiogenesis stimulation that 
mainly contributes to acceleration of human glioblastoma progression. These data are 
novel and strongly contrast with the previously described anti-angiogenic activities of 
p53. Interestingly, ∆133p53 modulates the angiogenic balance differently of p53, 
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without affecting the classical angiogenic VEGF or FGF-dependent pathways, through 
regulation of a distinct signalling pathway involving other angiogenic factors including 
ANG, HGF and ANGPTL4. Data from the double knockdown indicate that ∆133p53 
mechanism of action is partly dependent of p53, but also results from intrinsic activities. 
∆133p53 has first been shown to impair p53-mediated apoptosis by a dominant-
negative effect (Bourdon et al. 2005). This is the most logical mechanism for an 
isoform lacking the TAD but still capable to tetramerize with p53. However, further 
studies of the zebrafish ortholog of ∆133p53, named ∆113p53, have shown that this 
isoform antagonizes p53-induced apoptosis via activating bcl2L, and is able to 
differentially modulate p53 target gene expression (Chen et al. 2009). As regards the 
ability of ∆133p53 to prevent cellular senescence, this activity seems to be mainly 
attributable to its dominant-negative effect over p53-induction of microRNA miR-34a 
(Fujita et al. 2009). In the present study, we clearly show that the regulation of several 
anti- and pro-angiogenic factors – mainly IL12A and ANG – observed following 
∆133p53 knockdown is not dependent on the presence of p53, thus cannot result from a 
dominant-negative effect. Furthermore the effect of ∆133p53 on long term tumour 
progression in mouse is not dependent on p53. Among possible mechanisms, it can be 
proposed that ∆133p53 would interact with other transcription factors, such as HIF1-α. 
It might also exhibit a transactivating activity, as shown for ∆Np63, its corresponding 
isoform in the p53-related p63 gene: ∆Np63 contains a transactivation domain TAD2 
and is able to transactivate the hsp-70 promoter (Ghioni et al. 2002; Wu et al. 2003). 
Our study shows that ∆133p53 knockdown results in p53 induction. This 
phenomenon takes place at both protein and mRNA levels, suggesting that ∆133p53 is 
able to repress p53 gene expression. Recent reports have shown that p53 transactivates 
the alternative promoter giving rise to ∆133p53, thus providing a negative feedback 
regulation of the p53 response, also shown for the p53 related gene p73 (Nakagawa et 
al. 2002; Chen et al. 2009; Marcel et al. 2010). Our data showing that ∆133p53 would 
be an inhibitor of p53 mRNA expression provide additional complexity to this feedback 
mechanism. In addition, they also provide a hypothesis of mechanism allowing 
∆133p53 to antagonize p53 activity, different from its dominant-negative function.  
A protumourigenic role of ∆133p53, contrasting with the tumour suppressor 
effect of p53, has been suggested by previous studies. In addition to its anti-apoptotic 
and senescence-inhibiting activities, ∆133p53 abnormal expression has been detected in 
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80% of mammary tumours from patients, whereas it is not expressed in normal breast 
tissue (Bourdon et al. 2005; Chen et al. 2009; Fujita et al. 2009). The present study 
demonstrates for the first time the direct role of ∆133p53 in acceleration of tumour 
progression. This role results, at least in part, from ∆133p53 capability to stimulate 
tumour angiogenic conversion. Such a feature may be critical in tumours exhibiting 
wild type p53, representing about 72% of grade I and 35% of grade II glioblastoma, for 
which angiogenesis has been recognized as a key event in their progression to 
malignancy (Ohgaki and Kleihues 2007; Wong et al. 2009).  
Our data may find an important relevance in anti-angiogenic therapeutics of 
cancer, presently based on angiogenesis inhibitors targeting the VEGF signalling 
pathway. Such treatments have been have proven to be efficacious in patient survival, 
associated with a chemotherapy. However, while antitumoural effects and survival 
benefit are often evident, relapse to progressive tumour growth has been recently 
reported, reflecting multiple mechanisms of adaptation to antiangiogenic therapies 
(Ebos et al. 2009; Paez-Ribes et al. 2009). In this context, ∆133p53 may have a critical 
role by allowing angiogenesis. Thus, targeting ∆133p53 may have a strong impact in 
cancer therapeutics.  
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Figure 26. ∆133P53 knockdown prevents U87 tumour growth and angiogenesis 
in mouse xenografts. 
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Figure 26. ∆133P53 knockdown prevents U87 tumour growth and angiogenesis 
in mouse xenografts. 
C.\, Histogram representing analysis of mRNA expression of anti-angiogenic genes. 
pro-angiogenic D.\ markers and target genes – according to Applied Biosystem 
classification form. We considered as relevant repression (-) or induction (+) 
variations superior to two folds. Experiments were repeated twice. Details are 
presented in Sup. Table I.p=<0.05 vs the SiNON-treated group.Statistics done with 
Student test. 
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Supplementary Figure 1. p53 protein expression in U87 xenografts after 4 days 
(Extended western blot from Figure 25.F).  
Western blot from tumor xenografts. Each condition is represented by several 
samples specifically numbered. Open red rectangles refer to the samples of the 
figure 25F.
p53 55 kDa 
-Act 40 kDa 
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Supplementary Table I: Angiogenesis Taqman Low Density Array of ∆133p53 and p53 
knockdown. 
Moy p Moy p Moy p
TNF 3.43 0.08 1.37 0.20 4.70 0.16
ANGPT2 2.15 0.23 6.94 0.25 -3.12 0.13
PTN 1.48 0.28 2.06 0.05 1.43 0.37
VEGFC 1.28 0.21 3.50 0.04 1.20 0.27
CTGF 1.23 0.10 -1.07 0.28 -1.35 0.03
TGFB1 1.21 0.37 1.55 0.06 -1.25 0.20
FST 1.16 0.30 -1.28 0.17 -1.60 0.15
VEGFB 1.15 0.06 1.33 0.16 1.11 0.38
GRN 1.15 0.36 -1.04 0.08 -1.09 0.34
FGF1 1.03 0.48 1.00 0.50 1.50 0.08
FGF2 -1.03 0.48 -1.53 0.00 -0.90 0.36
IL8 -1.03 0.48 -1.02 0.43 1.02 0.48
TGFA -1.04 0.43 -1.12 0.04 -1.30 0.21
EPHB2 -1.07 0.45 -1.04 0.39 -1.17 0.14
CST3 -1.31 0.38 -1.62 0.10 -1.38 0.36
VEGF -1.80 0.09 -1.12 0.39 -1.86 0.04
HGF -2.01 0.01 1.06 0.41 -1.75 0.22
EDIL3 -2.58 0.10 -1.25 0.18 -1.84 0.20
MDK -2.77 0.01 -1.01 0.49 1.24 0.01
ANG -6.91 0.02 1.10 0.44 -5.08 0.07
VASH1 3.70 0.21 4.84 0.24 1.84 0.13
MMP2 3.51 0.02 3.21 0.05 2.02 0.20
IL12A 2.64 0.04 -2.55 0.05 2.63 0.17
CXCL2 1.78 0.20 2.35 0.15 2.34 0.20
TIMP2 -1.05 0.27 1.27 0.13 -1.65 0.04
HSPG2 -1.12 0.40 1.20 0.26 -1.72 0.19
TIMP3 -1.21 0.34 1.11 0.12 -1.45 0.16
ITGA4 -1.27 0.37 -1.12 0.23 -1.22 0.37
FBLN5 -1.32 0.17 2.07 0.28 1.05 0.49
ADAMTS1 -1.38 0.13 -1.48 0.05 -1.32 0.30
COL15A1 -1.46 0.28 1.16 0.29 -1.74 0.14
THBS1 -1.53 0.03 -1.44 0.02 -1.24 0.25
FN1 -3.08 0.09 -1.13 0.21 -2.94 0.09
COL4A2 -4.70 0.05 -1.61 0.10 -1.93 0.06
EDG1 5.23 0.15 1.29 0.38 3.62 0.25
NRP1 1.19 0.37 -1.04 0.32 1.14 0.36
TEK -1.01 0.33 -1.35 0.04 -2.32 0.06
PDGFRB -1.22 0.01 1.15 0.17 -1.04 0.34
ITGB3 -1.36 0.18 -1.10 0.26 -1.48 0.09
NRP2 -1.51 0.06 -1.41 0.08 -1.42 0.08
KDR -2.04 0.15 -2.15 0.12 -1.74 0.07
PDGFRA -2.39 0.08 -1.32 0.17 -1.55 0.31
ITGAV 1.30 0.06 1.13 0.16 1.12 0.19
ANGPTL2 1.07 0.09 -1.20 0.31 1.32 0.14
PGK1 -1.44 0.28 1.49 0.09 -2.65 0.09
ANGPTL4 -7.93 0.02 1.22 0.20 -3.15 0.07
Pro-Angiogenic factors
Anti-angiogenic factors
Angiogenesis targets
Angiogenesis markers
Si133p53 SiTAp53 Si133p53 + SiTAp53
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Supplemental Table II : Sequences of siRNAs and oligonucleotides. 
Si133p53-1  5’- GGAGGUGCUUACACAUG[dT][dT] -3’ 
Si133p53-2  5’-CUUGUGCCCUGACUUUCAA[dT][dT]-3’ 
SiTAp53  5’-GGAAACUACUUCCUGAAAA[dT][dT]-3’ 
FLp53 Forward  5’ CAGCCAAGTCTGTGACTTGCA 3’ 
FLp53/133p53 Reverse 5’ GTGTGGAATCAACCCACAGCT 3’ 
FLp53/133p53 Probe  5’TCCCCTGCCCTCAACAAGATGTTTTGCC-3’ 
133p53 Forward 5’ ACTCTGTCTCCTTCCTCTTCCTACAG 3’ 
18S Forward 5’ CAACTAAGAACGGCCATGCA 3’ 
18S Reverse 5’ AGCCTGCGGCTTAATTTGAC 3’ 
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F. Further insights into 133p53 role in angiogenesis 
  
F.I. Verification of Si133p53-2 efficiency  
In parallel to Si133p53-1 siRNA, we undertake the verification of another 
siRNA specific to the 133p53 mRNA in U87 cell line, named Si133p53-2. To verify 
siRNA efficiency, I did as well as in Figue 23 RNA quantification and included the 
previous Si133p53-1 for comparison.– Figure 28. The results showed that besides the 
effects observed in Figure 23, the Si133p53-2 was also capable to induce the 133p53 
mRNA degradation but to a less extend – 40% compared to 60% for Si133p53-1. 
These differences are explained by either the sequence stringency that triggers RNA 
interference and by the different factors that could be bound to the region of the 
133p53 5’UTR mRNA. However Si133p53-2 induced the overexpression of p53 
mRNA in the same amplitude of Si133p53-1. Interestingly the SiTAp53 did not 
induce inhibition of 133p53 mRNA expression. Indeed, as p53 is known to induce the 
activity of 133p53 promoter, we would have expected decreased expression of 
133p53mRNA. This dichotomy of response between knockdown and overexpression 
of p53 may be explained by the fact that overexpressed p53 induce a huge set of genes 
that participate and modify p53 to activate its transcription activity. On the contrary 
when disrupted or at “normal” levels, p53 does not reach the threshold sufficient to 
induce genes. Also of interest, the double knockdown Si133p53-1/SiTAp53 results in 
the expression of unchanged p53 mRNA levels and shows that the potency of p53 
siRNA disruption is balanced by the indirect effects of 133p53 mRNA disruption.  
 I further analysed the Si133p53-2 effects in functional analysis. I thus did 
CAM assays similarly to those presented in Figure 25. Si133p53-2 tumours showed a 
decrease of the number of vascularized tumours – Figure 29. These results show us that 
Si133p53-2 is also potent to inhibit angiogenesis.  
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Figure 28. 133p53 A.\ and p53 B.\ mRNA assessment U87 cells following SiRNA 
treatment using QRT-PCR. For 133p53 mRNA quantification 100ng of cDNA 
were used after RT, for p53 mRNA 10 ng. Experiments were repeated twice in 
duplicate, Mean is represented. Sample quantity is normalized with 18S rRNA using 
the 2
-Ct
 method and set to percentage of control. Sequence of SiRNAs are in 
Suppl. Table II. 
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Figure 29. Angiogenic appearance presented as the 
percentage of vascular – red - or avascular  - white -
tumours following treatments with the different 
SiNON and Si133p53-2 SiRNAs. 15 SiNON 
tumours were vascularized at 81% and 12 Si133p53-
2 vascularized at 58%. Experimental procedure was 
the same as in Figure 25.  
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F.II. EC migration & proliferation assays with U87 conditioned media. 
  F.II.1. EC treatment with conditioned media of siRNA transfected U87.
 Before starting in vivo studies I did some in vitro preliminary work on 
endothelial cells using adult bovine aortic endothelial cells – ABAE – and HUVE cells 
– HUVEC. The results obtained with the HUVEC is already showed above in the paper 
but I first worked with ABAE cells, which are much more convenient to work. I used 
the same protocol as mentioned for the HUVEC to obtain the conditioned media. Data 
show that SiTAp53 treatment enhances cell migration, whereas Si133p53 has an 
inhibitory effect – Figure 30A and Figure 30B. ABAE cell migration was also studied 
using Boyden chamber assays. The main difference between Boyden chamber and 
wound healing assays – apart from the technical aspect of the experiment – is that in 
Boyden chambers ECs actively cross a membrane and thus show an active migration. In 
wound healing migration can be mixed up with spreading of a layer of cell into the 
empty part of the Petri dish, and with proliferation if the experiment last long. The 
results in Boyden chamber confirmed our results in wound healing and exhibited the 
same pattern: inhibition of migration with Si133p53 and increase of migration with 
SiTAp53 conditioned medium – Figure 31.  
Similarly to HUVEC I did MTT experiments to analyse the proliferation of 
endothelial cells between the different conditions and obtained the same results: p53 
and 133p53 knockdown did not have an effect on endothelial cell proliferation – 
Figure 32.  
These results showed that conditioned medium of Si133p53 treated U87 cells inhibits 
in a similar manner migration of both lines without affecting their proliferation. 
However, SiTAp53 treatment resulted in increased of ABAE migration, which was not 
visible in HUVEC. Such a difference may be explained first by the overall migration 
rates. As we can notice, migration was almost complete and the wound recovered by 
HUVEC, but the recovery was just beginning in the ABAE cells. Increased migration 
was hence easier to observe in ABAE cells. Another explanation relies on the 
differences between these two cell lines that could explain more responsiveness in 
ABAE cells.  
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Figure 30. ABAE cell migration after treatment of U87 SiRNA treated condition 
medium. In summary, as in figure 24, U87 media were harvested 48h after SiRNA 
treatment and dead cells and cell framents removed by centrifugation. A wound is 
done with the tip of a 10 µl cone and conditioned media introduced for 18h. A.\ Photos 
are taken at the beginning and the end of the experiment. Experiment done twice, 
Mean is represented. B.\ Cells counts correspond to the number of cells that have 
invaded the wound. P<0,05 vs SiNON-treated Control. Statistics done with Test 
Student.
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Figure 31. Boyden Chamber assay. U87 cells transfected with the above mentioned 
SiRNAs are cultivated for two days in the lower compartment. As control, media 
containing FGF-2 or a FGF-2 blocking antibody were used. In the upper 
compartment, 100000 ABAE cells were deposited in the insert – for a 24 well/plate 
boyden chamber - and filled with condition media from the lower compartment for 
six hours. Experiment done twice, Mean is represented. At the end of the experiment 
insert were incubated in paraformaldehyde (4 % p/v) and stained with trypan blue, 
and cleaned to allow the counting of the migrating cells. Experiment done twice. 
Cell counts were done with the freeware ImageJ. 
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Figure 32. MTT experiment of ABAE cells after treatment of
U87 SiRNA treated condition medium. Experiment done twice, 
mean is represented, and measured after 48h of conditioned 
medium treatment. Experiment protocol was the same as Figure 
24A-B.\  
O
.D
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F.II.2. Conditioned media from U87 cell line overexpressing p53 
isoforms.
 Finally we performed experiments using conditioned media from U87 
transfected cells with plasmids expressing p53 isoforms constitutively – one isoform per 
condition. Overexpression of p53 was controlled by Western blot and quantitative RT 
PCR – Figure 33 and 34. The relative quantification of p53 mRNA isoforms reflects the 
fold increase of each overexpressed isoform compared to the endogenous one. As I put 
the same amount of each plasmid for each transfection – 1ug/6 cm dish of U87 cell line 
– the differences of fold variation reflect only the difference of endogenous expression 
between full length p53 and short length isoforms. Indeed, using a common set of 
primer for all isoforms I already noticed that full length p53 mRNA is expressed 
between twelve to sixteen times more than the 133p53 isoforms. I then did a western 
blot to control the expression of the p53 isoforms. The result I obtained can appear quite 
surprising, but they can be explained by at least two main reasons. First the antibody I 
used for p53 detection – Sapu – reveals with more efficiency full length isoforms than 
133p53 ones and more 133p53 isoform than 133p53 and 133p53 isoforms. 
The following table show a set of antibody that is able to bind specifically p53 isoforms 
– Table 5. However we still do not have specific antibodies for the  splice isoforms. 
We noticed that the  spliced isoforms are much more difficult to reveal since they 
seems to be highly unstable.  
Wound healing assays were however performed after EC treatment with 
conditioned media of U87 transfected by plasmids expressing the different isoforms. 
We first observed that p53 overexpression, in a consistent manner with the literature, 
inhibits ABAE cell migration. Secondly, we found that overexpression of p53 induced 
a milder inhibition of ABAE cell migration. This means that p53 is also able to block 
EC migration and modulates the secretion of tumours. For this, p53 might have also an 
impact on microenvironment surrounding the tumour. On the contrary we did not find 
significant modification of ABAE migration with p53 overexpressed conditions. 
Concerning the 133p53, 133p53 and 133p53 isoforms we found respectively 
inhibition for  and  isoforms and enhancement for  isoform.  
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These results seem in contradiction with data obtained from the knockdown 
experiments where Si133p53 clearly inhibits EC migration. Although we must 
remember that Si133p53 blocks expression of the three 133p53 isoforms – α, β, and 
γ – it is unlikely that 133p53 would be responsible on the effect on migration as the 
endogenous isoform is not detected in U87, even by qRT PCR – Figure 23. Our 
hypothesis is that the ratio of 133p53 versus p53 is of first importance for endothelial 
cell migration and possibly other related effects. When present in a low stoechiometry 
to p53, 133p53 would have its specific effect leading to silencing of p53 expression 
and expression of angiogenic factors as shown above with the 133p53 knockdown – 
Figure 27. However when expressed in non physiological conditions by plasmid 
transfection, 133p53 –  and  – seem able to have the same effect of p53 on 
migration, maybe by forming tetramers with p53 and having in that case a stimulatory 
effect rather than a dominant negative effect.  Thus it would be important to tightly 
control the level of expression of the isoforms in order to clearly decipher the 
underlying mechanisms.  
Sheep
Polyclonal
133p53
133p53
133p53
40p53
40p53
40p53
p53
p53
p53
Epitope
(aa)
++−−++−−
++++−++−−
+++−−+−−
++++−−+++−
++++++−+++−
++++−−+++−
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++++++−+++++
++++++−++++++
Sapu
CM1 
recomb
p53
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()
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(372–382)
DO-12 
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1801 
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DO-1/DO-
7 (20–25)
Rabbit polyclonalMouse monoclonal
Table 5. Specific human p53 antibodies. from Bourdon et al. 2007
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Figure 33.  Western blot showing p53 isoforms protein expression following their 
overexpression by plasmid transfection in U87. Same amount of plasmid was used 
for each isform – 1µg per plasmid per 6 well/plate following indications. p53 
immunostaining with Sapu antibody and -Actin with -Actin antibody 
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Figure 34. p53 A.\ and 133p53 B.\ mRNAs relative expression following 
siRNA treatment – qRT-PCR.Experiments were repeated twice in duplicate. 
Sample quantity is normalized with 18S rRNA using the 2
-Ct
 method and 
set to percentage of control. Experimental protocol described in figure 33 and 
qRT-PCR done according to the material and methods.
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Figure 35. Quantification of wound healing assay of ABAE cells treated with 
conditioned media from overexpressing p53 isoforms in U87 cells. Experimental 
protocol was the same as Figure 24.
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F.III. Construction and verification of inducible 133p53 isoforms 
lentivectors  
In order to be able to express controlled levels of ∆133p53 isoforms, we 
constructed a set of inducible lentivectors overexpresssing p53 isoforms. Transduction 
of lentivectors has couples of interests in research and in our particular case. It is 
possible to transduce all types of cells and get instantly a population of cells expressing 
at 100 % the gene of its interest. Lentivectors, as a subfamily of retrovirus family is able 
to integrate the genome and be expressed for long periods. Furthermore, inducible 
vectors allow controlling the synthesis of the protein of interest. Presented in the figure 
36, here are the specific features of the 3
rd
 generation lentivector pTRIP-TRE tight GFP 
vector, provided by the BiVIC platform in Toulouse. Of importance are the 5’ and 3’ 
long terminal repeats – LTR – modified for better safety and the pTRE promoter 
construction containing a minimal CMV promoter fused to a Tetracyclin Responsive 
Element.  
 We first cloned the 133p53,  and  isoforms – from pCMV plasmids 
containing each isoform – into the multiple cloning site – MCS – of the pTRIP-TRE 
tight MCS vector by a tri-molecular ligation. The control the contruct inducibility, we 
transfected these plasmids with/without a pTet-off plasmid – allowing constitutive 
expression of the isoforms in the absence of doxycyclin – into U87 cells and assessed 
the level of transfection by FACSCAN and measured pTet-off induction by western 
blot. As a control we transfected as well the pcDNA plasmids containing each isoform. 
 FACSCAN experiments showed us a level of transfection of 15% of cells with 
either a pcDNA-GFP plasmid or a pTRIP-TRE tight GFP vector. This shows us that 
despites previous experiments with better rate – more than 80% – transfection is a 
sensitive a variable technique that would strongly change results of an experiment. 
 Protein expression of the transfected inducible plasmids is shown in the figure 
37 and revealed in Western by Sapu antibody. As expected, pTRIP-133p53 isoforms 
and pTetOff co-transfections induced strong expression of the 133p53 isoforms 
whereas 133p53 isoforms expressed control plasmid did not yield sufficient 
expression to observe it in western. Strikingly, pcDNA-based as well as pTRIP-based 
plasmids containging the isoforms did not express the same amount of isoforms, 
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probably due to their different stabilities. Furthermore, as explained in the B.II.2 
paragraph, 133p53,  and  isoforms are not equally sensitive to Sapu revelation.  
Presently, lentivectors are being produced to be able to analyse the effect of 
expression of each isoform on angiogenesis and tumour growth. 
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Figure 36. A.\Schema of the pTRE-TRIP-Tight-MCS used for the cloning of the 
different 133p53 isoforms.  
MCS: Multiple cloing site; 3’ and 5’ LTR: Long terminal repeat - modified; AmpR: 
Amicilin Resistance; pUC ORI: pUC replication origin; RRE: Rev responsive 
element; minimal CMV + pTRIP-TRE: tetracycline responsive element fusioned to 
minimal cytomegalovirus promoter. 
B.\ Strategy for the construction of the pTRIP-TRE- 133p53 plasmids: tri-
molecular ligation of Fragment 1 from Sal1/Pvu1 digestion of pTRE-TRIP plasmid, 
Fragment 2 from BamH1/Pvu1 digestion of pTRE-TRIP plasmid and Fragment 3 –
, ,  - from Xho1/Bamh1 digestion of the pCMV133p53,  and . 
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Figure 37. Western blot of p53 and the 133p53 isoforms in U87 cells following 
overexpression by plasmid transfection. p53 and 133p53 immunostaining with 
sapu antibody with different exposures. 
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F.IV. Analysis of the secreted angiogenic factors from U87 cells. 
  
All the effects observed in ECs migration and tubulogenesis are due to the 
composition of the conditioned media. In order to analyse them, I first performed an 
ELISA –Fig 38. After 48h of treatment, I harvested the media and evaluated the levels 
of FGF-2 protein in the supernatants. As we can see no remarkable differences of FGF2 
secretion, this argued against an involvement of FGF2 in the effect de ∆133p53 on 
angiogenesis.  
FGF-2 secretion in U87 cells
Figure 38. FGF-2 ELISA assay of conditioned media from 
U87 cells treated by SiRNAs. Experimental protocol for 
harvesting the conditioned media has been described in 
Figure 30. Procedures for ELISA were done following 
manufacturer’s protocol. Experiment repeated twice in 
duplicate and Mean is represented 
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F.V. Proliferation of SiRNA transfected U87 cell lines  
As the effects of p53 and 133p53 are intrinsically related with cell survival, 
proliferation and death, we next analysed the proliferation of siRNA transfected U87 
cells by MTT. The results are presented in the following figure 39. This shows us first 
that there is barely any difference in proliferation between control treated cells and the 
p53 knockdown cells. On the contrary we can observe that Si133p53 treatment 
strongly affects U87 proliferation: At day 1 there is less catabolism of MTT products 
revealing less proliferating cells. When looking at MTT catabolism we can also see that 
the proliferation rate is smaller in 133p53 knockdown cells. When SiTAp53 is jointly 
added to Si133p53 treatment there is no notable difference. This means that the effect 
observed here in proliferation in not dependent of p53. Endogenous 133p53 is then 
able to induce cell proliferation independently of the full length p53 isoforms. However 
in these cancerous cells, Si133p53 treatment does not completely inhibit proliferation 
and still rapidly become confluent in vitro – from my own experience. Anyway these 
results could explain why in mice the Si133p53 treated U87 tumours progress not as 
quickly as the control and the SiTAp53 ones. Additionally these results confirm the 
taqman low density array, showing specific targets genes for 133p53.
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Figure 39. MTT proliferation assay in U87 cells treated by SiRNAs or FGF-2. 
Exprimental protocol is the same as Figure 24.  
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F.VI. Angiogenesis & tumour proliferation assessment in mice xenografts 
 In order to link the differences in tumour progression in mice xenografts with 
common parameters of tumour growth, observed when measuring the evolution of the 
tumour size until day 44, I analysed the tumours for their proliferation index and their 
vascularity. I used in immunofluorescence the Ki-67 proliferating cells marker, the 
CD31 endothelial marker and DAPI as nucleus marker. This allowed me to measure the 
proportion of Ki-67 positive cells and the total endothelial cell staining in tumour cells. 
Results are shown in the figure 40. As we can see none of the siRNA transfected 
tumours induced a difference in both parameters. This is due to the fact that tumours 
have been harvested too late to observe any phenotype. At this time the effects of 
siRNA are no more visible. However it seems that siRNAs can be effective for long 
time when transfected and then implanted into nude mice. For instance Filleur et al.
found that their siRNA targeting VEGF-A knocked down its target at 50% until day 13 
and was correlated with strong inhibition of cJ4 rat fibrosarcomas xenograft growth 
(Filleur et al. 2003). At day 44, it seems quite normal, although I have not done the 
proper measurements, that siRNA have not effect.This is the reason why we decided to 
do the experiment again and sacrifice the mice at day 10 – Figure 26.   
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Figure 40. Quantification of immunostaining for angiogenesis index and Ki-67 
for proliferation index in glioblastoma from cryosections of murine xerographs 
of U87 cells. For each conditions at least four samples were counted. 
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F.VII. Significance of the Angiogenesis Taqman Low Density Array. 
The absence of involvement of FGF2 encouraged us to perform the taqman low 
density array – TLDA – described in the article. In this part I will discuss more in 
details the results obtained by the TLDA.  
For this study I used the Human Taqman Angiogenesis array – provided by 
Applied Biosystem – which is a set of 94 genes contributing in angiogenesis or 
revealing a certain angiogenic phenotype, plus 2 controls. Present in this array are 28 
proangiogenic and 37 antiangiogenic factors that are produced by many normal and 
tumour cell types. Of course this is not an exhaustive list but it contains many important 
precursors and factors allowing getting a relevant map of the angiogenic transcriptome. 
10 markers of angiogenesis relate genes have been shown to be correlated to act upon 
angiogenesis and 14 targets of angiogenesis are receptors involved in angiogenic 
pathways. These genes are expressed in endothelial cells and thus are able to reflect the 
activation of these cells. There are also 5 markers of lymphangiogenesis.  
When I analysed the results I was first surprised by the strong difference in the 
number of pro and antiangiogenic genes expressed in U87 cell line. Indeed a large 
majority of antiangiogenic genes was not expressed or expressed in level so low that it 
could not be detected by TDLA and on the contrary the majority of proangiogenic genes 
was expressed – Figure 27A. It is not possible to make comparison at this stage as there 
is only one cell line observed.  However, Buckanovich et al. in their comparison 
between tumour vascular cells from ovarian cancer and vascular cells from healthy 
ovaries established a large profile of genes specifically expressed in tumour vascular 
cells (Buckanovich et al. 2007). In this profile 50 genes were overexpressed and 20 
were newly expressed.  
 We decided to take into account in this assay to detect the effect of ∆133p53 on 
gene expression only the genes with a variation greater than 100 % – inhibition or 
induction – and that had a p value inferior to 0,05.  
 F.VII.1. Antiangiogenic factors – Fig 26B
  F.VII.1.a. MMP-2 
Matrix metalloproteinase 2 – MMP2 - also called gelatinaseA is the most 
abundant MMP and is constitutively secreted by most cells. MMP-2 degrades collagens 
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present in the vascular basement membrane and in the interstitium and is strongly 
involved in tumour angiogenesis (Fang et al. 2000). MMP-2 is principally an 
angiogenic factor through it activity of remodelling the ECM that induces cell migration 
and invasion, this protein is also able to cleave the plasminogen to produce angiostatin. 
Additionally, degradation of ECM is not necessarily correlated with angiogenesis as 
excessive ECM remodelling hampers and disables functions of cell motility (Jackson 
2002). Particularly linked with our study MMP-2 is transcriptionnally induced by p53 
(Bian and Sun 1997). As a result of 133p53 knockdown, p53 is induced to activate 
MMP-2 transcription – Figure 27 B. On the contrary we should have obtained an 
inhibition of transcription following p53 knockdown. Another mechanism must be 
involved in MMP-2 regulation when p53 is disrupted. Further investigation would be 
interesting to unravel this complex system.  
  F.VII.1.b. IL12A. 
Interleukin-12 – IL-12A or p35 – is a protein that binds Interleukin-12 – IL-
12B or p40 – to form the heterodimer Interleukin12 – IL-12 or p70. IL-12 has been 
shown to prime couples of immune cells through the production of the interferon- – 
IFN- – which also is responsible of the antiangiogenic activity of IL-12 (Del Vecchio 
et al. 2007). In vivo studies revealed that IL-12 has potent antitumour and antimetastatic 
activities but partly due to its antiangiogenic activity (Nastala et al. 1994; Tahara et al.
1994; Voest et al. 1995). IL-12 antiangiogenic activity is defined by reduction of V3 
integrin, VEGF-A, MMPs and augmentation of IP-10, mig, LMP2 and 7, between 
others (Del Vecchio et al. 2007).  
In our study IL-12 seems to be tightly regulated by both p53 and 133p53 
isoforms. Indeed in this aspect p53 knockdown induces the downregulation of IL-12
and 133p53 knockdown induces IL-12’s upregulation. It is quite interesting to see 
that 133p53/p53 double knockdown results in increased IL-12 mRNA levels – not 
significant however – that would mean that 133p53 effect on IL-12 expression is 
predominant to p53’s. This result is quite in contradiction with previous work done of 
p53 +/+ and p53 -/- cells in mice where IL-12 levels has been correlated to p53 status 
although direct link has not been shown (Zheng et al. 2005; Tsai-Turton et al. 2009).  
  F.VII.1.c. COL4A2. 
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COLA42 gene is part of a big family of collagens described earlier on. 
Collagens 4 are the most expressed collagen type in basal membrane COL4A2 encodes 
Collagen alpha-2(IV) chain protein whose cleavage in C-terminus give raise to the 
Canstatin, an anti-angiogenic gene. Little is known however concerning its cleavage but 
increased collagen production is thought to enhance ECs migration and remodelling. As 
regards the 133p53 knockdown leads to COL4A2 inhibition of expression. It seems 
that it is depending on p53 because we cannot observe the same phenotype when p53 is 
disrupted. However basal levels of p53 do not enter in the regulation of COL4A2 
expression but rather an induction of p53 caused for instance in our study by Si133p53 
treatment. 
F.VII.2. Proangiogenic factors - Fig 26C
  F.VII.2.a. Angiogenin 
Angiogenin, a 14 kDa secreted protein bearing multiple proangiogenic facets, 
belongs to the ribonuclease superfamily with 33% of homology to the pancreatic 
ribonuclease A – for a complete review see (Gao and Xu 2008). This ribonuclease 
activity although weak, is essential for its proangiogenic activity. Angiogenin is also 
able to form a complex with ECs’s -actin involved in the conversion of plasminogen to 
plasmin. Plasmin in turn will be responsible for ECM and basement membrane 
degradation, key event for cell migration and invasion for tumour cells.  
Angiogenin induces also a signal transduction pathway via its specific receptor. 
This 170 kDa has still not been clearly characterized but the downstream events imply 
ERK1/2, protein kinase B AKT and Stress Associated Protein Kinase /c-jun N-terminal 
kinase – SAPK/JNK. These intracellular pathways are involved in the induction of cell 
proliferation by Angiogenin. In fact, expression of the 170 kDa receptor is allowed only 
when cells are not confluent, triggering cell proliferation. On the contrary, binding to -
actin occurs when cells are close to confluence and thus is a signal for the remodelling 
of the basal membrane and EC migration.  
Finally, Angiogenin is also capable to induce rRNA transcription via its 
translocation to nucleus by an ANG-binding element.  
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The strong inhibition of Angiogenin in our study by Si133p53 treatment in the 
U87 cell line is independent of p53. This factor is then a good candidate for the 
explanation of the blockade of tumour growth. Additionally, the separate pathways 
involved in cell migration and cell proliferation can suggest us that this factor has an 
important role in our system – we found an effect on migration but not on proliferation 
of ECs. These observations strongly put Angiogenin as a determinant factor involved in 
133p53 disruption.  
  F.VII.2.b. Midkine 
Midkine – MDK or Neurite Growth-promoting Factor 2 – is a basic heparin-
binding growth factor belonging to a family of three members, Pleiotrophin, retinoic 
acid heparin-binding protein and Midkine. Midkine has various actions in anti-
apoptosis, mitogenesis, transforming, tissue repair, inflammation, angiogenesis and 
fibrinolysis, and is expressed during embryogenesis but extremely repressed in adults. It 
is then overexpressed in tumours and is deeply involved as a marker of carcinomas (Dai 
2009).  
In our study Midkine is downregulated by Si133p53, dependently of p53.  
F.VII.2.c. Hepatocyte growth factor 
 Scatter factor/hepatocyte growth factor and its receptor tyrosine kinase c-met are 
involved in processes but particularly in tumour growth and angiogenesis (Abounader 
and Laterra 2005). Likewise other master regulators of angiogenesis such as FGF-2 and 
VEGF, HGF displays various means of actions but giving a complete set of them upon 
angiogenesis is not the subject at this point of investigation. As its strong involvement 
in angiogenesis, HGF regulation could appear of importance. However the mild 
induction observed in must be taken cautiously, although significant. 
F.VII.2.d. VEGF-C 
 As described previously, VEGF-C is mainly involved in lymphangiogenesis 
although it controls also formation of the vasculature. In our context VEGF-C mRNA 
expression is responsive to p53 knockdown. These interesting results suggest that 
VEGF-C and p53 have an unexpected link, indicating a novel argument for p53 to 
control tumour related lymphangiogenesis, tumour dissemination and metastasis. 
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F.VII.2.e. Pleiotrophin 
 Pleiotrophin – PTN – is the second member of a family of structurally related 
heparin-binding growth factors. Pleitrophin is a cytokine in which binding to heparin is 
a critical event permitting the binding to its receptor and its inhibition, the receptor 
protein tyrosine phosphatase – RPTP/. This receptor dephosphorylates -catenin, -
adducin, Fyn, GIT1-Cat and P190RhoGAP, ALK kinase and other receptor tyrosine 
kinase (Perez-Pinera et al. 2007). Pleiotrophin is a important activator of the angiogenic 
switch by initiating endothelial cell proliferation, migration, tube formation and 
regulates the levels of FGF-2 and VEGF-A. 
 The fact that p53 is involved directly an indirectly in the regulation of 
Pleiotrophin and Midkine, two homologs of the same family allow to hypothesize that 
there is a conserved element in their promoter targeted by p53 and 133p53. 
F.VII.3. The angiogenic marker ANGPTL4 – Fig 26D
Angiopoietin-like 4 protein  is part of the subfamily of angiopoeitin-like proteins 
which contributes in many functions like glucose and lipid metabolism, immune 
response and atherosclerosis. Angiopoietin-like protein 4 is induced under ischemic and 
hypoxic conditions suggesting a role in angiogenesis. It has also implications in cell 
migration, invasion and angiogenesis, tumour dissemination and metastasis (Stapleton 
et al. 2010). However the exact role of this protein in angiogenesis is still controversial 
as several studies contradict each other. (Le Jan et al. 2003; Cazes et al. 2006; Yang et 
al. 2008; Tian et al. 2009; Ma et al. 2010).  
ANGPTL4 is deeply involved in angiogenesis and regulation of its expression 
means a modification of angiogenic potency. The contexts in which ANGPTL4 clearly 
enhance or inhibit angiogenesis is still too elusive to conclude.  
In our context ANGPTL4 is strongly inhibited in response to Si133p53 and so 
would indicate that constantly with our results, ANGPTL4 exerts a proangiogenic 
activity. This modulation seems also to be dependent of p53 as the double siRNA show 
a milder inhibition of this factor. In conclusion this factor, although not clearly 
characterized, is of strong importance in our study.  
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CHAPTER 2:      
            
      Regulation of FGF-2 by p53
144 
A. p53 and translation 
A.I. Mechanisms of translation initiation. 
Translation is a master regulatory mechanism of protein synthesis involving the 
steps of initiation, elongation and termination. However it is generally thought that 
translation initiation constitutes the main step of translation regulation. In the following 
paragraphs I will only focus on this process describing two main translation initiation 
mechanisms that are the Cap dependent translation initiation mechanism – 5’end 
scanning translation initiation – and the Internal Ribosome Entry Site mechanism – 
IRES translation initiation.  
 The machinery involved in all types of translation initiation mechanisms is based 
on a pool of constitutive factors that participate in a two steps program: the attachment 
of the 43S pre-initiation complex and the encountering of the start codon which signals 
the formation of the 80S ribosome and start of translation. I will describe it briefly – 
compared to its enormous complexity and the amount of data available – considering 
Cap-dependent translation as the template mechanism and then comparing it to IRES-
dependent translation - for more information see the review (Jackson et al. 2010). 
  A.I.1. Cap dependent translation initiation. 
 Most eukaryotic mRNAs undergo this mechanism to deliver protein s to the cell. 
As a dynamic and continuous mechanism the assembling of 43S pre-initiation 
complexes involves either synthesis of ribosomosal proteins and the 18S ribosomal 
RNA, forming the 40S subunit, eukaryotic initiation factors – eIFs – and 
complementary factors, or the recycling of 80S post-termination ribosomal complexes 
dissociated into subunits. The 43S pre-initiation complex more specifically comprises, 
besides the 40S subunit, a set of eIFs engaged in the presentation of the Met-tRNA 
initiating anti-codon – eIF2-GFP-Met-tRNA ternary complex or eIF2TC plus co-
activating factors such as eIF3, eIF5 and eIF1 involved in ribosome scanning as well.  
The 43S pre-initiation complex is next recruited by the eIF4F cap-binding 
complex composed of the eIF4E which binds to the m7GpppG 5 terminal ‘cap’ 
structure of mRNA, the eIF4A mRNA helicase and eIF4G which enhances helicase 
activity. Additionally, two other mRNA helicase catalysers – eIF4B and H – can help 
the eIF4A protein and the Polyadenylation Binding Protein – PTB – joins the 3’ mRNA 
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end to the eIF4F complex, constituting a loop-like structure. After binding of the 43S 
complex to eIF4F to form the 48S complex, mRNA is unwound, which undoes 
secondary structures, and scanned from the 5’ end in direction to the 3’ end until it 
founds a start codon, in the same time eIF4E sticks to the cap structure of the mRNA 
and unbinds the eIF4F complex. The more secondary structures the 5’end have, the 
more ATP is needed for their unwinding.  
There are canonical and non canonical initiation codons. The canonical codon is 
AUG and with best extend GCC(A/G)CCAUGG – the Kozak sequence, and non 
canonical codons are CUG or UUG in eukaryotes. When the 48S subunit meets the 
initiation codon, it stops and triggers a mechanism that recruits the 60S subunit. In this 
role eIF1A plays an important role by maintaining recognition specificity. The open 
scanning-competent conformation of the 40S complex switches to a closed and locked 
codon-anticodon base pairing conformation through tightening its interaction with 
eIF1A and displacing eIF1 from the P-site – the peptidyl tRNA binding site on the 
ribosome. This move discards the repression of eIF1 upon eIF5 which is an eIF2-
specific GTPase-activating protein – GAP – leading to the dissociation of eIF-2-GDP 
from tRNA and partial release from the 40S subunit, GTP hydrolysis and Pi release. 
Following that the 60S subunit of the ribosome – composed of a 5S RNA, a 28S RNA , 
a 5.8S subunit and ribosomal proteins – plus eIF5B-GTP binds to the 40S complex and 
replace the others eIFs – eIF1, eIF1A, eIF3 and eIF2-GDP. Translation can proceed 
(Jackson et al. 2010).  
  
  A.I.2. IRES dependent translation initiation. 
IRESs, first discovered in uncapped viral mRNAs, are long highly structures 
composed of secondary and tertiary structures in the 5’end mRNA. Intensive research 
has yield to consequent lists of IRESs present in viral as well as cellular mRNAs that 
can be found for instance at www.rangueil.inserm.fr/iresdatabase/ or http://iresite.org/
(Bonnal et al. 2003; Mokrejs et al. 2010). Despite the consequent number of discovered 
cellular IRESs, their uniqueness of structure renders difficult the setting up of common 
features, common co-factors and solid consensus mechanism of translation initiation 
(Baird et al. 2006). For this reason, IRESs are mostly described by the conditions that 
induce their activity or on the contrary phenotypes resulting from their activation. IRES 
are present in proto-oncogenes, growth factors, receptors, and transcription factors, have 
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strong tissue specificity and are involved in many conditions such as apoptosis, cell 
cycle, development, hypoxia, ischemia, heat shock, myogenesis, ER stress and more.
The identification of IRESs is strongly challenged by stringent and complete set 
of control experiments to avoid the possibility of cryptic promoters, aberrant splicings 
or even sequences able to induce mRNA cleavage. In fact, couples of the discovered 
IRESs have been re-questioned, lightening up the difficulty to prove the functionallity 
of such structures (Hellen and Sarnow 2001; Kozak 2005; Baranick et al. 2008).  
IRES-dependent initiation of translation is still not a clearly definied mechanism 
due to the specificity of each IRES element. The 40S ribosomal subunit recognizes a 
specific feature in the 5’UTR of the mRNA and is directly recruited or recruited by 
IRES Trans-Acting Factors – ITAFs – such as ribosomal proteins, eIFs, miRNAs or 
other proteins (Fitzgerald and Semler 2009). In this process the eIF4F complex is not 
implied and most of the time no scanning mechanism neither occurs, impeding Kozak’s 
hypothesis of general mechanism of translation initiation. Numerous co-regulators of 
IRES activity mentioned above as ITAFs – PTB, unr, hnRNP C1/C2, hnRNP A1, 
hnRNP K, La antigen, DAP5, p53nrb etc… – are thought to give some more 
information on the IRES initiation of translation. Strikingly ITAFs can shuttle between 
nucleus and cytoplasm like hnRNP A1, which is involved in human rhinovirus type 2 
RNA – HRV-2, human apoptotic peptidase activating factor 1 mRNA – apaf-1 – and 
FGF-2 mRNA. Additionally, some hnRNPs like hnRNP A1 have been found in 
transcriptional complexes, associated to promoter (Paramasivam et al. 2009). These 
kind of evidences led us to hypothesize cross talks between transcription and translation 
mechanisms. As regards, we found a coupling mechanism of FGF-1A promoter/mRNA 
expression during muscle differentiation through the presence of a cis-acting sequence 
in the promoter A allowing specifically the induction of the FGF-1A IRES (Conte et al.
2009).  
 IRES dependent translation is generally activated when the cell undergoes some 
stress conditions – listed above – in which a least in a part of them, cap-dependent 
translation in down regulated. IRESs allow the cell to overcome general translation 
downmodulation and to produce smart, precise and rapid blow of specific factors that 
will help the cell to respond to a stringent context.  There are several mechanisms of cap 
dependent translation inhibition either induced by viruses or through regulation of eIFs 
availability and activity. For instance, enteroviruses and rhinoviruses are single strand 
RNA viruses and possess IRES elements to drive their translation. Not only their RNA 
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is directly translated after viral infection, but they also encode proteases that cleave 
eIF4G and PABP proteins, inhibiting cap-dependent translation. Levels of general cap-
dependent translation are also governed by a co-factor of eIF4E protein, eIF4E-binding 
protein – eIF4E-BP1. Under certain stresses or EncephaloMyoCarditis virus – EMCV – 
infection, this protein is underphosphorylated and able to fix eIF4E and thus inhibits 
eIF4F mediated translation initiation. Additionally, under endoplasmic reticulum – ER – 
stress, a double-stranded RNA-activated protein kinase-like ER kinase – PERK – is 
shown to be activated in response to ER stress and to phosphorylate eIF2-subunit – 
one of the three subunit of the eIF2 protein, thereby inhibiting cap-dependent translation 
initiation (Harding et al. 1999). 
A.II. p53 regulates translation 
  As mentioned in the introduction, p53 mainly acts through the regulation of 
transcription activity, but also through direct interaction with other proteins. In this part 
I will focus on its barely known ability of binding and regulating mRNA translation.  
  The mammalian target of rapamycin – mTOR – is critically involved in 
regulation of translation and many other processes like autophagy, cell proliferation and 
cell survival. To emphasize the importance of mTOR, it is to note that proteins that 
inhibit mTOR are often considered as tumour suppressors. Fen et al. have shown that 
p53 activation induces mTOR inhibition and consequently the dephosphorylation of 
eIF4E-BP1 and p70S6 kinase (Feng et al. 2005). Generally, mTOR activation induces 
p70S6 kinase activity that in turn will phosphorylate the S6 ribosomal protein, a co-
activator of protein synthesis. The first team who discovered the regulation of these 
proteins by p53 was of Clemens et al, whose work will be discussed in more in details 
below (Horton et al. 2002). These findings show that p53 is able to inhibit both cap-
dependent translation initiation and IRES-dependent translation initiation.  
 Translation inhibition by p53 is not restricted to the messenger class but also 
concerns ribosomal and transfer RNAs. Indeed, it regulates the activity of RNA 
polymerases I and III, potentially affecting the synthesis of components of the 
translational apparatus (Chesnokov et al. 1996; Cairns and White 1998; Budde and 
Grummt 1999). Furthermore, p53 can associate with ribosomes through covalent 
binding to the 5.8 rRNA (Fontoura et al. 1997). 
 The group of Clemens et al. has worked for several years on the interaction of 
p53 and eIF4E-BP1 (Horton et al. 2002; Constantinou et al. 2003; Clemens 2004; 
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Tilleray et al. 2006; Constantinou and Clemens 2007; Constantinou et al. 2008). They 
have shown that independently to the apoptotic pathway, thermosensitive p53 – p53ts – 
induces translation inhibition through dephosphorylation of eIF4E-BP1 and p70S6, and 
cleavage of eIF4G1 form and eIF4B, a phenomenon that induces cell death if p53ts 
overexpression lasts more than 16h. These authors have also shown this phenomenon in 
an inducible wildtype p53 context correlating with dephosphorylation and accumulation 
of eIF4E-BP1. Lately they have found that p53 induces irreversibly the truncation of 
eIF4E-BP1 which becomes more stable, binds eIF4E and target it to the proteasome. 
p53 is able to specifically target and modulate the translation of several mRNAs at their 
5’UTR such as its own mRNA, FGF-2 mRNA and cyclin dependent kinase 4 – cdk4 
(Ewen et al. 1995; Mosner et al. 1995; Galy et al. 2001; Galy et al. 2001). Particularly, 
our group has demonstrated that p53 is able to modify the structure of the 5’UTR of the 
FGF-2, leading to an inhibition of IRES activity. With FGF-2 5’UTR leader-CAT 
chimeric constructs, we have shown that this regulation is specific to the wild type p53 
but not DBD mutants. Interestingly a p53 mutant the for transactivating domain is still 
able to repress FGF-2-CAT expression, suggesting that transcriptionnally disabled p53 
can act upon FGF-2 translation. In this respect p53 – or its isoforms – can be considered 
as authentic ITAFs. Consistent with these results, Oberosler et al. demonstrated that in 
in vitro experiments p53 binds RNA as well as DNA and has strong RNA-RNA 
annealing activity suggesting another argument in favour of p53 activity over translation 
(Oberosler et al. 1993; Nedbal et al. 1997).   
All these findings allowed us to better understand the mechanisms controlled by 
p53. In fact the double layer of transcription-translation regulation corresponds to a 
smart answer of the cell to stress conditions thanks to p53. After a short and mild stress, 
the overall machinery of translation is halted diminishing the energy necessary for 
protein production and p53 induces a cell cycle arrest response. When on the contrary 
stress conditions last longer, p53 engage apoptosis pathways and irreversible translation 
arrest.  
Overexpression of p53 has couples of effects upon protein expression: it first 
inhibit translation through eIF4E-BP1, but it also induce the transcription of several 
target genes and thus their protein expression. Additionally, p53 properties towards 
mRNA show that it is able to inhibit specific IRES-dependent translation. In the respect 
to these evidences, we hypothesized that p53 could act on a more significant pool of 
mRNAs and modify their translation as well as their transcription.    
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B. Regulation of FGF2 expression by p53 
 B.I. Translational control of p53 
 In this study I used U2OS cells, a wildtype p53 osteosarcoma cell line. The 
advantage of this strain is, apart from its potential of growth and the easiness of cell 
culture, its easiness to be stably transfected by plasmids.  
 To study the rates of cap-and IRES-dependent translation a specific tool has 
been developed in the laboratory: the “Lucky Luke” bicistronic vector. In our particular 
situation, this vector possesses from 5’ to 3’ a constitutive and strong promoter, the 
Renilla Luciferase Open Reading Frame – ORF, the sequence of IRESs or hairpin 
sequence – inhibiting the ribosome to restart translation at second cistron, the Firefly 
Luciferase ORF and the -globin 3’untranslated region containing the polyadenylation 
site. The following figure 41 presents a schematic view of the bicistronic vector and the 
different plasmids used and constructed.  
Because transient transfection in cells occurs only in a part of them, and yields 
non physiological levels of transgene expression, we decided to select pools of stable 
cell lines expressing each construction mentioned above. This provides the advantage of 
a homogenous population expressing at least one copy of transgene per cell that equally 
map the whole genome of the strand. However amplification results in selection of the 
CAP
IRES
[An]
Renilla
Luciferase
Firefly
Luciferase
Luc R Luc F
40S 40S
The “Lucky Luke” bicitronic vector
Figure 41. Schematic representation of the “Lucky Luke” bicistronic plasmids. This 
vector allows the study of cap-dependent and IRES-dependent translation: The first 
Renilla Luciferase – LucR – is under cap-dependent translation whereas the Firefly 
Luciferase – LucF – is under IRES-dependent translation.  
Plasmids used for the experiments – Constructed by L. Créancier (Creancier et al.
2000; Creancier et al. 2001). 
pCRHL: CMV promoter, LucR ORF, Hairpin sequence, LucF ORF 
pCRFL: CMV promoter, LucR ORF, Human IRES FGF-2 sequence, LucF ORF 
pCRMP2L: CMV promoter, LucR ORF, Human IRES C-myc sequence, LucF ORF 
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most potently dividing cells – that for instance have integration in a gene that repress 
cell growth – to the expense of the other cells. Consequently I constructed three stable 
cell lines expressing the bicistronic vector mentioned above.  
Finally, in these selected cell lines, I did some siRNA transfections. Results are 
presented below – Figure 43 and 42.  
In the first experiments I used bicistronic vectors with CMV promoter and either 
FGF2 IRES or c-myc IRES mentioned above – Figure 41. Indeed, c-myc functioning as 
an oncogene and consequently in opposition to p53, the c-myc IRES, as well as the 
FGF2 IRES, seemed us a good candidate for translational regulation by p53.  
Here we show that knockdown of p53 induces an augmentation of FGF-2 and c-
myc IRES activities. Scrumble siRNA or various doses of Sip53 – targeting the exon 7 
– presented different firefly/renilla luciferases ratios. At low doses knockdown of p53 – 
15 and 30 nM – induce an increase in FGF-2 and C-myc IRES mediated translation but 
not in the Hairpin control. At high doses the same effect persists for the FGF-2 IRES 
but is inversed for c-myc IRES. Consequently the levels of p53 are important and can 
totally induce opposite responses.  
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Figure 42. IRES activity normalized in U2OS stable cell lines treated by different 
concentrations of Sip53 or Control SiRNA. Absolute values of IRES activities 
show that Hairpin activity in more than 10 times lower to other IRESs.  
Samples are lysed in Passive Lysis Buffer 1x and Luciferases luminescences are 
measured with a LB 960 Centro microplate luminometer –Berthold France SAS, 
Thoiry, France - using the Dual-Luciferase Reporter Assay System – Promega,
Charbonnières-les-Bains, France. Experimental procedure is following the 
manufacturer’s indications. Experiment repeated twice in duplicate and Mean is 
represented 
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Figure 43. p53 mRNA assessment U2OS cells following SiRNA treatment 
using QRT-PCR. Sample quantity is normalized with 18S rRNA using the 2
-
Ct
 method and set to percentage of control. Data presented are fold 
variation to SiScrumble Control SiRNA. Sip53 SiRNA sequence: 
5’GACUCCAGUGGUAAUCUACd[T]d[T] (Brummelkamp et al. 2002) 
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B.II. FGF-2 endogenous regulation by p53
In 1994, Ueba et al. demonstrated that overexpression of wildtype p53 induced 
repression of FGF-2 transcription through the binding to its promoter between -20/+50 
in U87MG and SKHepG2 cell lines. In the mean time they showed that the mutant p53 
induced FGF-2 transcription (Ueba et al. 1994). The protein encoded by this p53 mutant 
– 143Val-Ala – can still bind to the p53 DNA consensus element and can retain some of 
the transactivation properties of wild-type p53 (Funk et al. 1992; Zhang et al. 1993; 
Friedlander et al. 1996). In some particular sets it is even able to inhibit tumour growth 
(Simpson et al. 2005). However observations linking p53 transcriptional regulation and 
FGF-2 haven’t been confirmed elsewhere.  
On another hand, our laboratory has proved that p53 is also able to regulate the 
translation of FGF-2 using FGF-2-CAT chimeric constructs (Galy et al. 2001; Galy et 
al. 2001). However the endogenous levels of FGF-2 were not investigated. To answer 
this question we decided to analyse this aspect. 
 B.II.1. p53 knockdown
Surprisingly Sip53 treatment induced in U2OS cells a decrease of FGF-2 protein 
levels. This is shown in U2OS stably transfected cells or in native U2OS. This decrease 
was not correlated with a significant decrease in FGF-2 mRNA levels – Figures 44, 45 
and 46. In a previous work we ruled out the possibility of a decreased stability of FGF-
2-CAT constructs when cells were overexpressing p53 (Galy et al. 2001). 133p53 
does not seem to participate in this regulation as in none of the cell lines it changed 
protein or mRNA levels. As we can see in U2OS cell line Si133p53 treatment induced 
an overexpression of p53. At this point of the investigations we did not go further and 
did not analyse target genes of p53.  
These results are in contradiction to our previous results and to the work of Ueba 
et al. It can be argued first that in both studies mentioned above, none of them worked 
with the endogenous proteins but with plasmid constructions overexpressing p53 or 
chimeric constructions. Secondly and more importantly, in their cases they mimicked a 
stress resulting in p53 overexpression contrarily to my experiments. This may unravel 
specific action of p53 as its levels are thought to oscillate during cell cycle (Tyson 
2006). To answer this question we then decided to induce p53 expression.    
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Figure 45. FGF-2 and p53 mRNA quantification in U2OS cells following 
SiRNA treatment using QRT-PCR. Experiments were repeated twice in 
duplicate and mean is represented. Sample quantity is normalized with 18S 
rRNA using the 2
-Ct
 method and set to percentage of control. Sequence of 
SiRNAs are in Suppl. Table II. FGF-2 sense primer: 
CATCAAGCTACAACTTCAAGCAGA ; Anti-sense primer : 
CCAGTAATCTTCCATCTTCCT, obtained with Primer Express3.0
Software. 
Figure 44. Western blot showing p53 and FGF-2 protein expression following
sip53 transfection in U2OS stable cell lines.. p53 immunostaining with Sapu 
antibody and -Actin with -Actin antibody and FGF-2 with sc-79 antibody –
Santacruz Biotechnologies, Heidelberg, Germany.  
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Figure 46. Western blot showing p53 and FGF-2
protein expression following sip53 transfection in U2OS 
cells. .. p53 immunostaining with Sapu antibody and -
Actin with -Actin antibody and FGF-2 with sc-79 
antibody 
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B.II.2.Response to p53 induction
 B.II.2.a. Actinomycin D
We first use Actinomycin D – ActD – to induce p53 at 47 nM. ActD is used both 
for basic research and clinical research as a transcription inhibitor at high doses and also 
as a chemotherapeutic agent and formerly an antibiotic. Its toxicity is due its ability to 
bind DNA at sites of transcription initiation, rich in sequences GC but also RNA 
polymerase I and II (Sobell 1985). Through binding of RNA pol II ActD induce the 
activation of p53 and at some doses of ActD transcription inhibition can be avoided, 
leading to only p53 activation and cell cycle arrest (Choong et al. 2009). To note in our 
experiment the dose used for treatment is a high dose that can induce transcription 
inhibition.  
Following ActD treatment we can observe a double effect, one dependent to p53 
and the other that might result from RNA synthesis inhibition – Figures 47 and 48. As 
we previously observed, knockdown of p53 induce FGF-2 protein decrease, but when 
ActD is added and consistently with time it inhibits FGF-2 mRNA and protein presence 
– here is shown mRNA levels only after six hours of treatment.  
However it is quite difficult to interpret with ActD treatment as p53 activation is 
supposed from my previous experiments to induce FGF-2 protein levels and ActD 
inhibits FGF-2 transcription expression. To get rid of the transcription parameter, we 
decided to use doxorubicin 
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Figure 48. FGF-2 and p53 mRNA quantification in U2OS cells 
following ActD treatment using QRT-PCR. 
Figure 47. Western blot showing p53 and FGF-2 protein expression 
following ActD treatment in U2OS cells. .. p53 immunostaining with 
Sapu antibody and -Actin with -Actin antibody and FGF-2 with sc-
79 antibody 
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  B.II.2.b. Doxorubicin 
Doxorubicin – Dox– is of great use in chemotherapy although it has secondary 
effects such as heart injury. To overcome this issue liposomal derivatives have been 
engineered. As ActinomycinD its use must be tightly titrated to have best effects. Dox 
mode of action is intercalating DNA resulting in its impairment and its damage. It also 
inhibits the topoisomerase II and produce reactive oxygen species. For all these reasons 
Dox potently induces apoptosis. To note Dox does not induce transcription inhibition on 
the contrary of ActD.   
In this respect we induced two types of stresses: one short stress followed by a 
time of recovery or continuous stress until harvest. We have previously shown that short 
Dox stress does not induce apoptosis but rather cell cycle arrest so we wanted to see if 
the regulation by p53 was a survival response or an apoptotic one. We used Dox at the 
common dose of 1 µM.  
After dox treatment, FGF-2 rapidly decreases but then is expressed again to 
make up the levels of expression of the control – Figure 49 and 50.  This shows a 
double mechanism is which FGF-2 synthesis is first blocked and then after longer 
treatment is actively produced. As FGF-2 half life in solution is quite short – few hours, 
accumulation of FGF-2 can not be considered in this experiment (Nur et al. 2008)
 . mRNA levels assessment shows us that no significant variation of FGF-2 or 
p53 mRNA expression is observed. Regarding the treatment in its self, we can see there 
is no difference between a short stress followed by recovery – inducing cell cycle arrest 
– or continuous Dox treatment – inducing apoptosis. This means that the variations of 
FGF-2 protein levels can not be associated with an apoptotic stress but is more 
generally triggered by doxorubicin stress.  
However doxorubicin mean of action is not mediated by p53: for instance,  
Sphingosine Kinase 2 and the transcription co-factor FHL2 are involved in dox 
induction of p21 and cell death, independently to p53 (Martin et al. 2007; Sankala et al.
2007). Dox also induces ROS independently to p53 and induce apoptosis through Bax 
and Bcl-A modulation in p53 null cells SaoS-2 (Tsang et al. 2003). It is thus important 
to know if the downmodulation of FGF-3 we have observed is not due to a p53-
independent response. 
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Figure 49. FGF-2 and p53 mRNA quantification in U2OS cells 
following Dox treatment using QRT-PCR. 
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Figure 50. Western blot showing p53 and FGF-2 protein expression following
Doxorubicin treatment in U2OS cells. .. p53 immunostaining with Sapu antibody 
and -Actin with -Actin antibody and FGF-2 with sc-79 antibody 
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BII.2.c. Overexpression of p53 
To overexpress p53 in U2OS cells I used a Replication-defective adenovirus 
serotype 5 expressing p53 – Gift from P. Roberston – SuMO, Dundee. These viruses 
have the advantage to be strongly expressed in all types of cells.  
In order to better understand the dynamics of FGF-2 regulation by p53, I 
harvested my cultures at different times after infection. The results are presented in the 
Figure 51 and show the protein expression of p53 and FGF-2 in U2OS cells. 
As we can see, overexpression of p53 in U2OS did not have strong effect on 
FGF-2 protein expression – Figure 51. Even with strong expression of p53 aftr 36h of 
treatment, which should kills most cells, and apparently induces the proteolysis of p53 
into truncated forms of p53, no consistant variation of FGF-2 can be observed. For this 
reason, we concluded that if p53 is involved in the stress mediated inhibition of FGF-2 
protein expression, it is through modifications of p53 that enables it to bind FGF-2 
promoter.  
Therefore these results show us a complex mechanism in which induction of a 
p53 dependent stress hampers transiently induces FGF-2 expression by a mechanism 
still not clearly defined. As showed previously by our work and in the litterature, p53 
act upon transcription, translation but also upon FGF-2 bioavaibility. For this reason we 
decided to analyse the secretion of FGF-2.   
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Figure 51. Western blot showing p53 and FGF-2 protein expression following
adenovirus p53 infections in U2OS cells. The equivalent of a MOI of 1 was injected in 
U2OS media. p53 immunostaining with Sapu antibody and -Actin with -Actin
antibody and FGF-2 with sc-79 antibody 
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B.II.3. FGF-2 secretion 
 FGF-2 secretion is not a common mechanism as FGF-2 does not have a signal 
peptide, and does not take any conventional route for secretion. On the contrary it 
involves exocytotic vesicles, the -subunit of the Na
+
/K
+
-ATPase and the interaction 
with HSPGs (Florkiewicz et al. 1998; Taverna et al. 2003; Zehe et al. 2006). As p53 is 
involved in the bioavaibility of unbound FGF-2 through regulation of FGF-BP and 
heparanase expression, we wandered if modulation of p53 would modify the activity of 
these proteins and thus catalyse FGF-2 secretion.  
 As we can see knockdown of full length p53 induce less FGF-2 secreted. 
This is due to the decrease of FGF-2 protein levels – Figure 52. Through this ELISA in 
U2OS cell line, it appears that FGF-2 is not regulated by p53 through its secretion. 
Other techniques should be undertaken to better understand FGF-2 expression secretion 
and bioavaibility in the ECM such as pulse chase techniques for instance.  
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FGF-2 secretion in U2OS cells
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Figure 52. FGF-2 ELISA assay of conditioned media from 
U20S cells treated by SiRNAs. Experimental protocol for 
harvesting the conditioned media has been described in 
Figure 30.  
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The discovery of nine p53 isoforms constitutes a major breakthrough in p53 
genetics and molecular biology, linking back its phylogenetic tree from zebrafish to 
human and unveiling several new modulators of p53 activity (Bourdon et al. 2005). 
133p53 isoforms triplet i.e. ,  and  do not possess the p53 transactivation domain 
but most of the DNA binding domain and, the ability to bind p53 and impair its 
antitumour potency (Fujita et al. 2009; Aoubala et al. 2010). Besides the dominant 
negative activity on p53, 133p53 isoform has shown selectivity in inhibition of p53 
mediated transactivation. It is now established that following DNA damage p53 engages 
the 133p53/p53 negative feedbackloop resulting in upregulation of 133p53 and 
inversely inactivation of p53.  
In this manuscript I have focused my work to study p53 and 133p53 isoforms 
involvement in angiogenesis. I have demonstrated the major impact of 133p53 
isoforms for the formation of new blood vessels, the settlement of ectopic tumours 
xenografts and its progression in vitro and in vivo. By Taqman low density array I have 
identified new target genes of p53 and 133p53 such as IL-12, MMP2, Pleiotrophin, 
VEGF-C, HGF and ANGPTL4 and showed that 133p53 is capable to transactivate 
genes independently of p53 – Midkine and Angiogenin. These results are represented 
diagrammatically in Figure 55. Finally, I have shown that 133p53 disruption cause 
transactivation of p53 expression. 
Figure 55. Schematic representation of 133p53 effects on angiogenesis
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I also have investigated the regulation of FGF-2 by p53. Interestingly p53 
activity over FGF-2 protein expression is much more complex than previously thought. 
It appears that FGF-2 is not regulated through transcription or bioavaibility in the 
extracellular domain, but more by a translational mechanism implying p53 activation 
triggered by stresses such DNA damage treatment. p53 activation may result from a 
post-translational modification.   
A. Mechanistic considerations about the role of 133p53 
A.1. Which step and what mechanism are blocked? 
 Knockdown of 133p53 in vitro clearly result in a specific phenotype of cancer 
cells resulting in the induction of endothelial cell migration and tubulogenesis, but not 
proliferation – Figure 24, 30, 31 and 32. In consequence the molecules secreted by the 
tumour in the environment must act upon the remodelling of the cytosqueleton, through 
a motility process including sequentially: formation of filopodia sensing angiogenic 
stimulus, extension of lamellipodia, focal adhesion attachment to extracellular matrix by 
focal adhesions, contraction of the cell body, rear release and recycling – Reviewed in 
(Lamalice et al. 2007). Quite surprisingly, TLDA results show that neither FGF-1 nor 
FGF-2 are downregulated when 133p53 or p53 levels are disrupted – Figure 27. In 
parallel, I have observed no variation of FGF-2 secretion in U87 cells – Figure 38. On 
the contrary, Angiogenin, which upregulates endothelial cell migration by interacting 
with -actin and inducing plasmin activity, has its mRNA expression strongly decreased 
by 133p53 knockdown. -actin, expressed in smooth muscle cells but also in U87 cell 
line, may be cleaved from the extra-cellular domain of U87 cells, proceed to 
conditioned media and activate the plasminogen cleavage in endothelial cell cultures 
(Kim et al. 2007). It is also able to induce proliferation through its 170 kDa receptor or 
induction of rRNA transcription. For these reasons, Angiogenin, identified the present 
study, seems to be a good candidate to explain how 133p53 isoforms can inhibit cell 
migration and proliferation, and consequently angiogenesis.  
In the same assay, Midkine and heparin growth factor – HGF – mRNA levels are 
downregulated in Si133p53 condition. Although these latter regulations have less 
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amplitude than the Angiogenin mRNA regulation, they can be determinant for the 
induction of anti-angiogenic phenotype. MMP-2 mRNA levels in both 133p53 and 
p53 knockdowns are upregulated suggesting a complex mechanism. 
Finally, angiopoietin-like 4 protein is also strongly regulated by Si133p53 and 
could be essential in antiangiogenic and antitumoural activity of 133p53. The results 
obtained in this work would strengthen the hypothesis of an angiogenic factor which 
complex regulation can have opposite consequences. 
 It is now important to confirm these results by expressing each 133p53 isoform 
in U87 and to analyse 133p53 pro-angiogenic and pro-tumoural effects in other cell 
lines and link these effects with specific secreted factors. For this reason we have 
developed lentivirus vectors expressing each 133p53 isoform in an inducible manner 
in order to tightly control their levels of expression and thus the ratio p53/133p53 
which appears for us very important in 133p53’s activities.  
A.2. Intrinsic versus extrinsic activity of 133p53 
Taqman angiogenesis assay showed new target genes of p53 such as VEGF-C 
and pleiotrophin and concomitant new target genes of p53 and 133p53 such as IL-12. 
It reveals a novel and interesting aspect of p53 in lymphangiogenesis, although only 
correlations have been established between p53 status and tumour dissemination 
through lymph nodes and lymph node metastasis (Ruddell et al. 2008).  
 More importantly, TLDA teaches us that 133p53 is able to transactivate 
angiogenin independently of p53. This aspect is confirmed by in vivo measurements of 
tumour growth in 133p53 knockdown and double 133p53/p53 knockdowns. These 
results show us that at least angiogenin but maybe other factors triggered by 133p53 
are induced and facilitate tumour growth. Transcriptional activation domain is essential 
for p53 to have its basal transactivating activity, but 133p53 kept almost all the DNA 
binding domain sequence suggesting that 133p53 can still bind to DNA. Further 
investigation would permit us to see if 133p53 might have a transactivating activity by 
itself or or mediated by another partner.  
    
A.3. p53 mRNA regulation by 133p53 
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I have shown that 133p53 knockdown induce p53 mRNA expression. This 
additional layer of regulation in the loop constituted by p53 and 133p53 link even 
more tightly these two partners together. Consequently, low levels of 133p53 act on 
p53 mRNA transcription but when 133p53 is overexpressed – particularly for instance 
induced by p53 – it inhibits p53 by direct binding in tetramers. This indicates that 
133p53 acts by at leats two different mechanisms leading to p53 downregulation or 
inactivation, respectively. This regulation can be useful in response to an important 
stress inducing p53 activation, particularly to set back p53 to levels of unstressed cells. 
However in conditions of constitutive overexpression of 133p53 such as in cancers, 
p53’s activity is deeply impaired. This results in some cancers in a wildtype p53 
blocked by overexpression of 133p53. For this reason it is essential to take into 
account not only p53 but also 133p53 for the measurement of p53 potency. This 
approach could tell us about the real opportunity of using p53 mediated therapeutics. 
As mentioned above it is possible that 133p53 has intrinsic activity resulting 
from a transactivation activity - possibly mediated by its interaction with other partners. 
Several factors control p53 mRNA expression such as E2F1, NF-B and YY1 and NB1 
(Furlong et al. 1996; Benoit et al. 2000; Choi et al. 2002). It could be interesting to 
investigate if expression of these factors is regulated by 133p53. Finally another 
mechanism of p53 mRNA expression regulation could happen through modulation of 
p53 mRNA stability by enhanced degradation of p53 mRNA. In such a case we can 
hypothesize that 133p53 would directly bind to the mRNA through its DNA binding 
domain and influence mRNA stability. 
According to my results from TLDA, 133p53 intrinsic activity woud also exert 
itself on expression of specific angiogenic factors either by transactivation or by mRNA 
destabilization. 
B. Mechanism of translation regulation by p53. 
In this present study we have shown that endogenous p53 is able to modify the 
activity of FGF-2 IRES and its protein expression level, but not FGF-2 transcription – 
contrarily to previous work by Ueba et al. – nor its secretion – Figure 42, 44, 45 and 52. 
Hovever in normal culture conditions we could not show any regulation of FGF-2 
protein expression by 133p53 – Figure 46. Such an apparent contradiction may be due 
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to the fact that FGF2 mRNA translation occurs by both cap- and IRES-dependent 
mechanisms. In unstressed conditions the cap-dependent translation of FGF2 mRNA 
would be predominant and mask any effect of p53 on the IRES-dependent translation of 
FGF2 mRNA. However, when cells are stressed by doxorubicin, we observe a transient 
inhibition of FGF2 protein expression related to p53 induction. Although we have not 
definitively proven that FGF2 protein downregulation is directly due to p53, these data 
suggest that translational regulation of FGF2 mRNA translation would occur in stress 
conditions, when the cap-dependent translation is blocked. This would provide a real 
physiological significance to the effect of p53 on IRES-dependent translation.  
In previous reports we had already proposed the hypothesis that p53 could be a 
inhibitory ITAF able to inhibit translation by direct binding to the FGF2 mRNA (Galy 
et al. 2001). Here we have confirmed, by our knockdown approach, that endogenous 
p53 is indeed able block IRES-dependent translation, and that this effect is not limited 
to the FGF2 IRES as c-myc IRES is also regulated by p53. In this respect, molecular 
approaches such as BIAcore technology allowing us to identify and determine the 
quality of specific protein-mRNA interactions will be of interest to set the affinity of 
such interactions and elucidate the crosstalk between p53 and the other ITAFs such 
hnRNPAI defined as activators of the FGF2 IRES (Bonnal et al., 2005). 
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ANNEX
In order to prove that human p53 upregulates ∆133p53 in response to stress, I 
did Doxorubicin treatments in U87 cells and observed the protein expression of the 
p53 isoforms – Figure 54. As we can see, even if doxorubicin induce increased levels 
of p53 protein, I could not reveal the ∆133p53 isoforms and long exposure for 
revelation did not show more information – Data not shown.  
 
 Figure 54. Western blot of p53 in U87 cells after treatment of 1µM of Doxorubicin. 
Either cells were subjected to 1 hour of dox and 17h of recovery, or continuous 
treatment of doxorubicin during 18 hours. p53 immunostaining with Sapu antibody 
and β-Actin with β-Actin antibody. 
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